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Abstract
Interleukin-15 (IL-15) is a pleiotropic cytokine produced by macrophages and 
fibroblasts, which mediates biological activities primarily through binding to the p and 
y components of the IL-2 receptor, togetlier with its own unique a  chain. IL-15 
induces T ceU migration and activation, NK cell activation, B cell maturation and 
antibody production and monocyte activation. IL-15 mRNA is widely expressed in 
both immune and non-immune tissues and cells lines. However, the role of IL-15 in 
the context of any pathological situation remains unclear’. Therefore, the role of IL-15 
in a T helper-1 (Thl) disease prototype, rheumatoid arthritis (RA), and a Th2 disease 
prototype, asthma, was investigated in the present study.
IL-15 was identified in RA synovial fluids. Following IL-15-mediated activation, 
peripheral blood (PB) T cells were capable of inducing TNF-a production from a 
macrophage cell line, from syngeneic PB monocytes, and from synovial macrophage / 
synoviocyte co-cultures, through a cell-contact dependent mechanism which required 
no T cell cytokine synthesis. RA synovial fluid (SF) T cells exhibited similar 
properties, which were IL-15-dependent in vitro. IL-15 up-regulated CD69 
expression on CD45RO+ T cefls and neutr alisation studies determined that such CD69 
expression, in combination with LFA-1 and ICAM-1, was partly responsible for cell- 
contact mediated macrophage activation by T cells. Furthermore, a similar’ mechanism 
operated in regulating cell-contact-induced IL-15 production by monocytes. Thus, 
activated T cells appeared to be effective costimulators of TNF-a and IL-15 production 
by monocytes via cell-ceU contact, thereby generating a positive feedback loop. IL-15 
also modulated cytokine production and adhesion molecule expression by RA 
neutrophils. Finally, in a murine model, IL-15 blockade profoundly suppressed the 
development of collagen-induced arthritis (CIA). This was accompanied in vitro by 
marked reductions in antigen-specific proliferation and interferon-gamma (IFN-y) 
synthesis by spleen cells from treated compared with control mice and in vivo by
significant reduction in semm anti-collagen antibody levels. Taken together, these data 
clearly demonstrated an important role for IL-15 in the development of inflammatory 
arthritis.
Parallel studies established that epithelial cells and inflammatory leukocytes from the 
respiratory tract of asthma patients expressed IL-15. Moreover, such cells also 
expressed high levels of inducible nitric oxide synthase and produced NO in vitro. 
Expression of both IL-15 and iNOS was significantly suppressed in patients receiving 
inhaled corticosteroid therapy. In vitro studies demonstrated synergistic upregulation 
of TNF-a by IL-15 and NO providing evidence for interactions between radical 
inflammatory mediators and cytokines in chronic inflammatory responses.
A cknow ledgem ents
I would like to thank Prof. F.Y. Liew for allowing me to undertake these studies in his 
laboratory, who have provided me with advice and encouragement both within and 
outside the field of immunology over the last few years. I thank also Dr. Iain Mclnnes 
for his enthusiasm, constant encouragement and for putting up with me, his guidance 
together with lots of beer and pizzas has made this journey a wonderful experience. I 
thank also to Prof. Peter Wilkinson and Dr. Charhe McSharry for their- guidance and 
advice. I am grateful also to Prof. Roger StmTock for his support and for allowing me 
to undertake part of this work in his laboratory. The support of Prof. Neil Thomson 
and Dr. Max Field has been much appreciated.
I would like to thank all those in the Immunology Department, University of Glasgow 
and the Centre for Rheumatic Diseases, Glasgow Royal Infirmary who have provided 
me with friendship and support throughout this thesis. In particular, Drs, Damo Xu, 
Xiao-Qing Wei, Gui-Jie Feng, Billy Sands, David Piedrafita, Kaushik Chaudhuri, 
Miss Francis McGarry and Mr. Holger Ruchatz. I thank also Drs. Hilary Capell, Johri 
Hunter, Lorna Thomson and many other clinical staff for providing tissue samples 
during this study. I am also grateful to University of Glasgow for funding this 
studentship.
Finally, I would like to thank my parents for their continued love and support. So too, 
Sirene whose unfailing love, patience and kindness has been a great source of 
encouragement throughout last few difficult years, and without whom, I would never 
have finished.
List o f Contents
Page
Abstract 3
A cknow ledgem ents 5
List o f contents 6
List of tables 11
List of figures 12
Abbreviations 15
Chapter 1 General Introduction 19
1.1 Interleukin-15 20
1.1.1 The stmcture and genomic architecture of IL-15 22
1.1.2 Regulation of IL-15 expression and production 22
1.1.3 IL-15 receptor and signal transduction pathway 24
1.1.4 Functions of IL-15 27
1.1.5 IL-15 in pathology 31
1.2 Rheumatoid Arthritis 34
1.2.1 Pathology of RA 34
1.2.2 Involvement of T lymphocytes in RA 35
1.2.3 Fibroblasts in RA 39
1.2.4 Macrophages in RA 40
1.2.5 Neutrophils in RA 41
1.2.6 Cytokine production in RA 41
1 .3  Asthma 46
1.3.1 Introduction 46
1.3.2 Pathology of Asthma 46
1.3.3 Cytokine production in Asthma 48
1 .4  Nitric oxide (NO) as a “non-cytokine” mediator in Asthma 49
1.4.1 Regulation of NO syntliesis 50
71.4.2 Functional consequences of NO production in Asthma 54
1 .5  Regulation of cytokines and iNOS by glucocorticoids 56
1 .6  O bjectives 58
Chapter 2 Materials and Methods 59
2 .1  Patients and clinical samples 60
2 .2  Ethical considerations 61
2 .3  Reagents /buffers 61
2 .4  Cell culture 62
2.4.1 Peripheral blood mononuclear cell preparation 62
2.4.2 Synovial fluid mononuclear cell isolation 63
2.4.3 Isolation of neutrophils 64
2.4.4 Induced sputum culture preparation 64
2.4.5 Proliferation and cytokine production by human cells 65
2.4.6 Nitric oxide production by monocytes in vitro 66
2.4.7 Murine spleen cell preparation 67
2.4.8 Cell line maintenance 68
2.4.9 Cell contact protocols 68
2.4.10 Whole blood culture 70
2.4.11 Neuti’ophil culture and stimulation 71
2 .5  FACS analysis 71
2.5.1 Analysis of lymphocyte phenotype 71
2.5.2 Analysis of neutrophil receptor expression after stimulation 72
2.5.3 Human cell subset analysis 72
2 .6  Im m unohistochem istry 73
2.6.1 Alkaline phosphatase staining 73
2.6.2 Non specific esterase double staining with anti-iNOS 74
2.6.3 Conti'ol experiments 75
2.6.4 Photo-micrography 76
2.7 Animal Model of Inflammation 76
2.7.1 Induction of collagen induced aithritis (CIA) in mice 7 6
2.7.2 Anti-cytokine ti'eatment of CIA 77
2.7.3 Monitor of progression of CIA 7 8
2.7.4 Quantification of histology 7 8
2.7.5 Measurement of semm anti-collagen antibodies 79
2 .8  RT-PCR for mRNA expression in clinical samples 79
2.8.1 RNA exUaction 7 9
2.8.2 cDNA prepaiation 80
2.8.3 Polymerase Chain Reaction 80
2 .9  Cytokine assays 81
2.9.1 IL-15 ELISA 81
2.9.2 Removal of rheumatoid factor 82
2.9.3 General ELISA protocol 83
2 .1 0  NO measurement 84
2.10.1 Griess reaction 84
2.10.2 Chemiluminescence assay for nitrite / nitrate 84
2 . 11  Statistical Analysis 86
Chapter 3 Interleukin-15 mediates T cell dependent regulation
of tumour necrosis factor-a 89
Introduction 90
R esults 93
3.1 Assays employed for IL-15 detection and quantification in
biological fluids 93
3.2 Detection of IL-15 in synovial fluid 93
3.3 IL-15-dependent upregulation of TNF-a production from
macrophages 99
3.4 Induction of TNF-a production by cells of synovial origin 103
3.5 Effect of IL-15 on PB lymphocyte phenotype 107
3.6 Molecules involved in T lymphocyte / macrophage cell-contact 107
3.7 T cells stimulated with IL-15 induce monocyte production of IL-15 110
3.8 Induction of IL-15 production by cells of synovial origin 112
D iscu ssion
114
Chapter 4 IL-15 induces activation in RA synovial neu trophils 120
Introduction 121
R esults 123
4.1 Preparation of neutrophils 123
4.2 Expression of IL-15Ra mRNA in RA neuti'ophils 123
4.3 IL-15 induced expression of CD 11 b on human neutrophils 126
4.4 Induction of cytokine production by IL-15 activated neutrophils 128
4.5 Induction of noV6> protein synthesis by IL-15 134
D iscu ssion  136
Chapter 5 sIL -1 5 R a  adm inistration prevents m urine
collagen-induced a rth ritis  (CIA) 140
Introduction 141
R esu lts  143
5.1 Bioactivity of soluble IL-15Ra chain in vitro 143
5.2 sIL-15Ra administi ation prevents development of CIA 146
5.3 Histological analysis of joint destmction 146
5.4 Decreased humoral response to collagen in sIL-15Ra tieated mice 151
5.5 Reduction of serum cytokine levels in sIL-15Ra tieated mice 151
5.6 In vitro immunologic consequences of in vivo sIL-15Ra
administration 155
10
5.7 Discontinuation of sIL-15Ra administration facilitates disease
expression 158
D iscu ssio n  161
C hapter 6 N itric oxide and cytokine synthesis in A sthm a 165
In tro d u c tio n  166
R esu lts  168
6.1 Assay for nitrite in biological fluids 168
6.2 Nitrite / nitiate in serum from asthmatic patients 168
6.3 Expression of iNOS mRNA in induced sputum samples 171
6.4 Nitric oxide production in induced sputum cells 172
6.5 Induction of NO production in vitro in induced sputum cultures 174
6.6 Cellular localisation of iNOS in induced sputum cells 177
6.7 Do similar culture conditions induce human monocytôs to produce
NO? 181
6.8 Cytokine expression in sputum derived leukocytes 182
6.9 NO and IL-15 dependent regulation of TNF-a production 187
D iscussion 189
C hapter 7 G eneral Discussion 193
7 .1  R heum atoid A rthritis  194
7 .2  A sthm a 198
C on clu sio n  201
F u tu re  Studies 202
11
R eferences 
Appendix I 
Appendix II
Preparation of buffers 
Publications arising
203
251
253
List of Tables
Chapter 1
Table 1.1 
Table 1.2
Summaiy of human interleukin-15 
Evidence for IL-15 expression and production
21
32
Chapter 2
Table 2.1 
Table 2.2 
Table 2.3
Primaiy antibodies used in immunohistochemistry 
Secondaiy antibodies used in immunohistochemistiy 
Negative control antibodies for immunohistochemistiy
87
Chapter 3
Table 3.1 Recovery of IL-15 from IL-15 ' ‘spiked’ ’ RA synovial fluids 9 8
Chapter 4
Table 4.1 IL-15 stimulated the production of cytokine by purifled SF
neutrophils 133
Chapter 6
Table 6.1 
Table 6.2 
Table 6.3 
Table 6.4
Distr ibution of cells in induced sputum samples 
Nitrite production by induced sputum cultures
Production of TNF-a by cultured sputum cells
173
176
Immunohistochemical localisation of iNOS in sputum cells 180
183
12
List of Figures 
Chapter 1
Figure 1.1 Structural comparison of IL-15Ra and IL-2Ra chains 25
Chapter 3
Figure 3.1 
Figure 3.2 
Figure 3.3
Figure 3.4 
Figure 3.5
Figure 3.6
Figure 3.7 
Figure 3.8
Figure 3.9
Figure 3.10
Figure 3.11
Figure 3.12 
Figure 3.13
Standard curves for IL-15 ELISA 95
Detection of IL-15 & TNF-a in RA paired samples 96
Rheumatoid factor did not affect IL-15 quantification in 
RA synovial fluids 97
Double chamber culture of PB T and U937 cells 100
Activated PB T cells induced TNF-a production by U937 
and monocytes 102
Transcription and tianslation is required for cell-contact 
TNF-a production by monocytes and U937 104
Synovial T cells induce TNF-a production via cell contact 105 
Cell contact regulates TNF-a production by blood 
monocytes and synovial macrophages 106
FACS analysis of PB T cells following cytokine induced 
activation 108
Inhibition of T cell / macrophage activation by neutralising 
antibodies 109
Activated PB T cells induce IL-15 production by monocytes 
and U937 cells 111
Synovial T cells induce IL-15 production via cell contact 113 
IL-15 induced amplification of RA synovitis 119
13
Chapter 4
Figure 4.1 
Figure 4.2 
Figure 4.3
Figure 4.4 
Figure 4.5 
Figure 4.6 
Figure 4.7
Figure 4.8
Analysis by FACS of purified neutrophils 124
RT-PCR for IL-15Ra in RA synovial fluid neutrophils 125
FACS analysis of RA PB neutrophils following 
IL-15 activation 127
IL-15 upregulated CD 11b expression on RA PB neutrophils 129 
IL-15 induced cytokine production by SF neuti'ophils 130
Production of cytokines by IL-15 activated SF neuti'ophils 131
Cytokine production by SF neutrophils stimulated in vitro 
with IL-15 132
De novo synthesis of cytokines by neutrophils in response 
to IL-15 135
Chapter 5
Figure 5.1 
Figure 5.2 
Figure 5.3
Figure 5.4 
Figure 5.5 
Figure 5.6 
Figure 5.7
Figure 5.8
Figure 5.9 
Figure 5.10
Cloning and expression of sIL-15Ra 144
Neutralising activity of sIL-15Ra 145
Induction and sIL-15Ra treatment of collagen induced
ai thritis in mice 147
Recpmbinant sIL-15Ra inhibited development of CIA 148
sIL-15Ra administration prevented development of CIA 149
Histological assessment of the effect of sIL- 15Ra on CIA 150
Reduction in knee joint destiuction in sIL-15Ra
treated mice 152
Attenuation of semm anti-collagen antibody response in
sIL-15Ra-ti'eated mice 153
Effect of sIL- 15Ra ti'eatment on semm cytokine levels 154
Effect of sIL-15Ra treatment on antigen specific T cell
proliferation 156
14
Figure 5.11 Effect of sIL-15Ra treatment on antigen specific cytokine
production 157
Figure 5.12 Discontinuation of sIL-15Ra administration facilitated
antigen specific T cell responses 159
Figure 5.13 Cytokine production by spleen cells following sIL- 15Ra
withdrawal 160
Chapter 6
Figure 6.1 Standard cuiwes for nitrite / niti'ate estimation 169
Figure 6.2 Niti’ate concentration in serum obtained from asthmatic
patients 170
Figure 6.3 RT-PCR for iNOS in human respiratoiy samples 171
Figure 6.4 Production of NO by induced sputum cultures 175
Figure 6.5 Immunohistochemical identification of iNOS in
induced sputum cells 178
Figure 6.6 Co-localisation of non-specific esterase and iNOS in
induced sputum cells 179
Figure 6.7 Immunohistochemical localisation of IL-15 in induced
sputum cells 185
Figure 6.8 Percentage disti'ibution of IL-15 expression in induced
sputum cells 186
Figure 6.9 Induction of TNF-a synthesis by IL-15 and NO 188
15
Abbreviations
AA adjuvant aithritis
ADCC antibody dependent cellular cytotoxicity
APC antigen piesenting cell
BAL bronchoalveolai* lavage
BCG Bucillus Calmette-Guerin
bp base pairs
cAMP cyclic adenosine monophosphate
cDNA complementaiy deoxyribonucleic acid
CD cluster of differentiation antigens
CFA complete Freund’s adjuvant
CIA collagen induced ai’tliritis
Con A concanavaiin-A
CPR cytochrome P450 reductase
EAE experimental allergic encephalomyelitis
EBV Epstein Barr Virus
EC endothelial cells
ELISA enzyme linked immunosorbent assay
FAD flavin adenine dinucleotide
FCS foetal calf serum
FGF fibroblast growth factor
FÏTC fluorescein isothiocyanate
FMN flavin mononucleotide
yc common y chain
GM-CSF granulocyte macrophage - colony stimulating factor
HIV human immunodeficiency virus
HLA human leukocyte antigen
HSA human semm albumin
16
HTLV human T cell lymphotropic vims
ICAM intercellular adhesion molecule
IDDM insulin dependent diabetes mellitus
IFN interferon
Ig immunoglobulin
IL- interleukin-
IRS insulin receptor substrate
lU international unit
JAK janus-associated kinase
kD kilo-Dalton
L-NMMA N°-monomethyl-L-ai*ginine
LFA lymphocyte function antigen
LPS lipopolysaccharide
MCP monocyte chemoattractant protein
MHC major histocompatibility complex
MIP macrophage inflammatory protein
MMP matrix metalloproteinase
mRNA messenger ribonucleic acid
NAP N-acetyl penicillamine
NGS noimal goat semm
NK natural killer
NO nitric oxide
NOD non obese diabetic
NOS nitiic oxide synthase
NRS normal rabbit serum
OA osteoarthritis
OD optical density
PEL peripheral blood lymphocyte
PBMN peripheral blood mononuclear cell
17
PBS phosphate buffered saline
PET peripheral blood T cell enriched
PDGF platelet derived growth factor
PE phycoeiythrin
PFA paraformaldehyde
PG prostaglandin
PHA phytohaemagglutinin
PMA phorbol 12-myristate 13-acetate
RA rheumatoid arthritis
RANTES regulated upon activation noimal T cell expressed and secreted
RF rheumatoid factor
RNI reactive nitiogen inteimediates
ROI reactive oxygen intermediates
RT room temperature
RT-PCR reverse transcriptase polymerase chain reaction
s.d. standard deviation
s.e.m. standard eiTor of the mean
SCID severe combined immuno-deficiency
SE staphylococcal enterotoxin
SF synovial fluid
SFAC synovial fluid adherent cells
SFMN synovial fluid mononuclear cells
SFT synovial fluid T cell enriched
SNAP S-niti'oso-acetyl penicillamine
STAT signal transducers and activators of transcription
TES tris-buffered saline
TGF transfoiming growth factor
TEMP tissue inhibitors of metalloproteinase
TNF tumour necrosis factor
18
TSST toxic shock syndrome toxin
UTR untianslated region
VCAM vasculai’ cell adhesion molecule
VLA very late antigen
M molar
mM millimolar
mg milligram
ml millilitre
pg microgram
|il microlitie
|im micrometie
jiM micromolar
ng nanogram
nM nanomolai'
pg picogram
19
Chapter 1
General Introduction
20
1 .1  Interleukin-15 (IL-15)
Cytokines play an important role in regulating diverse biological processes, including 
proliferation and differentiation of hematopoietic cells (Arai, et al, 1990). Most 
cytokines exhibit a vaiiety of activities on several target cells, and synergy or cross­
talk aie often observed among activities of multiple cytokines. In addition, many 
cytokines elicit similar and overlapping activities on tai'get cells, suggesting that 
cytokine signaling pathways are non-lineai* and form a network with multiple potential 
cross-talk. The a-helical cytokines comprise a subset which includes more than 30 
factors. These cytokines bind to a unique class of receptors and include interleukins, 
colony-stimulating factors, and hormones (Bazan, 1990). Receptor family can be 
further divided into subgroups based on the use of shared subunits (Taga and 
Kishimoto, 1995; Leonard, 1996). For instance, the common y chain (yc) is a subunit 
of the interleukin-2 (IL-2), IL-4, IL-7, IL-9, and IL-15 receptors. This feature 
provides one moleculai" explanation for the biological redundancy occasionally 
described in this cytokine group.
Recently, the novel cytokine, IL-15 (synonym: IL-T), was simultaneously discovered 
in culture supernatants from two cell lines, the simian epithelial cell line, CV-l/EBNA, 
(Grabstein, et al, 1994) and the human T cell lymphoüopic virus I (HTLV-I)- 
associated adult T-cell leukaemia line, HuT-102 (Burton, et al, 1994; Bamford, et al,
1994), which stimulated proliferation of the murine T-ceU line CTLL-2. Many 
features are shared by IL-2 and IL-15, including the facts that both are members of the 
four a  helix bundle cytokine family. In addition, both utilize the (3 and yc receptor 
subunits for their action in T and NK cells and consequently share many biological 
properties when added to T, NK, and B cells (Table 1.1; Grabstein, et al, 1994; Giri, 
et al, 1994; Bamford, et al, 1994). Initially, it was not cleai- why two such appaiently 
similar cytokine activities aie produced. However, further analysis revealed 
differences between the two cytokines in terms of their cellular sites of synthesis.
21
Table 1.1 Summary of Human Interleukin-15
Properties Interleukin-15
Structure of cytokine 14 - 15 kDa, 114 aa 
Four helical bundle cytokine
Genomic structure 8 exon / 7 intron, chromosome 4q31
Cellular distribution of Skeletal muscle, kidney, lung, fi broblasts,
mRNA expression epithelial cells, and activated monocytes
Regulation of cytokine Transcription, tianslation & intracellular trafficking
expression Complex 5’ UTR with 10 AUGs 
Unusually long (48 aa) signal peptide 
3’ End of mature protein coding sequence
Receptor in T & NK cells IL-15Ra, IL-2(3, y chain
JAK/STAT signal Jakl/Jak3 (Janus-associated kinases)
transduction pathway Stat3/Stat5 (Signal Transducers and
in T cells Activators of Transcription)
Receptor in mast cells IL-15RX
JAK/STAT signal , Jak2
transduction pathway 
in mast cells
Stat5
(after Tagaya, et al, 1996b)
T
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Whereas IL-2 synthesis is primarily restricted to activated T cells, IL-15 mRNA is X
expressed in many non-lymphoid cells, including monocytes, fibroblasts, and 
endothelial cells and in normal human tissues, such as skeletal muscle, placenta and 
kidney (Grabstein, et al, 1994; Bamford; et al, 1994). Subsequent studies also 
revealed differences in post-tianscriptional regulation and in tlie specific receptors and 
signaling pathways utilized by the two cytokines (Bamford, et al, 1996a, Tagaya, et 
al, 1996b).
1 . 1 . 1  The structure and Genomic Architecture of IL-15
The human IL-15 gene maps to chromosome 4q31, whereas the murine IL-15 gene is 
localized to the central region of chromosome 8 (Anderson, et al, 1995a). Human IL- 
15 mRNA contains at least a 316 nucleotide (nt) 5’ untranslated region (UTR), a 
coding sequence of 486 nt and a 3’ UTR of at least 400 nt (Grabstein, et al, 1994).
The cDNA encodes a 162 amino acid (aa) peptide with a 48 aa leader sequence 
yielding a 114 aa mature protein (Bamford, et al, 1994). There is 97% sequence 
identity between human and simian IL-15 and 73% identity between human and 
murine IL-15. Recently, an alternative 21 aa leader sequence has been observed in 
many tissues, lung carcinoma cell line and T ceU lines (Tagaya, et al, 1997; Meazza, et 
al, 1997; Onu, et al, 1997). The IL-15 protein is a 14-15 kDa member of the 4 a~ 
helix-bundle cytokine family with two disulfide cross-links present at Cys42-Cys88 
(homologous to IL-2) and Cys35-Cys91.
1 . 1 . 2  Regulation of IL-15 expression and production
The factors which upregulate IL-15 protein synthesis aie poorly defined. IL-15 
mRNA expression is observed in many tissues in contrast to limited protein 
expression. Using northern blot and RT-PCR analysis, upregulation of IL-15 mRNA 
levels in murine and human macrophages may be induced by lipopolysaccharide (LPS)
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/ IFN-y, M. tuberculosis, T. gondii, and S. aureus (Bamford, et al, 1996b; Doherty, et 
al, 1996; Chehimi, et al, 1997). Furthermore, in monocytes or macrophages from 
patients with a wide range of infectious and inflammatory diseases, IL-15 mRNA is 
readily detected (Agostini, et al, 1996; Jullien, et al, 1997; Kotake, et al, 1997). 
However, it remains difficult to demonstrate meaningful quantities of IL-15 protein in 
the supernatants of many of these cells (Jonuleit, et al, 1997; Chehimi, et al, 1997; 
Jullien, et al, 1997). The discrepancies between studies may result from differences in 
the sensitivity of the CTLL-2 ceU clones and the ELISA systems employed. These 
observations suggest tight regulation of production of this potent cytokine activity.
IL-15 is predominantly regulated post-transcriptionally at the levels of protein 
translation and intracellular trafficking (Tagaya, et al, 1996b; Bamford, et al, 1997) 
rather than by transcriptional regulation, which is typical of many interleukins, 
including IL-2 (Paul & Seder, 1994; Kishimoto, et al, 1994). IL-15 translation is 
heavily down-regulated by a number of elements; in particular by the presence of 
multiple AUGs (5 in mice, 10 in humans) and the secondary structure in the 5’ UTR 
(Bamford, et al, 1996b). In general, the 5’ UTR of effectively translated messages are 
short, simple, and unencumbered by AUGs upstream of the initiation AUG. Kozak 
has emphasized that the presence of such AUGs in the 5’ UTR of may dramatically 
reduce the efficiency of their translation (Kozak, 1987 & 1991). Fusion of the IL-15 
mRNA with an HTLV-I R element in the HuT-102 ceU line deleted the AUG rich 5’ 
UTR sequence, leading to a marked increase in IL-15 mRNA transcription, translation 
and protein secretion (Bamford, et al, 1996b). Furthermore, the unusually long (48 
aa) IL-15 signal peptide together with that for the matum protein of IL-15 impedes the 
translation of the protein such that the quantity of IL-15 generated increased 
approximately 20-fold when the IL-15 signal peptide was replaced by that of IL-2 
(Bamford, et al, 1997). Recently, a shorter putative signal peptide (21 aa) was 
identified (Tagaya, et al, 1997) which shows a tissue distribution pattern that is distinct 
from that of the 48 aa signal peptide. This 21 aa signal peptide primaiily controls the
24
inti'acellular trafficking of IL-15 to non-endoplasmic reticulum sites, as compared with 
the 48 aa, and predominantly regulates the rate of protein translation as a secretory 
signal peptide. Finally, an inhibitory cis element is present in the 3’ coding sequence 
of IL-15, disruption of which leads to 5-10 fold increased protein expression 
(Bamford, et al, 1997). This stringent regulation of IL-15 production results in limited 
production of this cytokine under nonnal physiologic conditions, which will thus 
restrict its repertoire of functions while allowing efficient immune response against 
intracellulai’ infection.
1 , 1 . 3  IL-15 receptor and signal transduction pathway
(a) The type I IL-15 receptor
The functional similarities between IL-2 and IL-15 are reflected in shared utilisation of 
the 70/75 kDa IL-2R |3, and the 64 kDa yc receptor subunits. Thus, tlie effect of IL-15 
on activated T cells can be inhibited by antibodies against IL-2 |3 or y  chains but not 
against IL-2Ra chain. Similar data were obtained on analysis of IL-15 binding to cells 
transfected with different IL-2R subunits (Giri, el al, 1994; Grabstein, et al, 1994; 
Bamford, et al, 1994). Subsequently, a type I membrane protein has been identified in 
mice which binds IL-15 with high affinity (Giri, et al, 1995). Parallel studies in 
humans have identified a similai- receptor, designated IL-15R a-chain (Anderson, et 
al, 1995b; de Jong, et al 1996; Kennedy & Park, 1996). The IL-15Ra gene maps to 
human chromosome 10, adjacent to the IL-2Ra gene, with which it shares fragmented 
sequence homology. It is alternatively spliced to yield three active forms, each capable 
of high affinity binding to IL-15 (Anderson, et al, 1995b). Like IL-2Ra, it does not 
appeal’ to transduce signals, despite tlie presence of a 37 amino acid intracellulai’ 
domain. Both receptors share a conserved motif known as the GP-1 motif or the 
“Sushi” domain (Figure 1.1; Giri, et ai, 1995). IL-15Ra binds IL-15 with 1000-fold 
higher affinity than does IL-2Ra to IL-2, with no reported cross-reactivity (Giri, et al.
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1995). Moreover, IL-15Ra forms an unstable complex with IL-2Rpy, in contrast to 
the tight DL-2RaPy complex which results from the stabilising effect of IL-2Ra on py 
chain binding (Minami, et al, 1993; de Jong, et al, 1996). Thus, the up-regulation of 
IL-2Ra expression during T cell activation will effectively compete for available IL- 
2Py chain, with consequent down regulation of IL-15 mediated signalling, through 
disaggregation of weak IL-15Ra - py chain interactions.
Figure 1.1 Structural comparison of IL-15Ra and IL-2Ra chains
Potential N-linked 
glyeosylation site
^  à - i s  »  1st ' '
Signal Sustii domain Linkeif Sustii domain P ro /T hr Trans- Cytoplasmic 
hinge [Absent in IL-15R] rich region membrane domain
The widespread tissue distribution of IL-15Ra further distinguishes it from IL-2Ra. 
Whereas IL-2Ra is primarily expressed on activated T cells, IL-15Ra mRNA has 
been identified in numerous human tissues and cell lines, including activated T cells 
(Anderson, et al, 1995b). The functional significance of IL-15Ra expression in the 
absence of Py chain is currently unknown. Possibilities include the scavenging of 
“free” IL-15 at inflammatory sites, or the presentation of IL-15 to other IL-15 receptor 
bearing cells, thereby increasing the efficiency of ligand-receptor interaction. The 
widespread distribution of IL-15Ra, IL-2RP, and yc elements of the IL-15R system is 
one of the factors that underlies the pleiotropy of IL-15.
Expression of IL-2Ra and IL-15Ra appear linked. IL-15, like IL-2, upregulates the 
level of IL-2R0C on human B and T cells, but rapidly down-regulates the expression of
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IL-15Ra. Thereafter, lymphocyte responsiveness to IL-15 is reduced in comparison 
to IL-2 as measured by JAK3 kinase activation (Kumaki, et al, 1996). Thus, 
macrophage-derived IL-15 can enhance T cell activation during the early stages of an 
immune response, but thereafter down-regulate its own receptor, thereby enabling IL- 
2 to function as the principle T cell growth factor.
Following IL-15 binding to activated T cells, functional coupling of Janus-associated 
kinases (JAK) 1 and JAK3 with the IL-15 leceptor occurs (Johnston, et al, 1995). 
JAKl and JAK3 in turn activate and tyrosine phosphorylate insulin receptor substrate 
(IRS)-l and IRS-2, with subsequent tyrosine phosphoiylation and nuclear 
translocation of Stat 3 and Stat 5 (signal transducers and activators of transciiption) 
(Johnston, et al, 1995; Lin, et al, 1995). Other signalling events transduced by IL-15 
include phosphorylation of and p72®^  ^ and induction of Bcl-2, with resultant
protection or rescue from apoptosis (Miyazaki, et al, 1995; Akbar, et al, 1996).
(b ) The type II IL-15 receptor
The observation that mast cells proliferate to IL-15 but not to IL-2, led to the discovery 
of a novel receptor for IL-15», designated IL-15RX (Tagaya, et al, 1996a). This 60-65 
kDa IL-15 binding protein is different from all components (a , p, yc) of the IL-15R 
that aie present in T cells. Whether a cofactor membrane protein exists, or indeed 
whether this receptor enjoys wider cellular distribution is not yet known. In addition, 
it utilises a JAK2 / Stat 5 dependent pathway in mast cells which is distinct from that in 
activated T cells (Tagaya, et al, 1996a). These data further demonstrate that the 
functional profiles of IL-2 and IL-15 are not identical.
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1 . 1 . 4  Functions of IL-15
(a) T lymphocytes
IL-15 activates T cells as judged by several criteria. IL-15 induces proliferation of 
PHA activated CD4*  ^ and CD8+ T cells, CD3 activated PB T cells, T cell clones and 
yÔ T cells (Grabstein, et al, 1994; Nishimura, et al, 1996; Korholz, et al, 1997), with 
concomitant release of soluble IL-2 receptors (sIL-2R) (Treiber-Held, et al, 1996) and 
upregulation of CD25 expression (Korholz, et al, 1997). CD69 expression is 
upregulated on CD45RO+, but not CD45RA+, peripheral blood T cells, consistent 
with the distribution of IL-2Rp chain expression on memory T cell subsets (Minami, et 
al, 1993; Kanegane & Tosato, 1996). IL-15 mediates cytotoxicity, through generation 
of both CD8+ CTL and of lymphokine activated killer (LAK) cells (Grabstein, et al, 
1994; Bamford, et al, 1994). IL-15 induces T cell polarization, a recognised
prerequisite to activation, and migration in collagen gel or filter assays, with greater 
potency than either IL-8 or M IP-la (Wilkinson & Liew, 1995). Moreover, it 
redistributes adhesion molecules, including ICAM-3, -1 and -2, to uropods in the 
presence of p-integrin ligands, such as fibronectin and VCAM-1 (Nieto, et al, 1996). 
Thus, IL-15 might recruit T cells and thereafter, modify homo- or heterotypic ceU-cell 
interactions within inflammatory sites. Furthermore, IL-15 has recently been shown 
to rescue T cells from cytokine withdrawal-induced apoptosis, through selective 
induction of bcl-2 and bcl-xl (Akbar, et al, 1996; Salmon, et al, 1997), indicating that 
lymphocyte survival within inflammatory sites can be enhanced in the presence of IL- 
15.
Given its likely early expression in immune responses, the relationship of IL-15 to T 
cell subset differentiation, particularly in combination with IL-12, is clearly of interest. 
IL-15 primes naive CD4+ T cells from TOR transgenic mice for subsequent IFN-y, 
but not IL-4 production (Seder, 1996). Antigen specific responses in T cells from 
HIV^ patients in the presence of high-dose IL-15 exhibit increased IFN-y production
28
(Seder, et al, 1995) and preliminary data indicate that IL-15 might enhance IFN-y 
production if IL-12 is relatively deficient. Moreover, IL-15 may enhance production 
of IFN-y, TNF-a and IL-10 from activated PB T cells (Korholz, et al, 1997). 
However, IL-15 also induces IL-5 production from humm ûermatophagoides farinae 
II specific T cell clones, implying a positive role in Th2 mediated allergic responses 
(Mori, et al, 1996). Whether IL-15 prejudices Thl or Th2 responsiveness in 
uncommitted ThO cells (Mossman & Coffman, 1989) therefore remains unclear. 
CuiTent data indicate that its function as a T cell growth factor will likely sustain either 
Thl or Th2 cells, if already committed to that differentiation pathway.
(b ) Natural killer cells
IL-15 induces NK cell activation measured either by direct cytotoxicity, antibody 
dependent cellular cytotoxicity (ADCC) or by production of cytokines, including IFN- 
y, TNFoc, GM-CSF and M IP-la (Carson, et al 1994; Carson, et al, 1995; Bluman, et
al, 1996; Warren, et al, 1996). These data imply that IL-15, rather than IL-2, may be 
the primary activator of NK cells during early immune responses, in combination with 
IL-12. Furthermore, the failure to detect the IL-2 gene product within the bone 
marrow stroma and the presence of NK cells in IL-2-deficient mice leads to the 
suggestion that IL-15 may serve as a growth factor promoting NK cell differentiation 
and maturation from CD34^ hematopoietic progenitor cells (Mrozek, et al, 1996; 
Cavazzana-Calvo, et al, 1996). Recently, IL-15Ra subunit has been described to 
cooperate with IL-2Rpyc to transduce an intracellulai' signal to picomolar 
concentrations of IL-15 which in the absence of serum, can sustain resting NK cell 
survival for up to 8 days in culture (Carson, et al, 1997). In contrast, apoptosis was 
observed in a CD3‘CD56^ NK leukaemia cell line in vitro following costimulation with 
IL-15 and IL-12 (Ross & Caligirui, 1997). Thus IL-15 may play an important role-in 
regulating both NK cell development and its subsequent apoptosis. " •
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(c) B cells
IL-15 costimulates proliferation and immunoglobulin synthesis (IgM, IgG, IgA) by 
human B cells activated with either CD40 ligand or immobilised anti-IgM (Armitage, et 
al, 1995). A role has also been proposed for IL-15 as a growth factor in B cell chronic 
iymphoproliferative disorders (Trentin, et al, 1996).
(d ) Monocytes / Macrophages
IL-15 functions as an autocrine regulator of macrophage cytokine production, 
including IL-1, IL-6, IL-10 and TNF-a (Alieva, et al, 1997). IL-8 and monocyte 
chemotactic protein 1 (MCP-1) production is also upregulated from IL-15-activated 
monocytes, but is differentially regulated by IFN-y and IL-4 (Badolato, et al, 1997). 
IFN-y inhibits IL-I5-induced IL-8 secretion, but synergizes with IL-15 to enhance 
MCP-1 production. IL-4 inhibits both IL-8 and MCP-1 induction by IL-15. These 
data suggest that in response to stimuli, monocytes / macrophages may produce IL-15 
capable not only of inducing production of inflammatory cytokines, but also of 
promoting activation and infiltration of leukocytes.
(e) Neutrophils
IL-15, in contrast to IL-2, induces neutrophil moiphological changes, enhanced 
phagocytosis and de novo RNA and protein synthesis (Girard, et al, 1996). In 
addition, IL-15 delays apoptosis of neutrophils more efficiently than IL-2, further 
demonstrating the differential effects of IL-2 and IL-15.
(f )  Mast cells
IL-15 induces mast cell proliferation and activation. The presence of the IL-15X 
receptor in bone maiTow mast cells indicates a role in mast cell development along with 
IL-3 (Tagaya et al, 1996a).
Together, these properties reveal IL-15 to be a cytoldne that is unique in terms of the 
complexity of the response it may elicit. It represents a mechanism whereby local 
tissue cells can contribute to the eaify “innate” phase of immunity, providing 
enhancement of NK cell, neutrophil, monocyte / macrophage and subsequently T cell 
responses, prior to optimal IL-2 production.
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(g ) Thymic development
Early reports have implicated IL-15 in T cell development. Lymphocytes from IL-2Rp 
deficient mice do not proliferate to IL-15. These animals exhibit abnormal T cell 
development, with significantly reduced thymocyte numbers after 4 weeks (Suzuki, et 
al, 1995). Subsequent studies comparing the effect of IL-15 and IL-2 on thymocyte 
development have demonstrated that IL-15 may preferentially support differentiation of 
bipolar IL~2Rp'^, CD4', CDS" progenitor cells towards T yÔ or NK cell populations 
rather than to the T aP  subset (Leclercq, et al, 1996). Furthermore, IL-2 reduced 
thymocyte expansion in vitro through binding to IL-2Ra, in contrast to the 
proliferative effect of IL-15 through IL-15Ra expression (Willerford, et al, 1995; 
Leclercq, et al, 1996). Thus, IL-2 and IL-15 may exhibit diffemnlial effects in 
immature T / NK cell development.
(f )  Activity outside the immune system
The widespread tissue distribution of mRNA for IL-15 and IL-15Ra indicates that 
diverse functions may exist beyond the immune system. Addition of IL-15 to a 
cultured myoblast cell line modifies parameters associated with skeletal muscle fibre 
hypertrophy, which suggests tliat IL-15 may be an anabolic agent that increases 
skeletal muscle mass (Quinn, et al, 1995). In addition, IL-15 induces activation of 
endothelial cells and stimulates angiogenesis in vivo (Angiolillo, et al, 1997).
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1 . 1 . 5  IL-15 in pathology
If production of IL-15 were not prevented by tight ti'anslational control, the 
widespread expression of IL-15 transcripts could lead to constitutive protein 
production, thereby disrupting immune homeostasis. That such IL-15 expression 
could lead to immunopathology forms a basic tenet of this thesis. Evidence for 
involvement of IL-15 in human pathology, however, is sparse (Table 1.2). IL-15 
expression has been reported in human kératinocytes (Sorel, et al, 1996). It remains 
unclear whether UVB radiation upregulates IL-15 expression (Mohamadzadeh, et al,
1995), or inhibits its production, thereby contributing to UVB-mediated 
immunosuppression (Blauvelt, et al, 1996). It is uncleai* what contribution such 
expression makes to dermal pathology.
RA synovium is characterised by the presence of activated macrophages and 
fibroblasts, and by large numbers of activated T cells. Given its established cellular 
distribution and functional profile, IL-15 represents an attractive candidate cytokine for 
involvement in RA synovitis. Indeed, IL-15 is expressed by the synovial membrane, 
representing a pathway whereby T cells can be recruited and activated (Mclnnes, et al, 
1996b). An exciting possibility is that within the synovial membrane, IL-15 could 
direct T cell-mediated regulation of macrophage-derived cytokine production, 
particularly TN Fa, thereby driving the pro-inflammatory response. Furthermore, it 
may play an important role in activating neutrophils present adjacent to articular 
cartilage.
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Table 1.2 Evidence for IL-15 Expression and Production
Setting Organisms / Models References
Infection Mycobacterium leprae Jullien, et al, 1997
Mycobacterium tuberculosis 
Bacillus Calmette-Guerin (BCG) 
Toxoplasma gondii
Doherty, et al, 1996
Salmonella choleraesuis Nishimura, et al, 1996
Staphylococcus aureus Chehimi, et al, 1997
Herpes virus-6 (HHV-6) Flamand, et al, 1996
Human immunodeficiency virus (HIV) Agostini, et al, 1997; 
Kacani, et al, 1997
Hepatitis C Kakumu, et al, 1997
Inflammation Rheumatoid Aithritis & Mclnnes, et al, 1996b;
Reactive Arthritis Thurkow, et al, 1997; 
Kotake, et al, 1997
Sarcoidosis Agostini, et al, 1996
Ulcerative Colitis 
Crohn’s disease
Kirman & Nielsen, 1996
Autoimmune tliyroid diseases Ajjan, et al, 1997
Renal allograft rejection Strehlau, et al, 1997
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IL-15 has been localised in alveolai* macrophages of sarcoid patients, from whom 
pulmonary CD4+ T cells were found to proliferate to IL-15, implying a role in T cell 
mediated alveolitis (Agostini, et al, 1996). IL-15 induces mast cell proliferation and 
supports T cell clone-derived IL-5 production (Tagaya, et al, 1996a; Mori, et al, 
1996), these data together indicate that IL-15 might play a role in bronchial 
hypeiTeactivity although IL-15 has not yet been demonstrated in asthmatic bronchial 
samples. This thesis describes experiments designed to investigated the potential role 
of IL-15 in Thl and Th2 mediated pathologies. RA was chosen to represent the 
former and asthma, the latter.
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1 .2  Rheumatoid Arthritis (RA)
1 . 2 . 1  Pathology of RA
RA is a chronic inflammatoty disease, the aetiopathogenesis of which remains unclear. 
The clinical syndrome is characterised by remitting, relapsing inflammation within the 
synovial membrane, associated with progressive, erosive destruction of adjacent 
cartilage and bone. In RA marked synovial hyperplasia occurs. The membrane hning 
layer is increased, from 1-2 cells to 6-8 cells thickness, and contains increased 
numbers of type A macrophages as a result of increased extra-vascular migration 
(Edwards & Willoughby, 1982; Dreher, 1982). Local proliferation accounts for type 
B fibroblast-Iike (synoviocyte) expansion (Revell et al, 1987; Howat, et al, 1987). 
Large numbers of synoviocytes, macrophages and T and B lymphocytes are found in 
the interstitium, as are dendritic cells, mast cells and polymorphonuclear cells, 
particularly neutrophils (Duke, et al, 1982; Burmester, et al, 1983; Kennedy, et al, 
1988; Cush & Lipsky, 1988; Thomas, et al, 1994). In contrast to the acellular nature 
of normal synovial fluid (SF), inflammatoiy SF contains large number of neutrophils, 
along with T lymphocytes and macrophages. No basement membrane separates the 
membrane and fluid phase of synovium, indicating that egression from the membrane 
is a function of adhesion molecule expression and the presence of chemotactic 
gradients. Profuse angiogenesis is characteristic (reviewed by Colville-Nash & Scott,
1992) and endothelial differentiation may generate ‘high-endothelial venules’ 
(Freemont, 1987; Yanni, et al, 1993; Girard & Springer, 1995), reminiscent of those 
found in lymph nodes. Together with the presence of lymphocytic aggregates, these 
histological appearances resemble an active lymphoid tissue, implying that 
immunological processes are important in RA pathogenesis.
The production of cytokines and their soluble receptors has been recognised to be of 
critical importance in RA pathogenesis (reviewed by Feldmann, el al, 1996). In
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addition, high levels of adhesion marker expression are found on endothelial cells and 
leukocytes in RA synovial membrane and peripheral blood (Pitzalis, et al, 1988; Hale, 
et al, 1989; Gearing & Newman, 1993; Cronstein & Weissman, 1993; Johnson, et al, 
1993; Pitzalis, et al, 1994). Together with cytokine production, these molecules 
comprise a complex regulatory network which determines the activation, suppression 
and recruitment of inflammatory cells in the RA synovial membrane.
The mechanisms whereby the above cellular infilti'ate contribute to aiticular damage 
remain poorly understood. Deregulated production of matrix metalloproteinases 
(MMP) and tissue inhibitors of metalloproteinases (TIMPs) (Dayer, et al, 1986; 
GraveUese, et al, 1991; McCachren, et al, 1991; Firestein, et al, 1991), reactive 
oxygen intermediates (Blalce, et al, 1989; Mapp, et al, 1995), and prostaglandins 
(Dayer, et al, 1986) by synovial membrane cells has been described. Cytokines may
also exert direct effects through modification of chondrocyte or osteoblast / osteoclast
Ï;biosynthetic activity. Local production of autoantibodies by B lymphocytes leads to 
immune-complex formation, complement fixation, neutrophil activation and 
degranulation and may increase IL-lp and TNFa production (Chantry, et al, 1989; 
Plater-Zyberk, et al, 1992). Given such complexity, it is essential to identify the pre­
eminent cell type within the synovial membrane to choose therapeutic targets with 
maximum potential impact. Controversy, however, surrounds the nature of the 
optimum target - the T cell, the macrophage (or its products) or the synoviocyte?
1 . 2 , 2  Involvement of T lymphocytes in RA
T lymphocytes he central to the regulation of the normal immune response. The 
majority of synovial T cells are of the CD4 helper/inducer subset (Duke, et al, 1982;
Pitzalis, et al, 1987c; Cush & Lipsky, 1988) and are found in perivascular aggregates, 
which occasionally also contain germinal centres (Duke et al, 1982). CDS"  ^ cells are 
found in the transitional zone surrounding aggregates, or scattered throughout the
i
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interstitium. Synovial T cells are predominantly CD45RO"^, CD45RA", CD45RBdim, 
CD27", indicating advanced differentiation within the memory subset (Thomas, et al, 
1992; Matthews, et al, 1993; Morgan, et al, 1994). They express activation markers, 
including high levels of CD69 and MHC class II, particularly HLA-DR, (Pitzalis, et 
al, 1987a; Afeltra, et al, 1993; Fernandez-Gutierrez, et al, 1995) and several adhesion 
molecules, including ICAM-1 (CD54) together with the integrins, VLA-1 
(CD49a/CD29), VLA-4 (CD49d/CD29) and LFA-1 (CDlla/CD18) (Pitzalis, et al 
1988; Potocnik, et al, 1990; Laffon, et al, 1991; Thomas, et al, 1992; Pitzalis, et al, 
1994). Moreover, CD2, CD3 and CD4 levels are suppressed. A characteristic, and as 
yet unexplained, feature of synovial T cells is tire coincident expression of markers 
which normally appear in co-ordinated sequential fashion following antigen or mitogen 
induced activation. Thus CD69 is coexpressed with HLA-DR, VLA-1 or VLA-4, 
markers which do not normally appear until after CD69 levels subside (lannone, et al,
1994). Furthermore, the IL-2 receptor (IL-2Ra-chain - CD25) is present on only 
around 10% of cells (Pitzalis, et al, 1987a). Since IL-2 is the principle T cell growth 
factor in the normal immune response, alternative mechanisms must therefore operate 
to recruit and activate T cells in the synovial membrane.
Only a small number (-1%)' of synovial T cells are in cell cycle (Bonvoisin, et al, 
1984; Revell, et al, 1987; Qu, et al, 1994). The accumulation of synovial T cells 
therefore, most likely results from the preferential migration of memory T cells into the 
inflammatory synovium (Pitzalis, et al, 1988; Pitzalis, et al, 1991; Thomas, et al, 
1992; lannone, et al, 1994). A subpopulation of circulating CD4’*', CD45RO+, 
RBdim, CD27" memory T cells possess intrinsic migratory properties allowing 
transmigration into endothelial-coated collagen gels (Cush, et al 1992). Such cells 
express CD44, GDI la, CD26 and CD49, but not CD62L (Brezinschek, et al, 1995). 
CD27" memory T cells are usually cutaneous lymphocyte antigen positive (CLA) and 
represent a tissue-homing memory T ceU subset, in contrast to CD62+ lymph node­
seeking cells (Baars, et al, 1995). Activation is not a prerequisite for migration, and
37
although CD69+ T cells migrate more efficiently, the majority of cells with migratory 
potential are resting (Brezinschek, et al, 1995). Similarly, enhanced numbers of 
CD45RO+, CD45RBdim, CD27" T cell subset were recently identified in peripheral 
blood of RA patients compaied to controls, perhaps reflecting long-term systemic 
antigen stimulation (Kohem, et al, 1996).
In vivo, similar accumulation of CD45RO+ T cells into PPD-induced skin blisters has 
been observed (Pitzalis, et al, 1991) and subsequent FACS analysis shows the early 
presence of VLA-1 + and HLA-DR+ cells which must have resulted from preferential 
recruitment of preactivated cells (lannone, et al, 1994). Moreover, the interaction of T 
cells with endothelial cells led to up regulation of CD69 and HLA-DR expression. 
Thus, T cells appear to differentiate to a maturation stage at which egression from the 
circulation to tissue is enhanced. Tlie mature synovial phenotype can therefore be 
partially explained by preferential recruitment of differentiated memory T cells, with 
additional activation by endothelial cell contact during extravasation.
The functional significance of cell adhesion molecule expression extends beyond cell- 
ceU interactions (reviewed by Mojcik & Shevach, 1997). Synovial T cells express 
integrin receptors for extracellulai' matrix (ECM) components, including collagen, 
vitronectm and fibronectin (Rodriguez, et al, 1992; Pitzalis, et al, 1994; Kohem, et al, 
1996). Membrane interactions with the ECM are capable of further activating T cells 
within the synovial environment (Gilat, et al, 1996). A further consequence is 
upregulated production of matrix-degrading enzymes by T cells, such as heparanase, 
which facilitate movement through inflammatory tissues and thus enhance local 
migration.
Synovial lining layer cells and synovial T cells exhibit little evidence of apoptosis in 
vivo (Firestein, et al, 1995; Nakajima, et al, 1995). Analysis of relative levels of bcl- 
2, bcl-x and Bax gene expression in synovial T cells, suggests that survival may be
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attributable to the production of ‘stromal’ factors, as yet unidentified, produced by 
synovial fibroblasts, rather than by cytokine-mediated rescue (Akbar, el al, 1996; 
Salmon, et al, 1997). Thus, the synovial environment may represent a privileged site 
for memory T cell survival, contributing to the observed phenotype.
The functional capabilities of synovial T cells have been extensively investigated in 
vitro. T ceU clones derived from RA synovial membrane aie predominantly IFN-y 
producers (Miltenberg, et al, 1992; Quayle, et al, 1993; Cohen, et al, 1995), indicating 
that RA may be a Thl driven disease as has been suggested for reactive arthritis 
(Schlaak, et al, 1992; Simon, et al, 1994; reviewed by Sieper & Kingsley, 1996). 
Many T ceU clones were also capable of IL-10 production, but few produced IL-4 
(Cohen, et al, 1995). However, polyclonal synovial T cell populations exhibit 
deficient proliferation and IFN-y or IL-2 production in response to mitogens (Aaron, et 
al, 1991, Thomas, et al, 1992) and demonstrate impaired responses to recaU antigens 
(Verwilghen, et al, 1990). Impaired helper / inducer and suppressor function in vitro 
has also been reported (Chattopadhyay, et al, 1979; McCain, et al, 1984). In contrast, 
the CD45RO'^, RBdim, CD27" subset found within synovium is capable of potent B- 
ceU help having lost the ability to suppress immunoglobulin production in vitro 
(Thomas, et al, 1992), suggesting a role in autoantibody production in RA. However, 
taken together with their activated phenotpye, these observations have led to the 
suggestion that synovial T cells are in a state of ‘split anergy’, (Thomas, et al, 1992; 
Howell, et al, 1992) or of ‘frustrated activation’ (Pitzalis, et al, 1987). This might be 
a reflection of their maturation state, the presence of inhibitory factors in synovium, 
such as TGFp, IL-10, and prostaglandins, or result from interaction with synovial 
antigen presenting cells on entry to the membrane with resultant anergy (Salmon & 
Kitas, 1989; Fava, et al, 1989; Firestein & Zvaifler, 1990; Schwarz, 1990; Katsikis, et 
al, 1994).
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Evidence from several sources, however, strongly support a central role for T cells in 
RA pathogenesis (Panayi, et al, 1992; Panayi, 1993; Fox, 1997) and is listed below:
1. Abundance of T cells in synovial tissue and fluid.
2. Selective accumulation in the joint of specific T cell subsets defined by 
differentiation and activation markers.
3 Linkage of RA to specific class II MHC alleles.
4. Important role of T cells in animal models of inflammatory arthritis.
5. Improvement in RA with T cell-directed therapeutic approaches.
6. Presence of expanded oligoclonal T cell populations in RA.
Whether the T cell repertoire in RA displays a reproducible pattern of oligoclonality 
and whether synovial T cell responses to identifiable antigens aie important in RA 
remain points of confusion and controversy. Few antigen specific T cells need be 
present within an inflammatory lesion. In tuberculoid leprosy, fewer than 2% of T 
cells within the skin eruption ai'e M. leprae responsive (Modlin, el al, 1988). 
Similarly, bacteria-specific T cells in reactive arthritis are present at a frequency of 
-0.1% (Sieper, et al, 1993). The vast majority of T cells within the RA synovial 
membrane aie therefore likely to recognise inelevant antigens. Whether such cells 
contiibute directly to RA pathology, or are simply functional ‘bystanders’, is currently 
unclear.
1 .2 .3  Fibroblasts in RA
The contribution of the synoviocyte to RA has been subject to controversy. Synovial 
fibroblasts produce cytokines including TGFp, FGF, PDGF, IL-6, TN Fa and IL-lp 
and are significant sources of MMPs and of prostaglandins (Remmers, et al, 1991; 
Zvaifler & Firestein, 1994; Edwards, 1995). As such they comprise an important 
component of the inflammatoiy response in RA, but have been considered the
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inevitable result of chronic inflammatory infiltration. That they represent the primary 
lesion has also been proposed (Zvaifler & Firestein, 1994). Furthermore, synovial 
fibroblasts exhibit invasive properties in vitro and express adhesion molecules for 
ECM, particulai'ly vitronectin, which would facilitate migration into cartilage with 
ultimate formation of ‘erosions’ (Zvaifler & Firestein, 1994). The identification of 
somatic mutations of p53 in RA synoviocytes further indicates that autonomous, 
anchorage independent behaviour may be of pathologic significance (Firestein, et al, 
1997; Reme, et al, 1998).
1 .2 .4  M acrophages in RA
Macrophages, derived from the circulating monocytes, constitute some 30-50% of the 
cellular' pool in synovial membrane and like T cells, they exhibit features suggestive of 
activation. Ultrastructural examination demonstrates prominent filopodia, vacuoles, 
vesicles and rough endoplasmic reticulum (Athanasou, 1995) and histological studies 
show enhanced expression of complement receptors (C3b), Fc receptors and multiple 
adhesion molecules, including ICAM-1 and the p2 integrins (Theofilopoulos, et al, 
1980; Bimnester, et al, 1983; Athanasou & Quinn, 1991; Johnson, et al, 1993). 
HLA-DR up regulation has been widely reported, although the mechanism whereby 
this occurs is unclear' in the absence of IFN-y (Klareskog, et al, 1981; Burmester, et 
al, 1987; Firestein & Zvaifler, 1988). CD 14 and CD68 expression have been used 
extensively for identification purposes. However, the former is lost during maturation 
in the synovial membrane, and the latter may be found in intimai synovial fibroblasts 
(Wilkinson, et al, 1992), raising doubts as to its specificity outwith the lining layer. 
Non-specific esterase therefore probably remains the most reliable macrophage marker 
for histological purposes. The principle manifestation of macrophage activation 
however, is the presence of upregulated cytokine gene expression (Firestein, et al, 
1990) and of high concentrations of macrophage-derived cytokines detectable within 
synovial membrane and fluid.
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1 . 2 . 5  Neutrophils in RA
During active disease, SF is infiltrated by a variety of immune cells, of which 
neutrophils comprise between 60-90% of the total population (Zvaifler, 1997; Pillinger 
& Abramson, 1995). Neutrophils may be primed within the SF by a number of 
activation factors including immunoglobin aggregates and cytokines (Robinson, et al, 
1993a; Watson, et al, 1993). Furthermore, activated neutrophils can secrete many of 
the cytokines and chemoattractants found m RA SF including IL -lp , IL-8, TN F-a, 
TGF-p and leukotriene (LTB^) and possess a wide range of potent proteinases, 
hydrolases and MMP. In addition, then* ability to generate a series of oxygen and 
nitrogen intermediates may also contribute to inflammation (reviewed by Edwards & 
HaUett, 1997). They are also found in the cartilage / pannus junction suggesting a 
direct role in tissue destruction.
1 . 2 . 6  Cytokine production in RA
Numerous cytokines have been detected in the SF and synovial membrane and some 
have become the focus of therapeutic intervention, as it has become established that 
they play a central regulatory role in articular destruction. The pattern of cytokine 
production, however, has led to considerable controversy as to which of the cell types 
present in synovial membrane is the key element in pathogenesis (Panayi, et al, 1992; 
Firestein & Zvaifler, 1990).
The presence of many activated synovial T cells is not reflected in high levels of T cell 
cytokine expression in synovial membrane (Firestein & Zvaifler, 1987; Firestein, et al, 
1988; Chen, et al, 1993). Although IFN-y, and rarely IL-2, may be detected at the 
mRNA level by PGR or in situ hybridisation (Buchan, et al, 1988; Simon, et al, 1994; 
Bucht, et al, 1996; Kotake, et al, 1997; Klimiiik, et al, 1997), irnmunohistochemical 
localisation of protein has proven difficult, demonstrating expression in small numbers
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of cells only (Ulfgren, et al, 1995; Dolhain, et al, 1996). Neither cytokine has been 
consistently detected in synovial fluid or in synovial tissue cultures by ELISA, 
Moreover, IL-4 has not been detected by any means and the presence of IL-13 remains 
controversial (Isomaki, et al, 1996, Kotake, et al, 1997). These obseiwalions have 
cast doubt on the role of T cells in ongoing synovitis, on the basis that T cell effects 
should be ‘cytokine driven’. However, just as the frequency of antigen specific T 
cells in inflammatory sites is limited, so too is the level of T cell cytokine expression. 
Thus, IFN-y expression in leprosy skin lesions is seen in <1% of cells (Cooper, et al,
1989). Moreover, it has been recently recognised that the actual concentration of 
cytokine adjacent to its cell receptor in vivo may be maikedly higher than that predicted 
from in vitro measurements (Kaplan, 1996). The level of T cell cytokines thus far 
detected may therefore be sufficient to sustain a small number of arthritogen-specific T 
cells, but is unlikely to explain the extensive T cell activation described.
In contrast, macrophage derived cytokines have been relatively easily detected. These 
include IL-1 a , IL-lp, TNFa, IL-6, IL-8 and GM-CSF (reviewed by Feldmann, et al, 
1996) and encompass a broad range of pro-inflammatory activities. Investigations of 
their role in animal models and in vitro suggest that IL-lp and TNFa. may be of prime 
importance (Arend & Dayer, 1995; Maini, et al, 1995). TN Fa is produced by 
macrophages in the lining layer and at the cartilage-pannus junction (Chu, et al, 1992). 
It is present in up to 50% of RA synovial fluids and is detected in vitro after synovial 
tissue culture. Its bioactivities can explain several pathological features observed in 
RA and include upregulation of adhesion molecule expression, activation of osteoclast- 
mediated resorption of bone, suppression of anabolic effects of osteoblasts and 
chondrocytes, promotion of angiogenesis, enhancement of MMP and prostaglandin E^  
(PGEj) production, stimulation of fibroblast proliferation and activation of T and B 
lymphocytes and of endothelial cells (reviewed by Arend & Dayer, 1995; Feldmann, et 
al, 1996). TNFa also upregulates other cytokine production within the synovial 
compartment, since the addition of neutralising anti-TNFa antibodies to synovial
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tissue cultures inhibits the production of IL-1 P, IL-6, IL-8 and GM-CSF (Brennan, et 
al, 1989, Feldmann, et al, 1996). TNFa production is enhanced in murine CIA and 
adjuvant arthritis, and disease development and progression aie suppressed by 
treatment with anti-TNFa antibodies (Williams, el al, 1992; Staines & Wooley, 1994). 
Moreover, transgenic mice which express the human TNFa gene, develop erosive 
polyarthritis characterised by marked synovial hyperplasia (Keffer, et al, 1991; Butler, 
et al, 1997). The most persuasive evidence for a central role for TN Fa, however, lies 
in the amelioration of clinical and laboratoi-y parameters of disease activity in RA 
patients treated with ‘humanised’ monoclonal anti-TNFa antibodies (Elliott, et al, 
1994; Rankin, et al, 1995, Moreland, et al, 1997).
The activities of TN Fa overlap considerably with those of IL -lp . Thus, IL-lp 
upregulates MMP and PGE^ production, enhances caitUage breakdown and 
upregulates osteoclast activity, promotes angiogenesis and induces fibroblast 
proliferation. However in comparison to TNFa, IL-lp may exert more potent effects 
on chondrocyte and osteoclast activity and induces higher levels of MMP production 
from synoviocytes (Arend & Dayer, et al, 1995). In animal models, administration of 
IL -lp induces or upregulates inflammatory arthritis, and inhibition of IL -lp activity
down-regulates inflammatory disease (Van den Berg, et al, 1994). However, others 
have found IL-1 receptor antagonist (IL-lra) less effective than anti-IL-ip antibodies, 
suggesting that IL-1 may be of variable importance in different models (Wooley, et al,
1993). Nevertheless, clinical trials using IL-lra in RA have brought about clinical 
improvement, but remain at a preliminary stage (Campion, et al, 1996). Addition of 
anti-IL-ip antibody or IL-lra to synovial tissue cultures suppresses IL-6 and GM- 
CSF production, but does not influence TNFa production (Feldmann, et al, 1996). In 
combination with the in vivo effects of TNFa neutralisation, these data indicate that 
TN Fa lies proximal to other monokines, occupying the pivotal point in a cytpkine 
‘cascade’.
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TGFp, in both latent and active forms (Fava, et al, 1989; Chu, et al, 1991), and IL-10 
(Katsikis, et al, 1993) have been detected in synovial membrane and are capable in 
vitro of down-regulating macrophage activation and of opposing the effects of IL -lp 
and TN Fa. Although TGFP may induce synovitis when injected into rodent knees 
(Fava, et al, 1991), its role in the majority of animal models is anti-inflammatory 
(Kumvilla, et al, 1991; Brandes, et al, 1991). Increased levels of IL-lra, and of 
soluble IL-1, IL-2 and TNFa receptors (p55 and p75) aie also found in synovial 
membrane and in synovial fluid (Miossec, et al, 1990; Symons, et al, 1991; Deleuran, 
et al, 1992; Cope, et al, 1992; Duff, 1993; Firestein, et al, 1994). They usually inhibit 
the action of tlieir respective cytokines, although in low concentration, soluble TNFaR 
may stabilise the bioactivity of TNFa (Aderka, et al, 1992). These molecules provide 
evidence of an attempt within the synovial membrane to down-regulate the 
inflammatory process. Their net effect in tissue will be determined by the precise local 
balance of cytokine and antagonist. The cytokine network in RA therefore appears to 
represent a balance of pro- versus anti-inflammatory (repair) processes, in which the 
former dominates over time.
Chemokines comprise a further class of pro-inflammatory protein represented within 
synovium. Both C-X-C (a) chemokines, including IL-8, epithelial neutrophil 
activating peptide 78 (ENA 78) and melanoma growth stimulating activity (GROa), 
and C-C (p) chemokines, including macrophage inflammatory protein (M lP)-la, 
M IP-lp, RANTES (regulated upon activation normal T cell expressed and secreted) 
and monocyte chemoattractant protein (MCP)-l have been detected in RA synovial 
membrane (Seitz, et al, 1991; Koch, et al, 1991; Koch, et al, 1992; Rathanaswami, et 
al, 1993; Koch, et al, 1994a; Koch 1994b; Deleuran, et al, 1994; Hosaka, et al, 1994). 
Synovial fluid therefore contains chemotactic activity which is attributable to multiple 
factors which, in turn, exhibit considerable redundancy (Al-Mughales, et al, 1996). 
Their contribution to leukocyte recruitment occurs in combination with the increased 
expression of adhesion molecules characteristic of the synovial environment (Johnson,
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et al, 1993; Cronstein & Weissman, 1993; Pitzalis, et al, 1994). Specific 
reorganisation of adhesion molecules, such as ICAM-3 and LFA-1, to the tips of 
uropods follows chemokine exposure, thereby optimising ligand interactions at the 
point of cell-cell contact (Angel del Pozo, et al, 1996). However, the precise role of 
chemokine activity in RA is unclear, since in vitro transepithelial migration studies of 
lymphocyte recruitment have demonstrated that M IP-la and RANTES do not alter the 
phenotype or magnitude of peripheral blood lymphocyte invasion (Brezinschek, et al,
1995). It is therefore possible that their primary importance lies in regulating 
migration within the synovial membrane. In this respect, the recent demonstration that 
cytokine-ECM interaction can create high local concentrations of bioactive cytokine 
may be of relevance (Gilat, et al, 1996). An additional effect may be to potentiate 
neovasculaiisation, as demonstrated for IL-8 or ENA 78 (Koch, et al, 1991; Koch, et 
al, 1994b).
There is therefore little doubt that synovial macrophages occupy a central position in 
RA pathogenesis through cytokine secretion. Immune complexes, complement 
degradation products, bacterial or viral constituents and cell-cell contact have been 
proposed as stimulatory factors, but none is satisfactorily proven. Thus, although the 
effector role of TN Fa in RA is established, much less is known about the events 
initiating and maintaining TNFa production. Nor has a satisfactory explanation been 
provided to link the presence and activity of the majority of T cells with macrophages 
in synovial membrane, beyond the putative presentation of antigen and HLA-DR to a 
subset of disease-specific lymphocytes. Recently, IL-15 has been shown to directly or 
indirectly stimulate the expression of a series of inflammatory cytokines, including IL- 
1, IL-6, IL-10 and TNF-a. IL-15 is expressed by the RA synovial membrane and 
serves as a T-cell chemoattractant and activator (Mclnnes, et al, 1996b, Al-Mughales, 
et al, 1996). This functional profile indicated that it might be highly relevant in the 
context of rheumatoid pathogenesis. ■
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1 .3  Asthma
1 . 3 . 1  Introduction
The aetiology of asthma remains unclear despite numerous efforts to detennine those 
factors that lead to pulmonaiy damage and loss of function. The underlying 
inflammation leading to variable airflow limitation and airway hypeiiesponsiveness to 
various stimuli is often exacerbated by allergens (O’Byrne, 1988), respiratory tract 
infections (Empey, et al, 1976; Lemanske, et al, 1989), or environmental agents (e.g. 
air pollutants such as ozone or tobacco smoke) (McBride, et al, 1994). Localized 
cytokine and chemokine gene expression (Krug, et al, 1996), secretion of low 
molecular weight inflammatory mediators (Henderson, 1994), and the recmitment of 
specific leukocyte cell types (Bentley, et al, 1994; Poston, et al, 1992) have aU been 
shown to be critical events. In addition, complex inheritance patterns attest to the 
polygenic nature of the disorder (Daniels, et al, 1996).
1 . 3 . 2  Pathology of Asthma
Asthma is characterized by reversible airway narrowing and inflammation of the
airway wall, leading to epithelial cell damage, mucus plugging, stimulation of neural 
reflexes, and infiltration by inflammatory cells (reviewed by Bochner, et al, 1994), 
Structural changes to the airway wall, such as increased smooth muscle content and 
basement membrance thickening, associated with matrix deposition, aie also present 
(Ebina, et al, 1993). In moderate-to-severe asthma examination of bronchoalveolar 
lavage (BAL) cytology consistently reveals increased numbers of mast cells, 
eosinophils, and epithelial cell, while total lymphocytes, macrophages, and neutrophils 
are usually not different from controls (Durham, et al, 1984; Tomioka, et al, 1984; 
Beasley, et al, 1989; Wilson, et al, 1992). Activation of T cells in BAL fluids from 
asthmatic subjects has been documented. Both eaify (CD25) and late (HLA-DR,
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VLA-1) activation markers aie increased on T cells in asthmatics compaied to controls 
(Corrigan, et al, 1988; Wilson, et al, 1992; Robinson, et al, 1993b). Most of the T 
cells appear to be of the Th2 phenotype based on their pattern of expression of 
cytokine mRNA (Robinson, et al, 1992b). Macrophages from asthmatic subjects also 
appear to be activated (Cluzel, et al, 1987). In endobronchial biopsy studies in which 
lymphocytes were found to comprise the vast majority of mononuclear cells that 
infiltrate the asthmatic aimay, increased numbers of macrophages expressing CD68 or 
HLA class II antigens (but not CD14Q were identified also (Bradley, et al, 1991; 
Ollerenshaw & Woolcock, 1992; Ohashi, et al, 1992; Poston, et al, 1992). Most of 
the lymphocytes in the mucosa were T cells with increased CD25 expression (Bradley, 
et al, 1991; Bentley, et al, 1992). Increased numbers of eosinophils (Pin, et al, 1992; 
Fahy, et al, 1993) and basophils (Kimura, et al, 1975) have been found in induced 
sputum studies. Eosinophils from the sputum of asthmatic have a different surface 
phenotype titan then counterparts in blood, expressing ICAM-1, HLA-DR, and 
different levels of other markers (Hansel & Walker, 1992). Airway smooth muscle is 
also capable of responding to cytokines and growth factors released from 
proinflammatory cells by undergoing mitogenesis (Hirst, 1996). Furthermore, 
smooth muscle cells may act as effectors in perpetuating airway, inflaiumation by 
expressing and secreting chemokines (John, et al, 1997).
Many pathophysiological manifestations of asthma are associated with airway 
infiltration by leukocytes mediated by cytokines and chemokines. The extent of 
infiltration generally correlates with the severity of disease (Kelly, et al, 1989; 
Bousquet, et al, 1990; Walker, et al, 1991). In an antigen-induced mouse model, 
sensitized mice treated with aerosolized allergen develop leukocytic infiltrates of the 
aiiway lumen dominated by CD4^ lymphocytes and eosinophils (Blyth, et al, 1996). 
SCID mice fail to develop either aii"way eosinophilia or hyperresponsiveness after 
ovalbumin sensitization (Corry, et al, 1996). Furthermore, the depletion of CD4^ 
lymphocytes either by treatment with anti-CD4 antibodies or MHC class II gene
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knockout eliminated both eosinophil airway infilti'ation and airway 
hyperresponsiveness in antigen-challenged mice (Gavett, et al, 1994). Together, these 
results imply CD4^ T cells may play a ciitical role in asthmatic inflammatory response.
1 . 3 . 3  Cytokine production in Asthma
Cytokines, particularly those released by T cells, ai'c pivotal in mediating many 
inflammatory responses in allergic diseases. Two types of T-helper cell aiie 
distinguished by the pattern of cytokines secreted on activation. Thl cells release IL-2 
and IFN-y, whereas Th2 cells produce IL-4, IL-5, IL-10 (Mosmann, et al, 1986). 
Studies of T cell clones isolated in allergic diseases indicate that activated CD4^ cells 
release the characteristic profile of Th2 cytokines (reviewed by Mosmann & Coffman, 
1989; Kapsenberg, et al, 1991). Detectable levels of mRNA for TN F-a, IL-1, IL-4, 
IL-5, and GM-CSF have been reported in biopsies or BAL fluids, and a similar panel 
of cytokine proteins has been observed (reviewed by Bochner, et al, 1994). The 
source of these cytokines may include not only T cells but also macrophages, mast 
cells and eosinophils (Borish, et al, 1992; Broide, et al, 1992; Bradding, et al, 1992). 
In recent years, increasing evidence has suggested that activation of CD4^ Th2 cells 
plays a central role in the pathogenesis of bronchial asthma through expression of IL- 
4, which is essential for B ceU switching to IgE (Brestedt-Lindqvist, et al, 1988; 
Geha, 1992; Coyle, et al, 1995), and IL-5, which is required for the recruitment, 
activation and survival of eosinophils (reviewed by Gleich, 1990). Furthermore, the 
failure of both IL-4 and IL-5 deficient mice to develop eosinophil mediated aii*way 
infiltration or airway hyperresponsiveness following antigen challenge suggests that 
these cytokines aie each important components of proinBammatory cascades that result 
in the pathophysiological chaiges characteristic of asthma (Brusselle, et al, 1995; 
Foster, et al, 1996). In addition, IL-5 transgenic mice developed pathophysiologic 
changes in airways characteristic of asthma, including eosinophil infiltration, epithelial
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hypertrophy, goblet cell hyperplasia, increased mucus production and display airway 
hypeiTesponsiveness when challenged (Lee, et al, 1997).
Increased production of IL-1 (3 and TNF-a may be observed from alveolai' 
macrophages derived from asthmatic patients (Gosset, et al, 1991; Borish et al, 1992; 
Ackerman, et al, 1994) and TNF-a levels in sera obtained during bronchial asthma 
attacks are higher than those obtained in stable conditions (Kobayashi, et al, 1994). In 
asthma, IL-1 (3 and TNF-a are cytokines with a wide spectrum of proinflammatory 
activities including endothelial cell activation, upregulation of soluble and surface 
expression of adhesion molecules, induction of bronchial hyperresponsiveness and 
potent NOS induction. Further biological effects described previously in section 1.2.6 
may also be relevant (Walsh, et al, 1991; Dobrina, et al, 1991; Pigott, et al, 1992; 
Kips, et al, 1992; Liew, 1994). TNF-a increases chemokine RANTES production by 
human airway smooth muscle cells and bronchial epithelial cells in culture (Stellato, et 
al, 1995; John, et al, 1997). Together, these data demonstrate the complex network of 
cytokines likely involved in the pathogenesis of asthma. It has been suggested that 
abnormalities of IL-15 expression may participate in the pathogenesis of inflammatoiy 
disorders such as RA and sarcoidosis, however, its role in asthma has not yet been 
described.
1 .4  N itric oxide (NO) as a “non-cytokine” m ediator in Asthma
NO has emerged as an important inflammatoiy mediator in asthma (reviewed by 
Barnes & Belvisi, 1993; Gaston, et al, 1994; Barnes & Liew, 1995). Increased 
exhaled NO has been demonstrated in asthmatic patients (Kharitonov, et al, 1994 &
1996). Expression of iNOS mRNA and protein can be induced within airway 
epithelial cells and NO is produced by bronchial epithelial cells in culture (Robbins, et 
al, 1994; Watkins, et al, 1997). The pathophysiological consequences of increased 
NO production in the respiratoiy tract aie not yet known. NO itself is a
50
bronchodilator, and inhalation of high concentrations of NO results in a 
bronchodilatory response in asthmatic patients (Hogman, etal, 1993; Kacmarek, et al,
1996). This suggests that the increased level of NO may be beneficial in asthma by 
counteracting the bronchoconstriction produced by inflammatory mediators such as 
leukotiiene and histamine (Kuo, et al, 1992). However, NO may also have 
deleterious effects, as it may increase bronchial blood flow and plasma exudation in 
the airways (Kuo, et al, 1992; Bernareggi, et al, 1997). It is also possible that the 
production of endogenous NO may be involved in the orchestration of eosinophilic 
inflammation that characterizes asthma. High local concentiations of NO may also 
have cytotoxic effects on airway epithelial cells (Heiss, et al, 1994), and thereby could 
contribute to the patchy epithelial shedding described in asthmatic airways.
NO has recently been found to play an important role in experimental models of other 
chronic inflammatoiy diseases, such as experimental arthritis, which has many 
analogies with asthma (Stefanovic-Racic, et al, 1993 & 1994; Evans & Ralston,
1996). NO may also play a critical role in immunological responses to foreign protein, 
and has evolved as a non-specific defence mechanism to protect against invasion by 
bacteria, parasites and viruses (reviewed by Lyons, 1995; MacMicking, et al, 1997; 
Nathan, 1997; Fang, 1997). Asthma may be considered to be a subversion of the 
inflammatoiy response mounted against parasites, and thus NO may be involved in 
amplifying the inflammatory response In asthma.
1 . 4 . 1  Regulation of NO synthesis
Three isoforms of NO synthase (NOS) have been identified and their enzymology 
extensively studied (Bredt & Snyder, 1994; Nathan & Xie, 1994; Michel & Feron,
1997). Constitutively expressed endothelial NOS (eNOS) and neuronal NOS (iiNOS) 
are capable of rapid onset, short lived generation of low concentrations of NO 
(together temied cNOS). Inducible NOS (iNOS), in contrast, is present in cells only
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after specific up regulation which requires novel protem synthesis, but thereafter, 
generates high concentrations of NO over prolonged periods. NOS isoforms share 
30-40% homology with cytochrome P450 reductase (CPR), with consensus 
sequences for redox-active cofactors including NADPH, flavin adenine dinucleotide 
(FAD) and flavin mononucleotide (FMN) and during activation, they form dimers in 
the presence of teti'ahydrobiopterin, haem and L-arginine. However, unlike cNOS 
which is calcium dependent, calmodulin is tightly bound to a basic, hydrophobic site 
on iNOS, and enzyme activity is independent of ambient calcium concentration (Cho, 
et al, 1992).
iNOS was first cloned from murine macrophages and subsequently from human 
hepatocytes and chondrocytes (reviewed by Nathan & Xie, 1994; Geller, et al, 1993; 
Charles, et al, 1993), but not as yet from human macrophages. Human iNOS shares 
~50% homology with cNOS, and 80% with murine iNOS and is located on 
chromosome 17. Widespread tissue distribution of iNOS has been reported with 
expression observed in human kératinocytes, hepatocytes, osteoblasts / osteoclasts, 
chondrocytes, uterine smooth muscle cells, mesangial cells, deimal fibroblasts, 
neutrophils and respiratory epithelial cells. Expression in human tumours has also 
been detected, including colorectal adenocarcinoma and glioblastoma.
Considerable controversy surrounds the presence and activity of iNOS in human 
macrophages. Whereas some authors have demonstrated NO production directly, or 
L-arginme- / NO-dependent activity (e.g. Denis, 1991; Dugas, et al, 1995; 
Burkrinsky, et al, 1995; Zembala, et al, 1994), others have been unable to detect any 
evidence of iNOS activity at all (Schneemann, et al, 1993 & 1997). The required 
stimuli for iNOS up regulation in human macrophages appear to differ from those in 
rodents, and where NO production has been detected, it is of an order of magnitude 
lower than that obseiwed in rodent macrophages. Whether this represents a 
functionally significant difference in the precise role of NO in the generation of
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immune responses in rodents compared with humans remains unclear. Nevertheless, 
the widespread tissue distribution of iNOS confers upon host tissue cells of either 
species the ability to contribute to regulation of immune responses through high output 
NO generation.
iNOS has been suggested to be the predominant source of NO in inflammatoiy 
lesions. Given the ubiquitous effects of NO in inflammatory lesions it might be 
anticipated that many factors will control iNOS expression and activity. Thus, iNOS 
may be activated in vitro by cytokines, microbial products, particularly LPS and 
superantigen toxins, picolinic acid, cAMP-elevating agents and physical factors, 
including UV light or trauma (reviewed by Nathan & Xie, 1994; Lyons, 1995). 
Cytokmes appear to exert the major regulatory influence in vivo. IFN-y is a potent 
inducer of NO production by rodent macrophages and endothelial cells, in synergy 
with LPS (Liew & Cox, 1991). IL-1 (3 and TNFa also increase iNOS expression in 
many cells, either alone or in synergistic combination (Liew, 1994). Cytokine 
requirements vary with the species and tissue origin of cells. Thus, rodent smooth 
muscle cells respond either to IL-1 (3 alone, or in synergy with IFN-y or TN Fa, 
whereas human vascular smooth muscle cells require a combination of LPS, IFN-y 
and TNFa for NO production. Similarly, rodent hepatocytes respond to LPS alone, 
whereas human hepatocytes require a combination of LPS, IFN-y, TN Fa and IL-2 
(reviewed by Nathan & Xie, 1994; Liew, 1994; Lyons, 1995; MacMicking, et al,
1997).
Multiple inhibitory mediators have been described. TGF|3, IL-4, IL-8, IL-10 
(indirectly through effects on TN Fa production), IL-13, M IP-la, epidermal growth 
factor (EGF), PDGF, and FGF all oppose iNOS activation (reviewed by Nathan & 
Xie, 1994; Lyons, 1995; Liew, 1994). Species and tissue specificity appear 
important. TGFP inhibits rodent macrophage and endothelial iNOS expression, but 
enhances NO production in Swiss 3T3 fibroblasts (Gilbert & Hershman, 1993).
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Moreover, IL-10 has been shown to increase iNOS activity in avian osteoclasts 
(Sunyer, et al, 1996), as has IL-4 in human macrophages (Dugas, et al, 1995). The 
temporal sequence of ligand binding appears important, since pre-exposure of 
macrophages to LPS suppresses subsequent IFN-y induced NO production. Such 
observations emphasise the difficulties attached to extrapolation between species and 
ceU types. Furthermore, it has only recently been appieciated that iNOS may be 
‘constitutively’ present in human tissues, such as lung, retina, skeletal muscle or 
CNS, in the absence of specific up regulatory factors (reviewed by Nathan & Xie,
1994). This suggests that, in addition to a postulated responsive role in inflammation, 
iNOS may also be involved in normal physiological regulation.
Engagement of class II MHC either by allo-specific monoclonal antibodies, or by 
bacterial superantigens (SEE, TSST-1), in the presence of syngeneic lymphocytes, 
increases NO production by macrophages (Tao & Stout, 1993; Isobe & Nakashima, 
1992). Similarly, activation of macrophage NO synthesis follows crosslinking of 
CD69 by antibody. Cell-cell contact between T lymphocytes of both Thl and Th2 
subsets and macrophages leads to iNOS expression mediated in part through 
CD40/CD40 ligand and LFA-l/ICAM-1 (Stout, et al, 1996). Thus, homo- or hetero­
typic cell contact can induce NO synthesis in an inflammatory lesion. The ælative 
contribution of such mechanisms in the context of high levels of cytokine production is 
currently unclear.
L-N^-substituted arginines inhibit NOS activity in biological systems. L-N^ 
methylarginine (L-NMMA) is commonly used when no isoform specificity is 
necessary. No isoform specific inhibitor has yet been identified, although L-N® 
nitroarginine (L-NNA) exhibits relative specificity for cNOS as does L-N^ 
aminoarginine for iNOS. Aminoguanidine and N-iminoethyl-L-lysine ai'e further 
‘iNOS specific’ inhibitors often used in animal models. However, mice in which the 
eNOS, nNOS and iNOS genes lespectively have been specifically targeted have now
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been generated, allowing definitive investigation of the specific contribution of 
individual isoforms to be evaluated in different biological systems in vivo (Wei, et al, 
1995; MacMicking, et al, 1995; Huang, et al 1995).
1 . 4 . 2  Functional consequences of NO production in Asthma
(a) NO in acute inflammation
By virtue of its EDRF activity NO can induce vasodilatation through relaxation of 
vascular smooth muscle leading to eiythema (reviewed by Schmidt & Walter, 1994). 
Data from murine dextran- and carrageenin-induced models of inflammation indicate 
that NO also induces clinically detectable oedema formation, through alteration of 
endothelial penneability (Wei, et al, 1995). Thus, two features of the classical 
inflammatory response are regulated by NO. A further level of complexity lies in the 
interaction of iNOS with constitutive and inducible isoforms of cycloxygenase and 
their product, the prostaglandins. This suggests that NO produced by aiiway epithelial 
and inflammatory cells may result in increased airway oedema, thus worsening 
asthmatic inflammation.
(b) T ceil activation and cytokine synthesis
NO exerts bi-phasic effects on T lymphocyte responsiveness. Initial observations 
described inhibition of in vitro antigen or mitogen driven T cell proliferation, either by 
NO donors or by macrophage-derived NO in co-cultures (Merryman, et al, 1993). 
Subsequently, it was established that low dose NO significantly enhanced peripheral 
blood lymphocyte activation, measured by PHA-induced proliferation, increased 
glucose uptake, increased N F - kB  binding activity and activation of protein tyrosine 
kinase p56*^ *^  (Lander, et al, 1993). Moreover, in vitro and in vivo, L-arginine 
enhances lymphocyte proliferation, and increases NK cell and lymphokine activated 
killer activity (Park, et al, 1991). Of most interest however, has been the potential for
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modulating effects on functional maturation of T lymphocytes. Recent studies in 
murine T cell clones have established that NO preferentially inhibits Thl clonal 
proliferation to antigen, but had no effect on Th2 clones (Wei, et al, 1995; Liew, et al, 
1991; Taylor-Robinson et al, 1994). Moreover, proliferative responses by spleen cells 
to mitogen and to staphylococcal superantigens ai'e diminished in iNOS-deficient mice 
(Mclnnes, et al, 1998; Wei, et al, 1995). Thus, the local concentiation of NO and the 
maturational phenotype together influence the modulatory effect of NO on T cells. 
Amplification of the cellular immune response may be further modified by NO through 
induction of apoptosis (Albina, et al, 1993), and through altered T cell recirculation 
and tissue ingress referred to previously. In particular, P-selectin, which is down- 
regulated by peroxynitrite in vitro has recently been shown to recmit Thl, rather than 
Th2 cells to inflamed skin or joints in murine inflammatory models (Lefer, et al,
1997). One can speculate that through such pathways, local NO synthesis may further 
modify the nature of the T cell compartment within an inflammatory lesion.
It has been suggested that NO may play an important role in amplifying and 
perpetuating llie Th2 response in asthma (Barnes & Liew, 1995). iNOS may be 
induced in epithelial cells by exposure to proinflammatory cytokines such as TNF-a 
and IL-1P secreted by alveolar macrophages. It is possible that viral infections may 
also induce iNOS in airivay epithelial cells, augmenting the secretion of NO during 
asthma exacerbations. IFN-y has an inhibitory effect on cytokine expression by Th2 
cells in the lung (Nakajims, et al, 1993). The large amounts of NO generated in the 
ainvay epithelium can result in suppression of Thl cells with a concomitant reduction 
in the level of IFN-y, leading to proliferation of Th2 cells. Th2 cells may then produce 
several cytokines including IL-4, IL-5 and IL-10, which further suppress Thl cells.
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(c ) Monokine production
NO is also implicated in monokine production. Increased TNF-a production from 
PBMC exposed to NO-donors has been detected, although the cellulai- origin of TNF- 
a  in this system was not specified (Lander, et al, 1993; Bigler, et al, 1993). 
Production of cytokines, including IL-6 and TNF-a, by purified blood monocyte/ 
macrophages or macrophage cell lines has been variously reported to be suppressed or 
enhanced in the presence of exogenous NO-donors (Deakin, et al, 1995; Mclnnes, et 
al, 1996a). Recently, enhanced TNF-a production by endogenous NO was reported 
from human U937 cells transfected with functional eNOS or iNOS (Yan, et al, 1997). 
The mechanism underlying these observations is unknown, but may leflect 
modification of ti'anscription factors, such as NF-kB (Lander, et al, 1993) or function 
at least in part, through a cyclic adenosine monophosphate (cAMP)-dependent 
signalling mechanism (Wang, et al, 1997). NO has been demonstrated to induce 
TN Fa synthesis by synovial tissues from rheumatoid aithritis patients indicating that 
such observations likely have pathological relevance (Mclnnes, et al, 1996a). 
Together these data indicate tliat complex feedback loops exist whereby the effector 
function of NO overlaps with its immunomodulatory role to ‘fine-tune’ ongoing 
immune responses. ,
1 .5  Regulation of cytokines and iNOS by Glucocorticoids
Glucocorticoids, given either by inhalation or orally aie the most effective form of 
therapy in asthma, such that inhaled steroids represent the mainstay of therapy. 
However, the actual mechanism by which glucocorticoids reduce aii"way inflammation 
in asthma remains poorly understood. Steroids have been shown to inhibit the 
ti'anscription of most inflammatoi'y cytokines and chemokines (reviewed by Barnes,
1996). Asthmatic patients respond to prednisolone therapy with a reduction in 
eosinophils as well as a decrease in activated T cells expressing IL-4 and IL-5 mRNA
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transcripts but an increase in IFN-y (Robinson, et al, 1993b). Furthermore, cell 
surface molecules mediating antigen presentation (Giuliani, et al, 1995) or cell 
adhesion (Van de Stolpe, et al, 1993; Brostjan, et al, 1997) are reportedly 
downregulated. Glucocorticoids are also effective in inhibiting iNOS (Di Rosa, et al,
1990), and have been shown to inhibit the expression of iNOS in epithelial cells in 
culture (Robbins, et al, 1994). The rate of iNOS transcription is reduced, and 
although mRNA is briefly stabilised, translation is significantly retarded and 
degradation of iNOS protein is enhanced (Kunz, et al, 1996). NF-kB p50 or p65 
nuclear' tianslocation is unaffected, but NF-kB and not AP-1 binding in the iNOS 
promoter region is prevented (Kleinert, et al, 1996). Thus, a possible mechanism of 
action for glucocorticoids may be to inhibit NO production from epithelial and 
inflammatoiy cells, thereby increasing the proliferation of Thl cells, which produce 
IFN-y. This, in turn, may act on Th2 cells to suppress the production of IL-4 and IL-
5. Ex vivo evidence for iNOS suppression by glucocorticoids treatment of patients 
has thus far been lacking.
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1 .6  Objectives
The pathological events in both RA and asthma encompass components of both 
humoral and cell-mediated arms of the immune system. Recent evidence suggests that 
IL-15 may play an important role in inflammatory responses. Since IL-15 mRNA is 
widespread, aberrant regulation of ti’anslation could amplify autoimmune responses in 
a wide variety of tissues. The present thesis describes experiments designed to more 
precisely understand the pathways whereby IL-15 may conuibute to such host tissue 
damage. Moreover, the importance of interactions between cytokine networks and 
other inflammatory mediators, including nitric oxide, has only recently emerged, 
particularly in a pathological context. That IL-15- and NO-mediated events might be 
related was of particulai* interest to the author. Objectives of the present studies were 
therefore:
To investigate the role of IL-15 in RA pathogenesis, representing a Thl disease model;
• by measuring modulation of pro-inflammatory cytokine synthesis, 
particularly TNF-a, since the latter has proven a most promising therapeutic 
biological target
® by investigating the ability of IL-15 to modify synovial neutrophil function
* using an IL-15 specific antagonist within the murine collagen aithritis model.
To investigate the role of IL-15 and NO in the pathogenesis of asthma, representing a 
Th2 disease model;
® by determining where and how NO and IL-15 aie expressed / produced by 
human respiratory epithelial and immune cells 
® by investigating the functional consequences of the presence of NO and IL- 
15 within the respiratory tract 
® by investigating the impact of glucocorticoid therapy in modulating these 
responses.
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Chapter 2
Materials and methods
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2 .1  Patients and clinical samples
Synovial fluid and peripheral blood samples were collected from RA patients attending 
the Centre for Rheumatic Diseases, Glasgow Royal Infirmaiy and tlie Rheumatology 
Department, Gartnavel General Hospital who satisfied the 1987 American College of 
Rheumatology diagnostic criteria (Arnett, et al, 1988). Buffy coats were provided by 
the Scottish Blood Transfusion Seiwice (Law Hospital, Carluke, UK) within 2 hours 
of donation by normal volunteer donors.
Induced sputum samples were obtained from a total of 11 normals [all non-smokers, 8 
males and 3 females, aged (mean ± SD, range): 33.4+8.5, 23-47 year] and 21 
asthmatics [all non-smokers, 17 males and 4 females, aged: 42.4±13.1, 20-69 year]. 
All samples were collected at the respiratory research laboratory at Gartnavel General 
Hospital, Glasgow. Asthmatics were subdivided into those taking inhaled (3-2 agonist 
alone (non steroid-treated, albuterol, 200 pg as required), and those on additional 
inhaled steroid therapy (steroid-treated, beclomethasone dipropionate, budesonide or 
fluticasone propionate, dose range 400-1000 pg daily). In tlie inhaled steroid group, 
4 patients were also taking an inhaled long-acting (3-2 agonist (salmeterol, 100 pg 
daily), 2 were taking oral tlieophyllines (400 mg daily), and 1 was taking inhaled 
ipratropium bromide (120 pg daily). Baseline lung function was measured using 
spirometry and forced expiratory volume in 1 second (FEVl) was found to be lower 
in the asthmatic group whether expressed (mean ± SD) as absolute values (3.03 ±
0.97 litres vs 3.82 ± 0.96 litres) or as percent of predicted values (82 ± 19% vs 97 ± 
12%).
Sputum induction was performed as previously described (Pin, et al, 1992). Briefly, 
after volunteers were administered with albuterol 200 pg by metered-dose inhaler, and 
spirometty checked, sputum induction was started using hypertonic (3%) saline 
administered via an ultrasonic nebuliser (Schuco International Ltd, London, UK) over
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a period of 20 minutes. The subjects were encouraged to expectorate at any time 
throughout the procedure, and in addition inhalation was stopped every 5 minutes to 
allow expectoration, and to allow spirometi'y to be cairied out. The sample was 
collected in a steiile container and processed within 2 hours. Protocol dictates that the 
procedure be discontinued if FEVl falls by more than 20%, although this fall was 
only observed in one patient at the end of the sputum induction and was completely 
reversed by albuterol.
2 .2  Ethical considerations
Synovial fluid and blood samples were surplus to clinical requirements following 
routine therapeutic or diagnostic procedures and would otherwise have been 
discarded. These samples were collected only when clinically indicated, and informed 
consent was obtained from patients prior to research use of samples so obtained. 
Pennission from the Ethical Committee in West Glasgow Hospitals University NHS 
Trust was applicable to the use of induced sputum samples for research purpose (Use 
of Induced Sputum to investigate lung disease including Asthma, Protocol No. 
94/139; Dr. N.C. Thomson, Western Infirmary). AH animal experimentation was 
perfonned under project licence provided following UK Home Office review and were 
used only to address questions not amenable to in vitro study of human tissue. 
Experimentation was performed under Project Licence 60/1311, procedure 5 for the 
Collagen induced arthritis model in mice.
2 .3  Reagents / buffers
The source of reagents either purchased or donated is given in the text and tables. 
Details of preparation of buffers and reagents, where appropriate, are contained in 
Appendix I.
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2 .4  Cell culture
All culture media and supplements were obtained from Gibco BRL, Paisley, Scotland, 
UK. Dulbecco’s modified Eagle medium was supplemented with 2 mM L-glutamine, 
100 I.U./ml penicillin and 100 |ig/ml streptomycin (‘complete Dulbecco’s MEM’). 
Supplements were stored in 5 ml aliquots (xlOO final concenti'ation) at -20°C and 
added to medium prior to culture. RPMI was supplemented with L-glutamine, 
penicillin and streptomycin as above (‘complete RPMI’). Murine lymphocyte 
proliferation medium consisted of complete RPMI, 25 mM HEPES (Sigma Chemical, 
Poole, UK) and 2.5 pg/ml amphoteracin B. Iscove’s modified Dulbecco’s medium 
for whole blood culture was supplemented with penicillin, streptomycin and L- 
glutamine as above, and stored at -20°C in 50 ml aliquots until use. Foetal calf serum 
(FCS) was mycoplasma screened by the manufacturer, heat inactivated at 56°C for 30 
minutes in a circulating waterbath, then stored in 25 ml aliquots at -20°C. Culture was 
performed at 37°C in a humidified incubator with 5% CO^. Cells were counted directly 
using a Neubauer haemocytometer (Weber Scientific International Ltd, UK) on a 
Nikon Labphot microscope. Viabihty was assessed microscopically by trypan blue 
exclusion (0.1% trypan blue (Sigma), 0.1% acetic acid (BDH Lab. Supplies, Leics, 
UK), phosphate buffered saline[PBS]).
2 . 4 . 1  Peripheral blood mononuclear cell preparation
Mononuclear cell populations were obtained by density gradient centrifugation. After 
collection into heparinised sterile uni versais (10 I.U./ml preservative free heparin, Leo 
Laboratories Ltd, Bucks, UK), venous blood was diluted 1:2 in complete Dulbecco’s 
MEM. 5 ml diluted blood was layered over 5 ml Lymphoprep (Nycomed Pharma, 
Oslo, Norway) in a 13 ml conical tube and spun at 500g for 30 minutes at 22°C. The 
mononuclear fraction was collected and washed thrice in medium before adjustment to 
the required cell concentration. This population was designated peripheral blood
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mononucleai' cells (PBMC). Buffy coats from the Blood Transfusion Service were 
diluted 1:3 in complete Dulbecco’s MEM then prepared as for venous blood samples.
T lymphocyte enrichment was performed by negative selection using successive 
adherence steps to obtain a peripheral blood T lymphocyte fraction (PBTL). 
Mononucleai' cell suspensions obtained above were incubated at 2x10^ cells/ml in 75 
cm^ tissue culture flasks (Costar) for 1 hour, then non-adherent cells were further 
mcubated overnight in complete Dulbecco’s MEM, with 10% FCS. Cells remaining 
non-adherent were collected and washed thrice in medium before suspension to the 
desired concentration. Cellular purity was assessed by FACS analysis (FACScan, 
Bee ton Dickinson) for CD3, CD 14 and CD19 mai'ker expression (section 2.5). PB 
monocytes were prepared by selecting adherent cells during the T cell enrichment 
process described above. Cells which adhered after both the 1 hour and 16 hour 
incubation steps were removed using a cell scraper and maintained in 10% FCS at 
5x10^ cells/ml until required. Prior to use, they were first gently washed in situ to 
remove non-viable monocytes or residual non-adherent lymphocytes, then 
resuspended to the desired concentration. Cell purity was assessed by FACS analysis 
(section 2.5).
2 .4 .2  Synovial fluid mononuclear cell isolation
Synovial fluid obtained by joint aspiration from RA patients was collected with 10 
I.U./ml heparin, then diluted 1:3 in complete Dulbecco’s MEM. The mononuclear cell 
fraction was obtained using lymphoprep as before, and T cell enrichment was 
performed as described above for peripheral blood. The non-adherent fraction was 
designated synovial fluid T lymphocytes (SFTL). The adherent fraction was retained, 
resuspended to 5x10^ cells/ml and plated in 96 well flat-bottom plates (Nunclon) for 
cell-contact experiments (section 2.4.8). Cellular purity was assessed using cytopreps 
(section 2.6).
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2 . 4 . 3  Isolation of neutrophils
Neutrophils were isolated from peripheral blood and synovial fluid using lymphoprep 
as previousfjdescribed. Following centrifugation, the neutrophil rich pellet was 
hai'vested, contaminating erythrocytes were removed by adding equal volume of Tris- 
Ammonium chloride (0.21% Tris, 0.75% NH4CI in sterile distilled water) for 5 
minutes and washed twice in complete Dulbecco’s MEM. Adherent cells including 
monocytes / macrophages and lymphocytes were removed by two successive 
adherence steps at 37‘’C for 30 minutes. After purification, cells were washed twice in 
medium and resuspended in Dulbecco’s MEM supplemented with 10% FCS. Cells 
viability and purity were determined by Trypan blue exclusion and FACS analysis 
respectively (section 2.5).
2 . 4 . 4  Induced Sputum culture preparation
Sputum-expectorated cells mixed in an equal volume of complete Dulbecco’s MEM 
medium / 0.05% dithiotrietol (DTT, Sigma) were incubated at 3TC  for 15 minutes 
with constant agitation, then passed through Nytex membrane (Cadisch & Son, 
London, UK). Samples were washed four times in complete Dulbecco’s MEM 
medium to remove debris and salivary nitrite / nitrate, then resuspended in complete 
Dulbecco’s MEM with 5 pg/ml amphotericin B and 5% fetal calf serum. Cell viability 
was determined by trypan blue exclusion.
Primai'y cultures were established as follows. 100 |ll of heterogeneous sputum cells 
adjusted to 2x10^ cells/ml in complete Dulbecco’s MEM, 5% FCS, were plated into 96 
well Bat-bottom culture plates (Nunclon, Denmark). After 1 hour, stimuli were added 
at different concentrations in a total volume of 100 |il in complete Dulbecco’s MEM 
supplemented with 5% FCS, giving a final density of 1x10^ cells/ml in 200 pi (i.e. 
2x10^ cells/well). Cultures were maintained from 24 to 96 hours. Stimuli included
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staphylococcal enterotoxin B (SEB, stock 1 mg/mi, Sigma), lipopolysacchaiide (LPS, 
stock 1 mg/m\, Salnwnella enteritidis. Sigma), and recombinant human IL-15 (gift of 
Dr. D. Cosman, Immunex Corporation, Seattle, USA) at the concentrations indicated. 
Reagents were stored at -20“C as concentrated stock solutions before dilution in 
appropriate medium prior to culture. Nitric oxide synthase activity was inhibited m 
some cultures by addition of N^-monomethyl-L-arginine hydrochloride (L-NMMA, a 
gift from Dr. Hodson, Wellcome, Beckenham, UK). For cytokine study, sputum 
cultures or human monocyte cell lines (U937, THP-1; European Collection of Animal 
cell cultures, Salisbuiy, UK) were stimulated with nitric oxide donor S-nitroso-acetyl 
penicillamine (SNAP, Alexis Biochemicals, Nottingham, UK) and N-acetyl 
penicillamine (NAP, gift of Dr. I. Charles, The Cruciform Project, University College 
of London, UK) was used as a control. All chemicals were stored desiccated, at room 
temperature, and were dissolved immediately prior to use in appropriate medium, then 
filtered (Millex-GV 0.22 pm, Millipore, France). This solution was added to final 
culture. Culture supernatants were frozen at -20°C until assay for cytokine or nitrite 
production.
Cytospin preparations were made using a cytospin (Shandon, UK) after sputum cells 
been purified. Sputum samples were resuspended at 2x10^ cells/ml in PBS and spun 
at500rpm  for 5 minutes. Cytopreps were fixed in cold acetone, rehydrated in PBS 
for 5 minutes and stained with May-Griinwald-Giemsa - 300 cells were counted per 
sample.
2 . 4 . 5  Proliferation and cytokine production by human cells
Proliferation assays were performed in triplicate in complete Dulbecco’s MEM with 
10% FCS. 2x10^ PBMC, PBTL or SFTL in 100 |il were incubated in U-bottom 96 
well culture plates (Nunclon) for 24, 48, 72 or 96 hours. Stimulatory reagents or 
medium alone were added in a further 100 ql at twice tlie desired final concentration.
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30 minutes after seeding of cells to culture plates. 1 |iCi of ^H-thymidine (Amersham 
Life Science, UK) in 25 |il complete Dulbecco’s MEM was added to each well during 
the final 6 hours of culture before hai vesting onto a glass fibre filter (Packard, CT, 
USA) using a Micromate 196 Harvester (Packard). ^H-thymidine incorporation was 
measured using a Mati'ix 96, Direct Beta Counter (Packard). Because background 
counts varied considerably between individuals (range from 100 cpm to 3000 cpm), 
proliferation was expressed as a stimulation index derived as follows:
(mean counts per minute test culture)Stimulation index - (mean counts per minute medium alone)
Paiallel tiiplicate cultures in identical conditions were performed in 96 well plates for 
analysis of cytokine production by PBMC, PBTL and SFTL following stimulation. 
Culture supernatants were frozen at -70°C at different time points indicated in figures 
and assayed for cytokine concentration by ELISA in single batches (section 2.9). 
Reagents included recombinant interleukin-15, recombinant interleukin-2 (IL-2, R&D 
Systems, Abingdon, UK) and phytohaemagglutinin (PHA, Murex Diagnostics Ltd, 
UK), rabbit polyclonal anti-human IL-15 (‘azide free’, PeproTech, UK) and rabbit 
polyclonal anti-human IL-2 (‘azide free’, Genzyme Diagnostics, MA, USA ).
2 . 4 . 6  Nitric oxide production by monocytes in vitro
Production of NO by human monocytes was investigated using adherent PBMC, 
prepared as above (section 2.4.2), or monocyte cell lines (U937, THP-1; European 
Collection of Animal Cell Cultures, Salisbury, UK). Cells were incubated in the 
presence or absence of stimuli in 48-well culture plates at various cell concentiations 
(10^ to 4x10^ /ml) in complete Dulbecco’s MEM with 1 to 10% FCS for 24, 48, 72 or 
96 hours. Supernatants were frozen at -20°C until assay for nitrite concentration using 
the Griess reaction (section 2.10.1). Stimuli used were SEB, LPS, IL -ip , IFN-y and 
TN Fa as described in section 2.4.1. In some experiments, monocytes were first
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matured by incubation in 10 nM phorbol myiistate acetate (PMA, Sigma) for 6 - 4 8  
hours in 25 cm^ flasks, prior to addition of reagents.
In the absence of a recognised human monocyte / macrophage line capable of NO 
production, control experiments were perfonned using the murine macrophage cell 
line J774, which is known to produce nitrite after stimulation with 50 I.U./ml IFN-y 
and 10 ng/ml LPS. J774 cells harvested as described (section 2.4.7) were suspended 
in 100 |Lil complete RPMI, 5% FCS, at 2x10^ cells/ml in flat-bottom 96 well plates 
(Nunclon) and rested for 1 hour. Reagents were added in 100 [il, then cells were 
incubated for 24 hours before measurement of nitrite concentration in the supernatant 
by Griess reaction (section 2.10.1). Stimuli were SEB, LPS and murine recombinant 
IFN-y (donated by Genentech Inc., CA, USA) at concentrations indicated in the text. 
500 jlM L-NMMA was used as an inhibitory control, to confirm the involvement of 
the L-arginine-dependent NOS pathway (Nathan & Xie, 1994).
2 . 4 . 7  Murine spleen cell preparation
Murine spleens were dissected, weighed, cut into 2 mm fragments in a 10 cm petri 
dish (Sterilin, Middlesex, UK) and gently minced through a tea strainer, using a 10 ml 
syringe plunger. This cell suspension was washed three times in complete RPMI, 
passed through Nytex membrane to remove cellular aggregates and debris and 
resuspended to the desired concentration.
Proliferation assays for spleen (SC) were performed in triplicate in U-bottom 96 well 
culture plates (Nunclon) at 2x10^ cells/well in 100 pi proliferation RPMI with 10% 
FCS. Stimuli were added in 100 pi giving a final culture volume of 200 pi. 1 pCi of 
^H-thymidine was added during the final 6 hours of culture and plates were harvested 
as described in section 2.4.4. Cytokine production by SC was measured using 
supernatants derived from parallel triplicate cultures for various time in flat-bottom 96
-1
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well culture plates (Nunclon), in the presence or absence of stimuli. Supernatants 
were frozen at -70°C before cytokine assay in single batches (section 2.9). Stimuli 
included 0.1 to 10 pg/ml concanavalin A (Sigma) as positive control. Bovine type II 
collagen was used during in vitro studies of Collagen Induced Aithritis (CIA) in male 
DBA/1 mice at concentrations indicated. Collagen was resuspended to 1 mg/ml in 
proliferation medium supplement supplemented 10% FCS before dilution and use in 
culture.
2 . 4 . 8  Cell line maintenance
Human and murine monocyte (THP-1, U937 & J774) ceU lines (ECACC) were 
maintained in complete RPMI witli 10% FCS between 2x10^ and 5x10^ cells/ml with 
sub-culture every 2-3 days. CTLL cells (donated by Prof. A. Bradley, Dept. Surgery, 
University of Glasgow) were cultured in complete RPMI, 10% FCS supplemented 
with 10 I.U./ml murine recombinant IL-2 (Genzyme) between 10^  and 5x10^ cells/ml, 
with sub-culture every 2-3 days. For functional assays, cells were washed twice 
before suspension to the desired concentration and addition of indicated stimuli. 1774 
cells are normally adherent and were harvested by cell scraper, then rested for at least 
1 hour, after harvesting and washing, prior to addition of stimuli. Cell lines were 
regulaiiy tested for mycoplasma (Mycoplasma PCR ELISA kit, Boerhinger 
Mannheim, Germany). Cells were stored in complete RPMI supplemented with 10% 
FCS; 10% dimethyl sulfoxide (DMSO) in liquid nitrogen.
2 . 4 . 9  Cell contact protocols
The ability of T lymphocytes to regulate the pro-inflammatory activity of macrophages 
by direct cell-membrane contact may be investigated by fixing T cells after activation, 
but prior to co-incubation with macrophages (Vey, et al, 1992; Lacraz, et al, 1994). 
PBTL were cultured in 25 cm  ^ flasks (Costar) for 72 hours in 5% FCS, in the
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presence of medium alone, iiL-15 (100 ng/ml), rIL-2 (100 ng/ml), rIL-8 (100 ng/ml; 
R&D Systems), rM IP-la (100 ng/ml; donated by Dr G J. Graham, CRC Beatson 
Institute, Glasgow, UK) or, as positive control, a combination of 1 jig/ml PHA, and 1 
nM phorbol myristate acetate (PMA; Sigma). Cells were washed thrice then fixed for 
2 hours in filler sterilised (Millex-GV, Millipore, France) 1% paraformaldehyde in 
phosphate buffered saline (PBS; Sigma) at 4°C with gentle agitation. SFTL were 
prepared in identical conditions but were cultured with or without stimulus for only 24 
hours before fixation. Fixed cells were washed thrice, resuspended to 4x10^ cells/ml 
in RPMI, then immediately added in equal volume to 5x10^ cells/ml of either unprimed 
U937 cells, PB monocytes (section 2.4.2) or adherent synovial fluid derived 
macrophage / synoviocyte co-cultures (section 2.4.3) in 10% FCS in flat-bottomed 96 
well plates (Nunclon). After a further 48 hours, supernatants were harvested and 
stored at -70“C prior to TNFa estimation by ELISA (section 2.9.2). The in vivo 
capacity for cell-contact mediated macrophage activation by synovial lymphocytes was 
further investigated by direct fixation of freshly isolated synovial mononuclear cells 
(SFMC). Synovial fluid was prepaied through lymphoprep as before, then SFMC 
were cultured for 30 minutes in 10% FCS in 25 cm^ flasks (Costar), after which the 
non-adherent cells were fixed in 1% PFA. 4x10^ fixed cells/ml were cultured with 
U937 cells as described above. Supernatants were collected after 48 hours for TN Fa 
estimation.
Double chamber culture was performed in parallel experiments. PBTL were 
stimulated for 72 hours as described, then added without fixation at 4x10^ cells/ml to 
U937 cells at 5x10^ cells/ml. Identical cultures were established in which PBTL were 
separated from U937 cells by a culture-well insert (Falcon, Becton Dickinson) with a 
porous membrane (pore size: 0.45 p.m), which prevented cell-contact but allowed 
soluble factor mediated communication. Supernatants were harvested after a furtlier 
48 hours and TNFa concentrations estimated by ELISA.
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Some experiments were modified to investigate the contribution of surface markers to 
T cell / macrophage communication following IL-15 mediated activation of T cells 
(Isler, et al, 1993). Antibodies against CD69 (Becton Dickinson), LFA-1 and ICAM- 
1 (both donated by Dr N. Hogg, Imperial Cancer Research, London, UK) were 
diluted to 50 |lg/ral in PBS. Fixed T cells were pelleted by centrifugation at 250g for 
10 minutes, then suspended in 180 |Lil medium, to which was added 20 \x\ of 
neutralising antibody (final concentration 5 fig/ml), or control murine monoclonal 
IgGl (DAKO, Denmark) at equivalent concentration. Cells were incubated at 4°C for 
30 minutes, washed twice in cold Dulbecco’s MEM and adjusted to 4x10* cells/ml. 
These cells were added to monocyte preparations as before. These cultures were 
supplemented with 5 qg/ml human IgG (Sigma) to reduce non-specific Fc binding by 
cell bound antibody. In some experiments, increased concentrations of neutralising 
antibodies were employed up to a final concentration of 50 pg/ml.
2 . 4 . 1 0  Whole Blood Culture
Phenotypic maturation of peripheral blood lymphocytes to recombinant IL-15 or 
mitogens was investigated using FACS analysis by modification of a whole blood 
culture method (Bocchieri, et al, 1995). Blood was withdrawn, heparinised (10
I.U./ml) and immediately diluted 1:5 in complete Iscove’s medium. After addition of 
rIL-15 (100 ng/ml), rIL-2 (100 ng/ml) or PHA (1 pg/ml) to the diluted blood, tiiplicate 
cultures (500 pi each) in 48-well culture plates (Costar) were established and 
incubated for 3, 6, 24, 48 and 72 hours. Unstimulated, diluted blood was withheld to 
serve as ‘time 0’ negative control and analysed within 30 minutes of venesection. 
FACS analysis of these cultures was performed as described below.
1:1
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2 . 4 . 1 1  Neutrophil culture and stimulation
Neutrophils were resuspended in complete Dulbecco’s MEM supplement with 10% 
FCS. Cells were cultured in 96 well flat-bottom culture plates (Nunclon) at 2x10* 
cells/well at 37°C in 5% CO^ either with various concentrations of recombinant IL-15 
or medium alone. At time inteiwals up to 48 hours, culture supernatants were removed 
and frozen at -70“C until assay for cytokine production by ELISA.
For receptor analysis, peripheral blood neutrophils were cultured at 4x10* cells in 500 
pi with complete Dulbecco’s MEM, 10% FCS in 48 well culture plates. Cells were 
stimulated in the presence or absence of 100 ng/ml IL-15 or autologous cell-free 
synovial fluid (10% final volume). FACS analysis was perfonned at various time 
intervals as described below.
2 .5  FACS analysis
2 . 5 . 1  Analysis of lymphocyte phenotype after whole blood culture
Double immunofluorescence staining of peripheral blood lymphocytes following 
stimulation with cytokines or mitogens was performed by FACS analysis. 200 pi of 
blood / Iscove’s culture prepared and stimulated as described above were placed in a 
12 X 75 mm polystyrene tube (Falcon 2052, Becton Dickinson, UK). Primai'y 
antibodies employed were as follows: CD3 (FITC and PE), CD56 (PE), CD16 (PE), 
CD69 (FITC and PE), CD45RA (FITC), CD45RO (PE), CD19 (FITC) (all Becton 
Dickinson). 10 pi of primary antibody were added to cells at 4“C for 30 minutes. 
Negative control primai'y antibodies (IgGl FITC, IgGl PE; DAKO) of appropriate 
isotype and conjugate were added to pai'allel tubes and were similarly processed. 2 ml 
FACS^ Brand Lysing Solution was added (1:10 dilution of commercial stock 
contained 5% diethylene glycol, 1.5% formaldehyde; Becton Dickinson), vortexed for
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5 seconds, then cells were mcubated for 10 minutes at room temperature in the dark to 
facilitate eiythrocyte lysis. Leukocytes were recovered by spinning at 300g for 5 
minutes, then washed with 1 ml FACSFlow (Becton Dickinson) at 200g for 5 
minutes. Cells were resuspended in 200 pi FACSFlow and analysed on a FACScan 
(Becton Dickinson). Gates were set for lymphocytes using forward and side light 
scatter parameters. The percentage of FITC or PE positive cells, or of double labelled 
cells, was generated for lymphocytes within this region using Lysis II software 
(Becton Dickinson),
2 . 5 . 1  Analysis of neutrophil receptor expression after stimulation
Purified synovial fluid and cultured peripheral blood neutrophils were washes twice in 
cold medium and suspended at 2x10* cells/ml. Receptor expression was measured 
using antibodies to CD 11b, CD 11c (both PE labelled. Sigma), and in aU expeiiment 
appropriate isotype control antibodies (Dual Tag, IgGl FITC/PE, Sigma) were 
included. Cells were labelled as described above, washed twice in FACSFlow and 
fixed in 1% paiaformaldehyde in PBS prior to analysis. A total of 10,000 cells were 
collected per sample.
2 . 5 . 3  Human cell subset analysis
Cell preparations from peripheral blood and synovial fluid were analysed using FACS 
to determine cellular purity. Single ceU suspensions were adjusted to 10* cells/ml in 
serum free medium, then 100 |il were incubated with 5 ql of FITC or PE labeUed 
primary antibody in separate tubes (CD3 PE, CD 14 FITC, CD19 FITC; Becton 
Dickinson) and (CD 15 PE, CD56 PE; Sigma) for 15-30 minutes at 4°C in the dark. 
Cells were washed in 1 ml FACSFlow at 200g for 5 minutes, then analysed as 
described before. Lymphocyte, monocyte and neutrophil regions, determined by 
forward and side light scatter parameters, were examined to identify cell subsets 
present.
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2 .6  Immunohistochemistry
Freshly isolated and stimulated sputum cytospin preparations were made using a 
Shandon cytospin device. Sputum cells were cultured with 1 |ig/ml SEB and EPS 
(Sigma) in vitro for 24 h. Cells were washed twice in PBS to remove debris and 
resuspended at 2x10^ cells/ml in PBS and spun at 500 rpm for 5 minutes. Freshly 
isolated sputum cells were prepared in a similar manner. Cytospins were air dried and 
immediately fixed by immersion in acetone (BDH) at 4°C for 15 minutes. Sections 
were air dried for 5 minutes and stored at -20°C in an air / moisture tight container 
before use. 300 cells were counted per sample and data aie expressed as mean 
percentage ± SD.
Primary, secondaiy and negative control antibodies which were used, their source, 
species of origin, isotype and final working dilution are detailed in tables 2.1 to 2.3.
2 . 6 . 1  Alkaline phosphatase staining
Frozen sections were rehydrated in Tris buffered saline, pH 7.36 (TBS), for 10 
minutes and non-specific, Fc-mediated immunoglobulin binding was blocked with 
25% normal goat serum (NGS) / normal pooled human serum (PHS) (both supplied 
by SAPU, Scotland, UK) in TBS, for 30 minutes at room temperature. All incubation 
steps were perfoimed in a humidified slide container (Shandon). For all washes, 
slides were placed in a slide rack in 250 ml TBS at room temperature with gentle 
agitation for 5 minutes. Primary antibody (Table 2.1), diluted as required in 10% 
NGS / PHS was then incubated in 100 pi volume, overnight at 4°C. Sections were 
washed twice for 5 minutes before incubation with secondary biotinylated goat anti­
immunoglobulin antibody of appropriate species specificity (Table 2.2), diluted in 
10% NGS / PHS, for 1 hour at room temperature. After two further washes, alkaline 
phosphatase conjugated streptavidin, diluted 1:100 (5 pg/ml, DAKO), was added for
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1 hour at room temperature. Sections were washed once and bound antibody detected 
by incubation under light microscopic observation for up to 10 minutes with either 
Fast Red solution (Vector Laboratories, UK) per the manufacturers instructions, or i
with fast red salts prepared as follows. Fast red salt (Sigma) was dissolved to 1 
mg/ml in TBS, pH 8.2 containing 1 mg/ml naphthol-AS-MX phosphate (Sigma) and
Î
5% N.N.-dimethyl form amide (Sigma). Levamisole (Sigma) was added to 0.001 M n?
final concentration to inhibit endogenous tissue alkahne phosphatase activity, and the 
solution was filtered prior to use (Millipore). Finally, sections were dipped m 
Hanis’s haematoxylin (BDH) for 8-12 seconds to provide a nuclear counterstain and 
mounted using pre-wai'med aqueous mounting medium (GlycergeF^, DAKO).
2 . 6 . 2  Non specific esterase (NSE) double staining with anti-human 
iNOS
NSE may be visualised by incubation with a-naphthyl acetate or butyrate substiate 
and localises predominantly to macrophages with a characteristic cytoplasmic pattern, 
allowing distinction from lymphocyte expression (Meuller, et al, 1975). Cytospin 
sections were stained with rabbit polyclonal anti-human iNOS antisemm (Merck) as 
described above, but developed with fast blue (Vector, UK), without counterstain, to 
provide subsequent contrast with NSE staining (red-brown). Acid a-naphthyl acetate 
esterase stain (ANAE) was prepared as follows. Hexazotized pararosaniliiie was 
freshly prepared by mixing equal volumes of 4% sodium nitrite (BDH) with 40 mg/ml 
pararosaniliiie chloride (Sigma). The leaction mixture consisted of 10 mis 0.067 M 
phosphate buffer, pH 5.0 (9.85 ml 0.067 M KH^PO^, pH 5.0 added to 0.15 ml 0.067 
M Na2HP04.2H2 0  [appendix I]), to which was added 600 pi (6%) hexazotized 
pararosaniliiie and 100 pi (1%) 25 mg/ml a-naphthyl acetate (Sigma) dissolved in 
acetone (BDH) (10 mg dissolved in 400 pi). Before use this was adjusted to pH 5.8 
by addition of a few drops of 2 M sodium hydroxide (BDH). In order to remove the 
dai’k brown precipitates which might interfere with the labelling, the reaction solution
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was briefly spun at 10,000g for 1 minute prior to addition to the samples. Sections 
were incubated with 200 pi of reaction solution for 20 minutes at 4°C in the dark, then 
washed extensively in running tap water before mounting in glycergel without nuclear 
counterstain.
2 . 6 . 3  Control Experiments
Parallel sections were stained with negative control antibodies to confirm specificity of 
primary antibody binding. Murine monoclonal primai y antibodies were controlled 
with isotype matched monoclonal antibodies of iixelevant specificity (DAKO) used at 
equivalent concentrations (Table 2.3). Similarly, equivalent concentrations of purified 
rabbit immunoglobulin (DAKO) or 20% higher concentrations of non-immune rabbit 
seram (SAPU) seiwed as controls for primary rabbit polyclonal antibodies and antisera 
respectively (Table 2.3).
Cytospin sections were pre-blocked with noiinal goat serum. Goat secondary
antibodies, which had been previously solid-phase absorbed against human
immunoglobulins, were used to reduce background staining. The secondary
antibodies utilised did not bind tissues in the absence of primai y antibodies at the
concentrations indicated in the above protocol. Streptavidin conjugates, either alone, 
or in the presence of secondary antibodies, did not bind sputum cells directly.
Neutralisation of primary antibody staining for IL-15 and iNOS was carried out.
(i) Human rIL-15 seiwed as positive control for M l 12, which was originally raised 
against simian IL-15 (Grabstein, et al, 1994), and human rIL-2 (R&D Systems) was 
used as a likely candidate for cross-reactivity, given the similar quaternary structure 
and shared receptor specificity with IL-15 (reviewed by Tagaya, et al, 1996a). A dose 
range (0.5 - 100 pg/ml) of each cytokine was used.
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(ii) Valions peptides were used to test the specificity of iNOS detection. The 
immunising human iNOS peptide YRASLEMSAL (50 pg/ml) and iNOS peptide from 
a similar area of the C-terminus of rat iNOS YEEPKATRL (50 pg/ml) were gifts from 
Dr. R.A. Mumford, Merck Research Laboratories, USA. Recombinant human eNOS 
(50 pg/ml) was donated by Dr. I. Charles, Wellcome, UK. Primai"y antibodies were 
incubated with or without peptide / recombinant protein, either overnight at 4°C, or for 
2 hours at 37°C, in 10% NGS / PHS in TBS, pH 7.36, before addition to sections for 
subsequent staining as described (section 2.6.1).
2 . 6 . 4  Photo-m icrography
Photo-micrographs were obtained using an Orthoplan photo-microscope (Leitz, 
Germany) in tlie Medical Illustration Department, GRI. Colour prints were made on 
EKTAR 25 film (Kodak, UK), and in some experiments, 35mm colour slides were 
made with Ektachrome 64T film (Kodak) and colour prints were subsequently 
developed commercially.
2 .7  Animal Model of Inflammation
2 . 7 . 1  Induction of collagen induced arthritis (CIA) in mice
Collagen Induced Aithiitis (CIA) is a widely used experimental model of polyarthritis. 
It can be induced in susceptible strains of mice which express the H-2"‘ haplotype by 
immunisation with type II collagen (CII) and has histopathologic features in common 
with rheumatoid arthritis (Trentham, et al, 1977). Male DBA/1 mice (6-8 weeks old, 
Harlan Olac, UK) were obtained for use in this study. Animals were housed in the 
Joint Animal Facility, University of Glasgow, in accordance with the UK Home 
Office animal care guidelines. Mice were quarantined for 7 - 1 0  days before the study 
began.
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Bovine type II collagen (Sigma) was solubilised at 4 mg/ml in 0.0 IM acetic acid at 
4”C overnight. Next day collagen was emulsified in an equal volume of freshly 
prepared Freund’s complete adjuvant (Difco, Detroit, MI) supplemented with 5 mg/ml 
of heat killed Mycobacterium tuberculosis, H37RA (Difco). The DBA/1 mice were 
immunised intraderm ally by two injections at the base of the tail with a total of 100 pi 
of emulsion (CII; 200pg). At day 21 the animals were boosted with an 
intraperitoneal (i.p.) injection of 200 pg collagen in PBS. A gradual onset of 
arthritis was observed 7 - 1 0  days after the i.p. booster and animals were observed for 
up to 8 weeks for the development of arthritis.
2 . 7 . 2  Anti-cytokine treatment of CIA
To investigate the role of IL-15 in CIA, soluble IL-15 receptor alpha (sIL-15Ra) was 
administrated to collagen primed DBA/1 mice. sIL-15Ra was kindly provided by Mr. 
H. Ruchatz (Dept, of Immunology, University of Glasgow), it was expressed in E. 
coli M15 strain (Qiagen, Dorking, UK) and purified as 6x Flistidine-tagged fusion 
protein using a Nickel agarose purification system (Qiagen). The protein consisted of 
193 amino acid residues, 173 of which contained the “Sushi” domain, linker and 
Pro/Thr rich region of the native sIL-15Ra. The level of endotoxin contamination 
was less than 0.003 I.U. (< 6 pg/mg) of purified protein, as measured by Limulus 
amoebocyte lysate assay (E-toxate, Sigma). DBA/1 mice were injected 
intraperitoneally with (40 pg/animal, n = 60) of sIL-15Ra from day 22 for a period of 
14 days. As control, the same amounts of human serum albumin (HSA, Sigma) were 
given in a parallel study (n -  30).
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2 . 7 . 3  Monitor of progression of CIA
Arthritis progression was monitored daily using the following criteria: 
incidence of arthritis 
weight change
number of limbs involved / mouse
footpad / inter alveolar diameter - calliper measurement (Kroeplin, Germany) 
ai'ticular index - 3 points / limb, total 12/ mouse derived as follows by a 
treatment blinded observer: 
erythema alone (1) 
swelling and erythema (2)
erythema, swelling, and extension / loss of function (3)
2 . 7 . 4  Quantification of histology
At the end of the experiments hind limbs were removed above the knee and 
immediately fixed in 10% neutral buffered formalin for at least 72 hours. Paws were 
decalcified in 5% HNO3 for a further 72 hours, then 6 pm sections were cut using a 
bone cryostat (by Mr. P. Kerr, Dept, of Pathology, University of Glasgow). Sections 
were stained with haematoxylin and eosin using the standard method of the Dept, of 
Pathology, Western Infrmary, University of Glasgow. Quantification of arthritis was 
performed by two treatment-blinded observers (Dr. I. Mclnnes and the author) using 
scoring system described by (Joosten, et al, 1997). Briefly, tiie extent of 
inflammation, synovial hyperplasia and joint erosion were graded separately. For 
synovial infiltration and hyperplasia, a scale of 0-3 was established according to the 
amount of inflammatory cells in the synovial tissue. Joint destruction was scored on a 
scale of 0-3, ranging from ai^ ea with dead chondrocytes to complete loss of die 
articular cartilage. Scores were pooled and means ± SD were obtained.
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2 . 7 . 5  Measurement of serum anti-collagen antibodies
Serum anti-collagen II antibodies titres in pooled sera (N=5) obtained at the end of 
sIL-15Ra U’eatment were measured by ELISA. Briefly, 96-well micro-ELISA plates 
(Immulon 4, Dynatech, Succex, UK) were coated with 4 pg/ml bovine type II 
collagen in O.IM NaHjCOg overnight at 4°C, blocked with PBS/10% PCS and serial 
dilutions of sera were added. Bound total IgG was detected with HRP-conjugated goat 
anti-mouse IgG (Genzyme) or biotin-conjugated anti-mouse IgGl or IgG2a (2 pg/ml, 
PharMingen, CA, USA) respectively, and developed as section 2.9.2. Plates were 
read at 630nm.
2 .8  RT-PCR for mRNA expression in clinical samples
Induced sputum cells, synovial lluid T cells and neutrophils were pelleted by 
centrifugation at 450g for 5 minutes, immediately resuspended in 400 pi RNAzoF^ 
(Biogenesis, Bournemouth, UK) and were also snap frozen and stored at -70^C. 
Reverse transcription-polymerase chain reaction (RT-PCR) was performed as 
previously described (Kawasaki, 1990).
2 . 8 . 1  RNA extraction
Total mRNA was extracted using RNAzoF’^  (Biogenesis) as described (Chomczynski 
& Sacchi, 1987). Frozen cell pellets were disrupted in 400 pi RNAzol using a P I000 
Gilson Pipette. To this was added 40 pi chloroform (Sigma) followed by shaking foi­
ls seconds and rest on ice for 5 minutes, before centrifugation at 12,000g for 15 
minutes at 4°C. The aqueous phase was added to an equal volume of isopropanol 
(Sigma), rested at 4°C for 15 minutes, then spun at 12,000g for 20 minutes at 4°C. 
The pellet was resuspended in 800 pi ice-cold 75% ethanol, spun at 12,000g for 8 
minutes, dried under vacuum for 10 minutes, then resuspended in 20 pi distilled
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water. RNA concentration was determined by its optical density at 260nm and 280nm 
(Sambrook, et al, 1989) per the following formula:
- [(62 X odjgo) - (36 X odjgo)] x dilution of sample = “RNA” pg/ml
2 . 8 . 2  cDNA preparation
cDNA was prepared using the following mixture: 0.5 pi 40 I.U./pl RNasin RNase
inhibitor, 2 pi containing 0.5 pg random primer, 4 pi 5x RT buffer (375 mM KCl, 15
mM MgClj, 250 mM Tris-HCl, pH 8.3), 2 pi containing 0.25 pM of each dNTP, 2 pi 
10 mM DTT (all Promega, Southampton, UK) and 1 pi containing 200 units Moloney 
murine leukaemia virus reverse transcriptase (Gibco BRL). 2 pg RNA in 8.5 pi was 
heated to 90°C for 5 minutes, cooled on ice then added to the above mixture giving a 
final volume of 20 pi. After sitting at room temperature for 10 minutes, the reaction 
was performed at 37‘^ C for 1 hour.
2 . 8 . 3  Polymerase Chain Reaction (PCR)
PCR was performed as follows. 2 pi of tlie above reverse transcription reaction 
mixture (approximate 0.1 pg cDNA) was mixed with 10 pi lOx reaction buffer (500 
mM KCl, 15 mM MgCl^, 0.01% gelatine, 100 mM Tris-HCl pH 8.3), 2 pi containing 
0.2-0-3 pM of each primer, 4 pi containing 40 pM of each dNTP (Promega), and was 
then made up to 99.5 pi with water. This mixture was heated to 95"C for 5 minutes 
then cooled on ice before addition of 0.5 pi Taq DNA polymerase (Promega) and was 
overlaid with 50 pi mineral oil (Sigma). A Techne PHC-3 Dii-Block Cycler was 
programmed to give the desired cycle conditions detailed below with respective 
primers used. After the PCR, 20 pi of the reaction product was visualised by 
elecU'ophoresis on 1% (w/v) agarose gel containing 0.5 pg/ml ethidium bromide 
(Sigma) with a DNA 1 kb ladder (Gibco BRL).
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Oligonucleotide primers specific for human iNOS were a gift from Dr 1. Charles 
(Wellcome, Beckenham, UK) - 5’-GCCTCGCTCTGGAAAGA-3’ and 5’- 
TCCATGCAGCAACCTT-3’ and were used to amplify a 500 bp fragment. Human 
chondrocyte iNOS cDNA (Dr I. Charles) and p-actin oligonucleotide primers - 5'- 
CCACACTGTGCCCATCTACGAGGGGT-3’ and 5’-AGGGCAGTGATCTCCTTC 
TGCATCCT-3’ (Genosys, Cambridge, UK) were used as internal controls. Reaction 
conditions for iNOS and P-actin PCR amplification were 95°C (35 secs), 55°C (60 
secs), 72°C (120 secs) for 35 cycles. The double nucleotide sequence of the PCR 
product was derived by Dr X.Q, Wei (Dept, of Immunology, University of Glasgow) 
and found to be identical to that predicted from human chondrocyte iNOS (Charles, et 
al 1993; Genbank database No X73029). Oligonucleotide primers specific for human 
IL-15 receptor alpha chain (hlL-15Ra) were kindly provided by Dr. D.M. Anderson 
(Immunex Corp.). The two primers designed to amplify a 305 bp fragment that 
would include the entire transmembrane and cytoplasmic coding domain plus an 
addition 100 bp of 3’ non-coding sequence. The sense primer - 5’- 
ACACCACTGTGGCTATCTC-3’, which corresponds to nt 690-708 of GenBank 
U31628 and the anti-sense primer - 5’-GGTGAGCTTGCTCCTGGAG-3’, 
coiTesponds to the complement of not 977-995 of GenBank U31628.
2 .9  Cytokine assays
2 . 9 . 1  Ï L 1 5  ELISA
A commercial sandwich enzyme linked immunosortent assay (ELISA) was employed 
to detect IL-15 in biological fluids (R&D Systems). 96-well micro-ELISA plates 
(Immulon 4, Dynatech) were coated with 2 }ig/ml mouse monoclonal anti-human IL- 
15 (MAB647) in bicarbonate coating buffer (O.IM NaH^COg, pH 8.2) overnight at 
4°C, using a working volume of 100 pi. Plates were washed twice with PB S/0.05 % 
Tween 20 (PBS/Tween) and blocked with 200 pi 10% heat-inactivated PCS in PBS
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for 2 hours at room temperature (RT). After two washes with PBS/Tween, 100 pi !
' I
aliquots of standard and samples (synovial fluid was diluted 1/4 in PBS/Tween) were |
added and incubated at RT for 2 hours. After four washes with PBS/Tween, bound i
IL-15 was detected using 100 pi biotinylated mouse anti-human IL-15 (BAM247) 
diluted to 200 ng/ml in PBS/10% PCS and incubated for 2 hours at RT. Plates were 
washed six times and 100 pl/well of peroxidase conjugated extravidin (Sigma), diluted
1:1000 in PBS/10% PCS was added and incubated for further 30 minutes at RT.
After eight final washes, plates were developed with 100 pi TMB Microwell 
Peroxidase Substrate (Kirkegaard & PeiTy Laboratories, MA, USA) and the optical 
density read at 630 nm in an automated plate reader (MR5000 ELISA reader, j
Dynatech). The lower limit of detection of this assay was 1.5 pg/ml (Pig. 3.1a).
Similar results were obtained by replacing the primary antibody MAB647 with sIL- 
15Ra (2 pg/ml) as a source of “capture” anti-cytokine. Lower level of sensitivity was 
5 pg/ml (Pig. 3.1b).
2 . 9 . 2  Removal of Rheumatoid factors
Although IL-15 can be detected within the synovial lining layers in rheumatoid patients 
(Mclnnes, et al, 1996b; Thurkow, et al, 1997), the precise levels presence within 
synovial fluid remains controversial. It has been suggested that the contaminating 
rheumatoid factors (RP) could (jo'ifk the quantification of IL-15 within synovial fluids 
(Carson, 1997). RP are antibodies directed against the chai ged tertiary structure of the 
IgG Pc fragment. They occur in all immunoglobulin classes including IgM, IgG and 
IgA. Thus, RP can potentially “cross-link” the primary antibody with the detecting 
antibody, giving rise to false positive results. In order to eliminate this possibility, RP 
were removed from synovial fluid using y-globulin coated polystyrene beads (RapiTex 
RP, Behring, Milton Keynes, UK). Briefly, 100 pi of synovial fluid was incubated 
with equal volume of y-globulin coated polystyrene beads at RT for at least 30 minutes 
in an eppendorf tube with constant shaking. After centrifugation (10 min, 13,000 g)
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theclaiified supernatant was collected, diluted with equal volume of PBS/Tween and 
IL-15 was assayed as described above. The author observed removal of RF did not 
significantly alter the results obtained by the above ELISA system, thus, levels of IL- 
15 detected within synovial fluid in this study are unlikely due to RF interference.
2 , 9 . 3  General ELISA protocol
Human TNFa and murine TNFa, IFN-y, IL-4, IL-6 and IL-10 were detected in 
culture supernatants or biological fluids by ELISA, with paired capture and 
biotinylated detection monoclonal antibodies for each cytokine (PharMingen). 
Imraunolon 4 micro-ELISA plates were coated overnight at 4°C with capture 
monoclonal antibody at 2 pg/ml in bicarbonate coating buffer. Wash steps were 
performed as described above. Plates were blocked with PBS/10% PCS for 2 hours, 
incubated with test samples, or twofold standard dilutions of recombinant cytokine (10 
ng/ml - 10 pg/ml) in triplicate for 2 hours, and bound cytokine was detected for 1 hour 
with 1 pg/ml biotinylated detection monoclonal antibody diluted in blocking buffer. 
Peroxidase-conjugated extravidin was added for 45 minutes (1:1000; Sigma), 
developed with 100 pi TMB Microwell Peroxidase Substrate (Kirkegaard & Peiry 
Laboratories, MA, USA) and the plate was read at 630nm as above. Modifications for 
the other cytokines: human IL -la  and IL-8, coating: 2 pg/ml murine monoclonal 
antibodies (Genzyme); second antibodies: polyclonal rabbit anti-human IL -la  or IL-8 
(both at 1 pg/ml); and peroxidase-conjugated donkey anti-rabbit IgG (1:1000, Jackson 
Immuno-research Lab, West Grove, PA). The lower limit of detection in each assay 
was as follows:-
mTNPa 10 pg/ml hTNPa 10 pg/ml
mIPN-y 80 pg/ml hIL -la 5 pg/ml
mIL-4 20 pg/ml hIL-8 40 pg/ml
mIL-6 20 pg/ml
mIL-10 80 pg/ml
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2 .10  NO measurement
Nitiic oxide (NO) production may be estimated by measuring the concentration of its 
oxidative products, nitrite or nitrate anion (Archer, 1993).
2.10 .1  Griess reaction
This is a colorimetiic assay for nitrite concentration (Green, et al, 1982). Reagents 
were prepared as follows: solution A - 0.1% a-naphthyl-amine (Sigma) in distilled 
water and solution B - 1% sulfanilamide (Sigma) in 5% phosphoric acid (Sigma). 
Both were stable stored in the dark at 4°C for 2 months. The Griess reagent was 
obtained by mixing equal volumes of solution A and B immediately prior to use. A 
sodium nitrite stock solution (10 pg/ml. Sigma) was diluted twofold to provide a 
standard curve (72.5 nmol/ml - 1 nmol/ml). The assay was performed in triplicate, by 
placing 50 pi of either test culture supernatant, or standard dilutions of nitrite in 
identical medium, into a flat-bottom 96 well plate, after which 50 pi Griess reagent 
was added to each well. The plate was incubated for 10 minutes at room temperature 
in the dark, and thereafter, the colorimetric reaction was measured at 570nm 
(reference filter at 630 nm) in an MR5000 ELISA reader (Dynatech) and the test nitrite 
concentration estimated from the stand aid curve. The lower limit of sensitivity was 2 
nmol/ml.
2 . 10 .2  Chemiluminescence assay for nitrite / nitrate
The presence of high protein concentrations in serum and synovial fluid leads to 
precipitation in the acid pH environment of the Griess reaction. This may interfere 
with colorimetric assessment, therefore, a chemiluminescent assay for nitrite was also 
used (Aoki, 1990; Palmer, et al, 1987). A reflux reaction was created by continuously 
boiling 75ml glacial acetic acid (BDH) with 25ml 6% sodium iodide (BDH) in a 250ml
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Pyrex reaction flask, through which was passed a low flow of nitrogen gas. 50 pi of 
test sample, or standard nitrite solution prepared as above, was injected directly into 
the leaction flask using a Hamilton syringe (Sigma). in tlie sample is
immediately reduced to NO*, which is carried in gaseous phase through a condenser 
and a cold trap, created with a glass U-tube surrounded by “dry ice” to remove acetic 
acid vapour, and on to a chemiluminescence NO analyser (Dasibi Environmental 
Corporation, Japan). NO reacts with ozone causing photoemission which may be 
detected and converted to a digital readout. The photomultiplier signal is proportional 
to the nitrite concentration in the original sample, allowing the generation of a standard 
curve and estimation of nitrite concentration in test samples. Sensitivity for this assay 
was 2 nmol/ml nitrite.
Nitrate concentration in biological fluids may be estimated by first reducing nitrate to 
nitrite using the enzyme nitrate reductase (Sigma). To measure 50 samples, reaction 
buffer was prepared as follows: 500 pi 5 mg/ml NADPH (Sigma), 500 pi 4.15 mg/ml 
FAD (Sigma), 500 pi KH^PO^, pH 7.5, 950 pi distilled water and finally, 50 pi 34 
rag/ml nitrate reductase, immediately after which 30 pi reaction buffer was added to 30 
pi sample in a flat-bottom 96 well plate. The reaction was incubated at 37°C for 2 
hours, after which nitrite produced was measured by chemiluminescence as described 
above. Standard curves for sodium nitrite and sodium nitrate were included in the 
reductase reaction to provide a control for the efficiency of the reduction. This was 
calculated for the conversion of 100 pM sodium nitrate to sodium nitrite as shown 
below and was routinely >75%.
Nitrate reduction (%) = x 100(ppb nitrate)
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2 .1 1  Statistical Analysis
Data were collated and statistical analyses performed using Minitab software for 
Macintosh. Means were compared using either a two-tailed student's t-test or the 
Mann-Whitney test. Paired data were compared using the paired student's t-test, or 
using Wilcoxon's signed sum of ranks test. Spearman rank conelation test was used 
to coiTelate cytokine levels in synovial fluid. Significance was accepted at p<0.05.
87
*K- •++
D
LA
I
O
I
01
ts>
LA
erao
I
i
i I
GO Ch1 o
1
I
""OI
to
I
I
LA
II
S
g
g
OQatopo
I
I
toLaO
Ei
1
X3I
p .
g  g?I
T3t
o
I
•X -
Iuo
g9
I
g-a*1 1 1
13I
p
O
I
&
go
>§•
GOIgc«
H
CD
ll§
GOI
..S'
Table 2.2 Secondary antibodies used in immunohistochemistry
Host Antibody Specificity Conjugate Concentration Source
species
Goat polyclonal mouse biotin  ^ 4 DAKO
immunoglobulins
Goat polyclonal rabbit biotin 3 pg/ml DAKO
immunoglobulins
Table 2.3 Negative control antibodies for immunohistochemistry
Host species Antibody type Specificity Source
Mouse
Mouse
Rabbit
Sheep
Sheep
IgGl
IgG2a
Serum
Serum
Aspergillus niger 
glucose oxidase * 
Aspergillus niger 
glucose oxidase  ^
Non-immune
Non-immune
Immunoglobulin - Non-immune 
affinity purified
DAKO
DAKO
SAPU
SAPU
Sigma
* neither constitutively nor inducibly expressed in mammalian cell systems.
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Chapter 3
Interleukin-15 mediates T cell dependent 
regulation of tumour necrosis factor a
90
Introduction
Interleukin-15 (IL-15) is a novel cytokine with biological functions similar to those of 
IL-2 but with no significant amino acid sequence homology. IL-15 is derived from 
several cell types, including macrophages and fibroblasts (Grabstein, et al, 1994; 
Burton, et al, 1994). It uses the IL-2 receptor p and common y  chain subunits, 
together with an unique a-chain, IL-15Ra (Giri, et al, 1995), through which it 
induces T cell chemotaxis and activation together with B cell maturation and isotype 
switching (Wilkinson & Liew, 1995; Ai'mitage, et al, 1995). It enhances NK cell 
cytotoxicity and cytokine production, activates neutrophils and modifies monokine 
secretion (Carson, et al, 1995; Girard, et al, 1996; Alieva, et al, 1997). Thus IL-15 
potentially mediates diverse effects at multiple stages of the immune response.
Rheumatoid arthritis (RA) is a chronic, presumed autoimmune disease chaiacterised 
by synovitis associated with adjacent cartilage and bone destruction. The pathologic 
lesion consists of extensive infiltration of the synovial membrane by T lymphocytes, 
which aie mainly of the CD45RO"  ^ “memory” phenotype, plasma cells and 
macrophages, together with the presence of activated fibroblast-like synoviocytes 
(Duke, et al, 1982). Within the synovial membrane, high levels of pro-inflammatoiy 
cytokines aie detectable, including TNF-a, IL-1, IL-6, IL-8 and GM-CSF 
(Feldmann, et al, 1996), leading to the suggestion that RA is predominantly a 
“macrophage-led” process (Firestein & Zvaifler, 1991). T cell-derived cytokines such 
as IFN-y, IL-2 and IL-4 may be detected at the mRNA and protein level but aie only 
found with low cellular frequency (Simon, et al, 1994; Dolhain, et al, 1996, Kotake, 
et al, 1997). Together, these observations have raised questions as to the functional 
contribution of T lymphocytes in RA.
Recent studies in our laboratory have revealed several functional properties of IL-15 
with potential relevance to rheumatoid pathogenesis. These include promotion of
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inflammatory cell recmitment in vivo following footpad injection in mice primed with 
either C. Parvum or type II bovine collagen and in chemotactic assays in vitro, 
induction of human T cell polarization and invasion into collagen gels (Wilkinson & 
Liew, 1995; Mclnnes, et al, 1996b). Responding migratory T cells are mainly of the 
CD45RO+ phenotype (Al-Mughales, et al, 1996). IL-15 can be identified immune- 
chemically in RA synovial membrane and RA synovial fluid (SF) contains potent 
chemotactic activity attiibutable, at least in pait, to the presence of IL-15 (Mclnnes, et 
al, 1996b; Al-Mughales, et al, 1996). Moreover, RA peripheral blood T cells exhibit 
enhanced proliferative responses to rIL-15 compai'ed with T cells from normal 
controls. These data strongly suggest that IL-15 plays a critical role in T cell 
recruitment and activation in RA in the relative absence of IL-2.
The relationship of IL-15 to other cytokines in the RA synovial membrane is cuiTently 
unclear. Studies in animal models and of synovial tissue in vitro have shown that 
macrophage-derived TNF-a is a key factor in the inflammatory processes occurring in 
RA (Feldmann, et al, 1996). TNFa appears pivotal in regulating synthesis of other 
pro-inflammatory cytokines, particularly IL-lp, which in turn is important in 
enhancing chondrocyte bioactivity and the production of matrix metaUoprotemases 
(MMP) (Dayer, et al, 1986; Ai*end & Dayer, 1995). These observations formed the 
basis for successful clinical trials of anti-TNF-a antibody in RA, thereby confirming 
the importance of TNF-a (Elliot, et al, 1994; Rankin, et al, 1995; Moreland, et al, 
1997). Those mechanisms promoting monocyte / macrophage production of TN F-a 
in RA joints are not yet understood, but will likely provide rich therapeutic potential. 
Following mitogen stimulation in vitro, T lymphocytes can induce macrophage 
production of cytokines and MMP by cell-contact (Vey, et al, 1992; Lacraz, et al, 
1994). The identification of IL-15 in RA where it apparently serves as a T-cell 
activation factor, provided the opportunity to test the hypothesis that a similar T cell- 
contact-mediated macrophage activation pathway might operate in the context of RA.
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The cuiTent studies were performed to address the possibility that IL-15-activated T 
cells might regulate monocyte TNF-ct production. Furthermore, as human and murine 
monocytes have been shown to express IL-15 following activation with conventional 
stimuli (Carson, et al, 1995; Doherty, et al, 1995), the ability of T cells to costimulate 
monocyte IL-15 production via cell-contact was investigated. These studies suggested 
that IL-15-activated synovial T cells, can exert pro-inflammatory effects through a cell- 
contact dependent mechanism, in the absence of local antigen recognition or cytokine 
secretion. They further raise the possibility that a positive autoregulatory loop exists 
involving both TNF-a and IL-15.
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3 .1  Assays employed for IL-15 detection and quantification in  
biological fluids
A commercial sandwich ELISA was employed to detect IL-15 in biological solutions, 
using a murine monoclonal anti-human IL-15 antibody (MAB647) for capture and a 
biotinylated mouse anti-human IL-15 (BAM247) for detection. The lower limit of 
detection of this assay was 1.5 pg/ml (Figure 3.1a). To further investigate the 
specificity of “IL-15” detection in RA synovial fluid (SF) and serum samples, the 
primary “capture” antibody was subsequently replaced by murine soluble IL-15 
receptor alpha (sIL-15Ra, kindly provided by Mr. Holger Ruchatz, Department of 
Immunology, University of Glasgow). This assay demonstrated specific binding of 
recombinant human IL-15 with a lower detection limit of 5 pg/ml (Figure 3.1b). 
Recombinant human IL-2, IL-1, TNFa, IFN-y and purified IgG were not detected in 
the latter ELISA system.
3 .2  Detection of IL-15 in SF
Although IL-15 has been reproducibly detected immunochemically within the synovial 
membrane of RA patients (Mclnnes, 1996b; Thurkow, et al, 1997), the precise levels 
present within SF remains controversial. Synovial fluids were therefore collected 
from 53 RA patients. IL-15 was detected in 30/53 RA SFs in the range 10-1128 
pg/ml (median of positive samples 198 pg/ml) by ELISA using paired murine 
monoclonal antibodies (BAM247 & MAB647). Next, matched synovial fluid and 
serum samples consecutively acquired in the clinic from 18 RA patients were 
compared. SF was found to contain significantly higher levels of IL-15 than serum iii 
matched samples (185.6 ± 43.4 vs 86.8 ± 26.1, p<0.005, Figure 3.2a), although it 
was of interest that IL-15 was detected even in some sera. Since TNF-a has been 
reported to be present in large quantity in SF of RA patients (Feldmann, et al, 1996), 
levels of non-receptor bound TNF-a were determined in these samples. SF contained
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significantly higher concentrations of TNF-a than serum samples (260 ± 65.5 vs 
127.7 ± 42.9, p<0.005). Moreover, Figure 3.2b shows that the concentration of IL- 
15 and TNF-a in SF, was significant coirelated (p<0.005, Spearman’s rank test), 
suggesting a possible link between the two cytokines.
It was possible that rheumatoid factor (RF) could render the quantification of IL-15 
within SF inaccurate (Carson, 1997 ). RF are antibodies directed against the charged 
tertiaiy structure of the IgG Fc fragment and may be of any immunoglobulin class 
including IgM, IgG and IgA. Thus, RF could potentially “cross-link” the primary 
antibody with the detecting antibody, giving rise to false positive results in ELISAs. It 
was important to investigate this possibility prior to seeking IL-15 in routinely 
acquired SF. RF were therefore removed from SF from 29 RA patients and IL-15 
levels were compared prior to and after RF removal using both ELISA systems. 
Figure 3.3 shows that the concentration of IL-15 present within SF was similai* in the 
presence or absence of RF test, p<0.001).
Moreover, SF samples with intermediate to high levels of RF (n=12) were artificially 
“spiked” with recombinant IL-15, then submitted to the commercial ELISA - the 
recovery rate observed was between 90 - 102% (Table 3.1). Together, these results 
demonstrate not only the specificity of the IL-15 detection system, but cleaily indicate 
that IL-15 is detectable in RA SF.
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Figure 3.1 Standard cui-ves for IL-15 ELISA
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rIL-15 was diluted two-fold in PBS / 10% PCS and submitted to assay with (a) R&D 
IL-15 sandwich ELISA as described in section 2.9.1. Serum and synovial fluids were 
diluted in PBS / Tween then assayed as for the standard, (b) Murine sIL-15Ra is 
employed as a “captuie” antibody to confirm the specificity of IL-15 detection as 
previously described. Sensitivity was typically 1.5 pg/ml and 5 pg/ml respectively.
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Figure 3.2 Detection of IL-15 & TNF-a in RA paired samples
a
M 150
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Synovial fluid
b 1000-,
800-
p<0.005
0 100 200 300 400 500
IL-15 (pg/ml)
Serum and synovial fluids from RA patients were collected (n=18), and assayed for 
IL-15 presence by ELISA, (a) Levels in SF were significantly higher than in serum 
(p<0.001, paiied t-test), a significant conelation was also observed between detectable 
levels of IL-15 in serum and SF (p<0.005). (b) IL-15 and TNF-a levels in RA SF
were significantly coirelated (p<0.005).
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F igure  3.3 Rheumatoid factor did not affect IL-15 quantification in RA synovial 
fluids
400-
300
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Pre-incubated 
with y-globulin
100 -
Pearson = 0.937; p<0.001
200 300 4000 100
IL-15 (pg/ml)
Rheumatoid factors were removed from synovial fluids using y-globulin coated 
polystyrene beads as described in section 2.9.2. IL-15 levels in SF were then
compared prior to (x-axis) and after (y-axis) RF removal and found to be similar 
( test, p<c0.001 ).
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Table 3.1 Recoveiy of IL-15 from IL-15 “spiked” RA synovial fluids
Patient
No.
Original IL-15 
(pg/ml)
Spiked IL-15 
(pg/ml)
Recovered IL-15
(pg/ml)
% Recovery
1 53 250 243 97.2
2 350 750 720 96.0
3 1128 1500 1396 93.1
4 16 100 90 90
5 50 250 232 92.8
6 15 100 96 96
7 210 500 454 90.8
8 110 250 238 9 5 ^
9 27 100 93 93
10 482 750 713 95.1
11 526 750 683 91.1
12 127 250 255 102
RA synovial fluids were spiked with recombinant human IL-15 at concentration 
indicated above and assayed using IL-15 ELISA as before. Recovered concentrations 
were compared to expected concentrations and expressed as percent recovery.
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3 .3  IL-15-dependent up-regulation of T N F a production from  
macrophages
The functional consequences of IL-15 expression in the synovial compartment were 
next explored. Previous studies have established that peripheral blood (PB) and SF T 
cells from RA patients exhibit brisk proliferative responses to IL-15 in excess of those 
to mitogens e.g. PH A. Moreover, IL-15 directly induces TNF-a production by SF T 
cells in vitro under these conditions but not from PB T cells (Mclnnes, et al, 1997). 
However, macrophages aie the major source of TNF-a in RA synovitis (Chu, et al, 
1991b), and so the effect of IL-15 on TNF-a production by macrophages was 
investigated. Addition of IL-15 (1-100 ng/ml) to cultures of unprimed macrophage 
cell lines (U937 and THP-1) or blood-derived monocytes (n=3) from normal donors 
failed to induce TNFa production.
These data implied that in RA, IL-15 might mediate its primary effects on 
macrophages via indirect pathways. Within the RA synovial membrane, T cells and 
macrophages aie found in close proximity, and exhibit reciprocal adhesion molecule 
expression. Therefore, the possibility that IL-15-activated T cells could induce TNF- 
a  synthesis by monocytes / macrophages via cell-contact was addressed. PB T cells 
from noiTnal donors were stimulated with IL-15 or mitogen (PHA / PMA) for 72 
hours, then co-cultured in double-chamber wells, either in contact with, or physically 
separated by a semi-permeable membrane from U937 cells. TNF-a production was 
observed only in cultures in which IL-15-stimulated T cells and macrophages were in 
direct contact (Figure 3.4). As expected, PHA / PMA-stimulated T cells induced 
TNFa production in the presence or absence of co-culture (Figure 3,4). These data 
indicated that a cell-contact event between IL-15-activated T cells and macrophages 
was capable of inducing TNF-a production.
F igure 3.4 Double chamber culture of PB T and U937 cells
100
TNF (pg/ml)
U937 alone
PB T cells alone 
(medium)
pre-culture
stimuli
U937
+
PB T cells
PHA/PM A
IL-15
medium
4 0 0
T cell / macrophage cell-contact is required for IL-15-induced TNF-a production. 
PHA (1 Fg/ml) / PMA (1 nM) or IL-15 (100 ng/ml) activated PB T cells were cultured 
in contact with (solid bars), or separated by semi-permeable membrane from (hatched 
bars), unprimed U937 cells. IL-15-activated T cells required cell-contact to induce 
TN Fa production by U937 cells. Data ai'e mean ± s.e.m. of tiiplicate cultures, 
representative of 3 similar experiments.
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To clarify whether T cell cytokine production was required in addition to cell-contact, 
and to confirm that macrophages were the primaiy source of TNFa in these mixed 
cultures, T cells were fixed in 1% paraformaldehyde (PFA) before co-culture with 
macrophages. PFA fixation is known to prevent T ceU cytokine production but 
preseiwes cell-membrane integrity, thus providing a simple experimental system foi- 
investigation of cell-contact mediated effects (Vey, et al, 1992; Lacraz, et al, 1994). T 
cells from PB of nornial individuals (n=10) were therefore cultured for 72 hours with 
medium alone, cytokines or, as positive control PHA / PMA. They were 
subsequently fixed in 1% PFA, then co-cultured with U937 cells for a further 48 
hours. Preliminary experiments have established that pre-stimulation with 100 ng/ml 
IL-15 was optimal for induction of T cell-mediated macrophage activation, at a ratio of 
8:1 T cells:U937 (Mclnnes, et al, 1997).
As previously reported, PHA / PMA activated T cells consistently induced 
macrophage TNF-a synthesis in this system (Lacraz, et al, 1994). Similarly, PFA 
fixed-T cells, previously stimulated with IL-15 (100 ng/ml) induced production of 
significant concenti'ations of TNF-a by U937 cells (Figure 3.5a). In contrast, prior 
activation of T cells with IL-2 (100 ng/ml) was effective in inducing TNF-a 
production only in some dopors, and did so at lower levels (Figure 3.5a, p<0.003 vs 
IL-15-activated PB T cells, Wilcoxon). This was unlikely to be due to a dose- 
response effect, since the concentration of IL-2 used (100 ng/ml) was supra-optimal, 
and because IL-2 and IL-15 had identical induction profiles for T cell proliferation and 
polarization (Wilkinson & Liew, 1995; Mclnnes, et al, 1997). Identical results were 
obtained when highly purified autologous peripheral blood-derived monocytes (>92% 
CD 14+, <2% CD3+ by FACS analysis) were used instead of U937 cells (Figure 
3.5b), demonsti-ating that these results aie unlikely to be due to an allogeneic effect 
between T cells and macrophages. Finally, TNF-a production could be significantly 
reduced by pre-tieating PB monocytes and U937 cells with cycloheximide or
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Figure 3.5 Activated PB T cells induce TNFa production by U937 and monocytes
a
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U937 alone 
IL-15 
EL-2 
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IL-15n.-2
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XL-15-activated T cells induce TNFa synthesis by macrophages. PFA-fixed IL-15 
(100 ng/ml)-activated PB T cells from normal donors induced TN Fa production by
(a) U937 cells (n-10), or (b) autologous PB monocytes (n=3), at significantly higher 
levels than did IL-2 (100 ng/ml)-activated T cells (**p<0.003). IL-8 (100 ng/ml) or 
M IP -la  (100 ng/ml) activated T cells (n=2) were ineffective. Sensitivity of TN Fa 
ELISA was 10 pg/ml. Data are mean ± s.e.m.
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actinomycin D, inhibitors of protein synthesis and mRNA translation respectively 
(Figure 3.6 a&b), thereby confirming that macrophages were the primary source of 
cytokine synthesis in co-cultures.
3 .4  Induction of TNF-a production by cells of synovial origin
To determine whether a similar mechanism might operate in vivo in RA, freshly 
isolated SF mononuclear cells from RA patients (n=8) were immediately fixed with 
1% PFA without prior stimulation and then added directly to U937 cells. Significant 
TNF-a production was observed after 48 hours in all co-culture supernatants (Figure 
3.7a), demonstrating that synovial T cells activated in vivo can induce TN F-a 
production by macrophages through cell-contact. It was of interest to determine 
whether IL-15 was required to maintain this property of synovial T cells ex vivo. SF 
T cells were therefore cultured for 24 hours with medium alone, IL-15 or IL-2, then 
fixed with PFA, before co-culture with U937 cell as before. TN F-a was produced 
only when synovial T cells were maintained in IL-15 or, to a significantly lesser 
extent, in IL-2 (p<0.01, Figure 3.7b).
Similar results were obtained using autologous peripheral blood monocytes (instead of 
U937 cells) which were obtained from each RA patient at the time of joint aspiration 
(Figure 3.8a). To confirm that synovial macrophage TN F-a synthesis could be 
enhanced by this pathway, PFA-fixed PB T cells from 4 RA patients were added to 
autologous synovial macrophage / synoviocyte co-cultures (>75% CD68+, <3% 
CD3"^ by cytoprep analysis). TNF-a synthesis was observed only with prior 
activation of PB T cells by IL-15 (Figure 3.8b). Together, these data demonstrated 
that synovial T cell-mediated upregulation of TNF-a production by macrophages 
through cell-contact could occur in RA, and indicated that IL-15 within the synovial 
membrane enhanced this activity.
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Figure 3.6 Transcription and translation is required for cell-contact TNF-a 
production by monocytes and U937
a
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PFA-fixed activated PB T cells from normal donors were cultured with (a) autologous 
PB monocytes (n=3), or (b) U937 cells (n=3) in the absence (solid bar) or presence of 
2 lag/ml cycloheximide (dotted bar) or 2 pg/ml actinomycin D (hatched bar). 
Supernatants were collected after 48hr and TNF-a was determined by ELISA. Data 
are mean ± s.e.m, **p<0.005.
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Figure 3.7 Synovial T cells induce TNF-a production via cell contact
a
U937 alone 
SF mononuclear cells + U937
SF mononucleai' cells alone
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IL-15 is required to sustain synovial T cell-mediated cell-contact induction of TNF-a 
synthesis. PFA fixed RA SF T cells induced TNF-a synthesis by U937 cells, 
whether (a) fixed immediately (n=8), or (b) after culture for 24 hours (n=10) in the 
presence of IL-15 (100 ng/ml). Culture with IL-2 (100 ng/ml) induced significantly 
less TNFa synthesis (*p<0.01 compared with IL-15). Data are mean ± s.e.m.
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F igure  3.8 Cell contact regulates TNF-a production by blood monocytes and 
synovial macrophages 
a  TNF (pg/ml)
100 20 0  3 0 0  4 0 0  5 0 0  6 0 0
SF T alone 
PB monocytes alone 
IL-15stimulus monocytes 
+ SFT cells medium
TNF (pg/ml) 
50 100 150 200
SF adherent cells alone
PB T cells alone
” mediumstimulus 
SFAC + PBT IL-15
Blood-derived and synovial monocyte / macrophages produce TN Fa after cell-contact
activation, (a) PFA-fixed RA SF T cells activated by IL-15 (100 ng/ml) induced 
TNFa synthesis by RA blood monocytes from the same donor patients (n=3). (b) IL- 
15-activated T cells induced TNFa synthesis by synovial macrophage / synoviocyte 
co-cultures (*p<0.01). PB T cells from RA patients (n=4) were stimulated with 
medium alone or IL-15 (100 ng/ml) for 72 hours, then PFA fixed prior to addition to 
synovial macrophage / synoviocyte co-cultures. Data are mean ± s.e.m.
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3 .5  Effect of IL-15 on PB lymphocyte phenotype
The ability of single cytokines to induce cell division and to sustain cell-contact 
mediated macrophage activation suggested that those responding cells were of an in 
vivo primed, differentiated T cell subset. Thus, experiments were performed to 
characterise alterations in T cell-surface phenotype following activation with IL-15, 
compared with IL-2, on different peripheral blood lymphocyte populations. Whole 
blood cultures were employed to avoid T cell activation during purification. Both IL-. 
15 and IL-2 up-regulated CD69 expression on CD3"^ lymphocytes, which was 
detectable in whole blood cultures within 16 hours and remained present up to 72 
hours (p<0.005. Figure 3.9a). Since circulating T cells recruited to synovial 
membrane are predominantly of ‘memory’ phenotype, the effect of IL-15 on CD69 
expression in tlie CD45RO+ subset was next examined. CD69 expression was 
elevated within 16 hours, and enhanced seven-fold in CD45RO+ PB T cells by 72 
hours after addition of IL-15 in vitro (p<0.02. Figures 3.9b).
3 .6  M olecules involved in T lymphocyte / m acrophage cell-contact
Many surface receptors have been implicated in T cell / macrophage membrane 
contact, including the LFA-1 and CD69 (Vey, et al, 1992; Isler, et al, 1993). The 
contribution of these markers to tlie production of TNF-a by monocytes after contact 
with IL-15-activated T cells was therefore investigated using neutralising monoclonal 
antibodies. TNF-a production by PB T cell / U937 co-cultures (n=4) was 
significantly reduced by neutralization of LFA-1 (p<0.02) or ICAM-1 (p<0.03) and 
almost completely abrogated by addition of anti-CD69 antibody (p<0.001. Figure 
3.10a). Paiallel experiments (n=4) demonstrated similar involvement of CD69 
(p<0.001), LFA-1 and ICAM-1 (both p<0.01) on the production of TNF-a by blood- 
derived monocytes induced by IL-15-activated T cells (Figure 3.10b). In contrast an 
isotype-matched murine monoclonal antibody of iirelevant specificity at identical
s i
108
Figure 3.9 FACS analysis of PB T cells following cytokine induced activation
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IL-15 up regulates expression of CD69 on PB T cells, (a) CD69 expression on CD3^ 
PB T cells stimulated with IL-15 (100 ng/ml), or IL-2 (100 ng/ml) in vitro for 72 
hours (n=6, **p<0.005 compared with medium alone), (b) CD69 expression was 
enhanced in CD45RO^ T cells up to 72 hours (*p<0.02, **p<0.002 compared to 
medium alone) by addition of IL-15 (100 ng/ml) or IL-2 (100 ng/ml) in vitro. N o  
significant difference between IL-15 and IL-2 was detected. Data are mean ± s.e.m.
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Figure 3.10 Inhibition of T cell / macrophage activation by neutralising antibodies
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Inhibition of cell-contact induced TNFa synthesis by antibodies to cell surface 
markers. PFA-fixed IL-15-activated PB T cells were cultured with (a) U937 cells, or 
(b) PB monocytes. Pre-incubation of the fixed T cells with neutralising antibodies to 
CD69, LFA-1 or ICAM-1 significantly inhibited TNFa synthesis compaied to IgGl 
control antibody U'eated cells (*p<0.001, **p<0.03, "^**p<0.01). Polyclonal human 
IgG (5 pg/ml) was present in all cultures to block Fc binding. Data are mean ± s.e.m. 
from four separate experiments.
% inhibition was calculated as follows:
100 { - Gt synthesis with neutralising antibody present) ^
(TNF - a  synthesis without neutralising antibody)
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concentration failed to block the effects of IL-15 on cell-contact mediated TNF-a 
production. Thus, at least CD69 and the LFA-1 / ICAM-1 pathway were implicated in 
IL-15-activated T cell-mediated macrophage activation.
3 .7  T cells stimulated with IL-15 induce monocyte production of 
IL-15
Human and murine monocytes have been shown to express IL-15 in response to LPS, 
mycobacteria, or Toxoplasma gondi (Carson, et al, 1995; Doherty, et al, 1995). 
However, the mechanisms involved in inducing monocyte production of IL-15 in RA 
synovium are not yet understood. The ability of T cells to costimulate monocyte IL-15 
production was therefore investigated.
PB T cells purified from normal donors were stimulated with IL-15 as described 
above, then fixed in 1% PFA and co-cultured with either autologous PB monocytes 
obtained from the same donor or U937 cells. Whereas unstimulated T cells did not 
induce monocyte IL-15 production, T cells pre-stimulated with IL-15 (100 ng/ml) 
induced significant IL-15 production by macrophages after 48 hours culture in three of 
eight experiments (Figure 3.11a). This IL-15 production by PB T-cell / monocyte or 
U937 co-cultures (n=3) could be significantly reduced by neutralisation of LFA-1, 
ICAM-1 or CD69 (p<0.05), suggesting that T cells costimulation of IL-15 is in part 
mediated via these molecules. In addition, IL-15 production could be significantly 
inhibited by pre-treating monocytes or U937 ceils with actinomycin D or 
cycloheximide (Figure 3.11 b&c), thereby excluding the possibility that shedding of 
previously added rIL-15 could explain the observations. Moreover, IL-15 synthesis 
was also induced by PHA / PMA activated T cells in which no iiL-15 was added.
I l l
Figure 3.11 Activated PB T cells induce IL-15 production by monocytes and U937 
cells
I  Monocytes 
^  U937
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Anti-ICAM-1
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(a) IL-15 activated PFA-fixed PB T cells induced IL-15 synthesis by U937 cells or 
monocytes from the same donor (n=3). Pre-incubation of the fixed T cells with 
neutralising antibodies to CD69, LFA-1 or ICAM-1 significantly inhibited IL-15 
synthesis. IL-15 synthesis was significantly reduced by cycloheximide or 
actinomycin D (n=2) when PFA-fixed IL-15-activated PB T cells were cultured with
(b) PB monocytes, or (c) U937 cells, indicating that transcription and Uanslation was 
required. Data are mean ± s.e.m., *p<0.05, **, p<0.005.
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3 .8  Induction of IL-15 production by cells of synovial origin
To assess whether a similar mechanism might operate in RA, SF T cells from RA 
patients (n=5) were cultured either in medium alone or with IL-15 (100 ng/ml) for 48 
hours, then fixed in PFA before addition to autologous synovial monocyte / fibroblast 
co-cultures. IL-15 synthesis was induced only by IL-15-activated synovial T cells but 
not by unstimulated controls. This confirmed that stimulated SF T cells expressed cell 
surface molecules which could tiigger SF adherent cells to produce IL-15 (Figure 
3.12) and indicated tliat IL-15 could thereby pai’ticipate in its own up-regulation 
through this cell contact dependent pathway leading to a positive feedback loop.
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Figure 3.12 Synovial T cells induce IL-15 production via cell contact
Control
Cell-contact SFT
SFT/lL-15
SF Ad. cells THP-1
IL-15 (pg/ml)
IL-15 activated, PFA-fixed RA SF T cells induced IL-15 synthesis by SF adherent 
cells from the same donor (n=5). Lower levels of production were observed with 
U937 and THP-1 cocultures (n=5). Data are mean ± s.e.m.
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D iscu ssion
The inflammatory cytokines TNF-a, IL-lp, IL-6, IL-8 and GM-CSF are considered 
major participants in the cytokine network in RA (Feldmann, et al, 1996). Data from 
collagen-induced animal aithritis models (Williams, et al, 1992) and from recent 
clinical trials in RA patients (Elliott, et al, 1994; Rankin, et al, 1995; Moreland, et al, 
1997) indicate that TNF-a occupies a pivotal position in the regulation of synovial 
inflammation. However, the factors which up regulate TNF-a production in RA 
remain unclear. Data presented here demonstrate that IL-15 is critical in this process.
IL-15 was detected by ELISA in RA synovial fluids at significantly higher levels of 
than in serum in matched samples. This activity coiielated with SF TN F-a 
concentrations and remained after removal of rheumatoid factor. IL-15-induced 
proliferation and direct TNF-a production in T cells derived from synovial fluid is 
enhanced compared to those from blood, showing that T cell responsiveness to IL-15 
was upregulated in vivo (Mclnnes, et al, 1997). However, T cells represent only a 
minor source of TNFa compared with macrophages in RA synovium (Chu, et al, 
1991b). A number of studies (Vey, et al, 1992; Isler, et al, 1993; Lacraz, et al, 1994), 
have shown that monocytic cells secrete IL -lp, TNF-a and MMPs in response to 
signals mediated by contact with activated T cells. Moreover, it has been suggested 
that cell-contact mediated activation of T helper cell subsets as they transmigrate may 
be a step in the priming of T cells for the effects of cytokines and growth factors 
within inflammed tissue (St Louis, et al, 1993).
IL-15-activated PB T cells induced significant TNF-a production from either 
unprimed U937 cells, autologous blood-derived monocytes, or RA synovial 
macrophage / synoviocyte cultures, by a cell-contact dependent mechanism, which 
could be inhibited by pre-treatment with actinomycin D or cycloheximide. Thus, 
freshly recruited IL-15-activated T cells may contribute to TNF-a synthesis by
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activating macrophages within the synovial membrane. Furthermore, freshly isolated 
SF T cells behaved like IL-15 activated PB T cells, indicating that this pathway likely 
operates in vivo in RA. IL-15 was required to maintain this activity in vitro, because 
synovial T cells cultured in the absence of IL-15 for 24 hours lost this ability. Thus, 
synovial T cells under the control of IL-15 are clearly able to activate monocytes to 
produce TNF-a. Significantly, recent recruited CD 14+ monocyte / macrophage 
constitute the major source of TNF-a in the synovial membrane (Chu, et al, 1991b).
The next critical question was to determine which factorsregulate IL-15 synthesis. 
Despite the widespread expression of IL-15 mRNA in a variety of cell and tissue 
types, including placenta, kidney, lung, liver, fibroblasts, and activated monocytes 
(Grabstein, et al 1994), it has been difficult to demonsh'ate meaningful quantities of 
IL-15 protein in the culture supernatants of most cells and cell lines. IL-15 is 
predominantly regulated post-transcriptionally at the levels of translation and 
intracellular tr afficking (Bamford, et al, 1997). In humans, IL-15 mRNA consists of 
a long 5’ untranslated region (UTR) including 10 multiple upstream AUGs, which 
may dramatically reduce the efficiency of its translation (Bamford, et al, 1996). 
Furthermore, the IL-15 signal peptide is usually long (48 a a s ) , and together these 
factors contribute to the inefficiency of IL-15 protein release (Bamford, et al 1997, 
Gnu, et al, 1997). When monocytes were incubated with fixed, IL-15-stimulated SF 
T cells, significant levels of IL-15 production were detected in these supernatants. 
Thus, activated T cells appear to be effective costimulators of TNF-a and IL-15 
production by monocytes via direct cell-cell contact. Actinomycin D inhibition 
experiments had further confirmed the absolute requiiement of mRNA translation in 
IL-15 synthesis, suggesting that the IL-15 mRNA pool store may not be sufficient for 
IL-15 synthesis. IL-15 production could also be significantly reduced by 
cycloheximide, thus excluding the possibility that it was derived either from 
intracellulai' pool of inactive protein present within the monocytes or shedding of liL- 
15 previously fixed onto T cells. The reasons for the variable induction of monocyte
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IL-15 production by stimulated PB T cells and SF T cells ai*e not yet clear. As 
discussed below, it has been shown that SF T cells isolated from matched samples 
were enriched with activated (CD69^) memory (CD45RO^, Rb'*'"‘) subset when 
compared with PB T cells (Kohem, et al, 1996). It is possible that the variation in IL- 
15 production may be explained partly by such T cell phenotype variation, as T cells in 
different states of activation may respond differently to the exogenous stimuli.
The synovial T cell population is predominantly CD45RO+, RBdim, CD27", implying 
advanced differentiation (Thomas, et al, 1992; Kohem, et al, 1996). They often 
simultaneously express early (CD69), mid (HLA-DR) and late (VLAl) markers of 
activation, perhaps initiated by interactions with endothelium during extravasation 
(Burmester, et al, 1987; Pitzalis, et al, 1987a; Pitzalis, et al, 1988; Potocnik, et al, 
1990; Laffon, et al, 1991; lannone, et al, 1994; Fernandez-Gutierrez, et al, 1995), and 
subsequently modified by the cytokine environment within synovial tissue, 
particularly IL-15. The finding that IL-15-induced CD69 expression was prhnaiily 
restricted to CD45RO+ T cells is compatible with these observations, and with a recent 
report comparing the effect of IL-15 on naive and memory T cell CD69 expression 
(Kanegane, et al, 1996). T cell contact-mediated macrophage activation, driven by IL- 
15, is therefore consistent \yith the recognised phenotype and functional profile of 
synovial T cells. It provides a pathological role, but implies no local antigen 
recognition and requires no cytokine secretion, consistent with the polyclonality of 
synovial T lymphocytes, and their lelative absence of cytokine expression. The 
majority of T cells at sites of inflammatory lesions need not be antigen-specific. In 
leprosy skin lesions and reactive arthritis SF, limiting dilution analysis has shown that 
only 0.1-2% of T cells aie specific for the relevant bacterial protein (Modlin, et al, 
1984; Sieper, et al, 1993). A similar situation may exist in RA synovial membrane.
The cell-contact pathway for macrophage activation by T cells in synovium is likely to 
utilise multiple cell surface molecules. T cell surface molecules CD69, GDI la  (LFA-
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1), CD2 and CD40L have been suggested to regulate production of several monokines 
including IL-ip, TNF-a and IL-12 (Manie, et al, 1993; Isler, et al, 1993; Wagner, et 
al, 1994; Shu, et al, 1995). As expected, the LFA-1 / ICAM-1 pathway was 
implicated by the present study. Following chemokine-induced polarization, T 
lymphoblasts redistribute adhesion molecules, such as ICAM-1 or ICAM-3, to the tips 
of uropods and IL-15 has recently been shown to exhibit similar properties (Nieto, et 
al, 1996; Angel del Pozo, et al, 1996). The data also implicated CD69 in cell-contact. 
Increased CD69 expression occurs in vivo on RA synovial T cells (Laffon, et al, 
1991; Fernandez-Gutierrez, et al, 1995) and has been reported in other autoimmune 
diseases, such as multiple sclerosis and chronic active hepatitis at sites of inflammation 
(Garcia-Monzon, et al, 1990; Perrella, et al, 1993). The CD69 activation pathway is 
linked to the TOR / CD3 receptor complex (Rincon, et al, 1989). The large 
cytoplasmic domain of CD69 is probably involved in signal transduction (Tesli, et al, 
1989). Both IL-2 and IL-15 upregulated CD69 expression equally in PB 
lymphocytes, but IL-2 was significantly less efficient than IL-15 at inducing T cell- 
dependent macrophage activation, either in PB cells, or in synovial cells. This imphes 
that other receptors which are involved in cell-contact are preferentially upregulated by 
IL-15, compared to IL-2, and also indicates that the precise combination of surface 
markers present is likely to be of critical importance
In combination with the divergent effects of IL-15 and IL-2 in generating PB and SF T 
cell-induced macrophage activation, these findings show, in an immunopathological 
setting, that IL-15 can exhibit effects distinct from IL-2 on the same target cell 
population. This has implications for IL-15 receptor expression within the synovial 
membrane. It is possible that IL-15Ra-chain binding modifies the signal generated by 
IL-2Rp or common y chain occupancy, although the a-chain has no apparent direct 
role in signal transduction (Giri, et al, 1994; Giri, et al, 1995; Anderson, et al, 
1995b). The distribution of IL-15R a-chain compared to IL-2R a-chain in the 
synovium however, is currently unknown and discordant expression in different
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subsets may pai’tially explain these data. Alternatively, IL-15RX expression may be 
of relevance (Tagaya, et al, 1996a).
Thus, it is attractive to hypothesise that under the continuing influence of IL-15, newly 
aiiived T cells within the synovial membrane can up regulate TN Fa production by 
macrophages, predominantly through cell membrane contact. This may generate a 
positive feedback loop, whereby IL-15 produced by activated macrophages maintains 
T cell-induced synthesis of TNFa, which can further activate macrophages to produce 
IL-15 (Figure 3.13). Therefore, IL-15 or IL-15Ra antagonists represent potential 
approaches to attenuating RA and perhaps other inflammatoiy diseases. Further 
efforts aie required to determine the identity of other molecules involved in T cell / 
macrophage contact and to establish which factors up regulate IL-15 production, 
thereby generating further rational targets for novel therapy.
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Figure 3.13 IL-15 induced amplification of rheumatoid arthritis synovitis
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Synovial macrophage - or fibroblast - derived IL-15 mediates recruitment and 
activation of T lymphocytes and confers upon them the capacity for macrophage 
activation / TNF-a production through cell-contact, in the absence of significant IFN-y 
synthesis. Such cell-cell interactions are likely modified by local cytokines e.g. IL-1, 
IL-6 and TNF-a (Sebbag, et al, 1997).
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Chapter 4
IL-15 induces activation in RA synovial neutrophils
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Introduction
Rheumatoid aithritis (RA) is characterized by chronic infiltiation of the synovial 
membrane by T lymphocytes, plasma cells and macrophages. Together with activated 
fibroblast-like synoviocytes, this constitutes pannus, an invasive tissue capable of 
eroding into adjacent cartilage and bone. While disease pathogenesis clearly involves 
the multiple interaction of these cell types (Aiend & Dayer, 1995; Feldmann, et al, 
1996; David, 1997), increasing evidence suggests that infiltration of the synovium by 
activated neutrophils may also contribute to the inflammatory process and subsequent 
pathology.
During inflammation, the nomially acellular synovial fluid (SF) is infiltrated by a 
variety of immune cells, of which neutrophils comprise between 60-90% of the total 
population (Zvaifler, 1973; Pillinger & Abramson, 1995). Similarly, neutrophils 
represent the majority (>70%) of inflammatory cells in the SF of rats with adjuvant 
arthritis (Santos & Tipping, 1994), and administration of neutrophil depleting 
antibodies in the same model leads to significant improvement in joint inflammation 
(Santos, et al, 1997). Accumulation of neutrophils and desti'uction of cartilage are also 
a prominent feature of bacterial septic aithritis (Goldenberg and Cohen, 1976). 
Activated neutrophils can secrete many of the cytokines that are detectable within RA 
SF including IL-1, IL-8 and TNF-a, together with a wide range of potent proteinases, 
hydrolases and matrix metalloproteinases. Their ability to generate a seiies of reactive 
oxygen and nitrogen intermediates may also contribute to inflammation (Kitsis & 
Weissmann, 1991; Edwards & Hallett, 1997). Neutrophils require æquential priming 
then activation. In RA SF neuti'ophils may be primed within the inflammed joint by a 
number of activation factors including immunoglobulin aggregates and cytokines 
(Robinson, et al, 1993a; Watson, et al, 1993).
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IL-15, an IL-2-liIce cytokine has been identified within the synovial membrane of RA 
patients (Mclnnes, et al, 1996b; Thurkow, et al, 1997). IL-15 is a pleiotropic cytokine 
derived from several cell types including macrophages and fibroblasts, which mediates 
its activity through a heterotiimeiic receptor consisting of a unique IL-15Ra chain, in 
combination with the (5 and y chains of the IL-2 receptor (Tagaya, et al, 1996b). IL-15 
can exert a variety of immunological effects and may play an important role in the 
pathogenesis of RA as described in chapter 3.
Human neutrophils have been shown to express both the p and the y chains of the IL-2 
receptor, whereas the IL-2Ra is undetectable (Liu, et al, 1994; Nakarai, et al, 1994). 
Recently, IL-15 has been described to modulate phagocytosis, cytoskeletal 
rearrangement and apoptosis in blood neutrophils (Girard, et al, 1997). However, the 
role of IL-15 in cytokine synthesis and adhesion molecule expression by neutrophils is 
cuiTently unclear. The present studies were undertaken to determine whether, in 
addition to its effects on T cells, IL-15 might also promote neutrophil recruitment and 
activation through enhancement of adhesion molecule and cytokine / chemokine 
expression respectively.
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4 .1  Preparation of Neutrophils
Neuti'ophils were isolated from peripheral blood (PB) and SF of RA patients by 
centrifugation over lymphoprep as described in Section 2.4.3. Adherent cells 
including monocytes, fibroblasts and lymphocytes were removed by two successive 
adherence steps at 37“C for 30 min. The purity of the neutrophil prepaiations thus 
obtained was 94 ± 5% (mean ± sem. Figure 4.1) judged by morphology on Giemsa- 
stained cytopreps and FACS using analysis using the neutrophil maiicer CD 15. 
Remaining cells were B lymphocytes (CD 19, <3%), T lymphocytes (CD3, <2%) and 
monocytes (CD 14, <1%). Neutrophils were used within one hour of preparation.
4 .2  Expression of IL-15Ra mRNA in RA neutrophils
IL-15 mediates its effects through the IL-2R(3 and IL-2Ry chains, both of which aie 
known to be present on neutrophils (Liu, et al, 1994; Nakarai, et al, 1994). However, 
it remained uncleai* whether IL15Ra, the third component of the IL-15 heterotrimeric 
receptor was present on neutrophils. In the absence of available reagents at the protein 
level, IL-15Ra expression in RA SF neutrophils was sought at the mRNA level. RT- 
PCR was performed using primers specific for human IL-15Ra (Anderson, et al, 
1995b) which were designed to amplify the entire transmembrane and cytoplasmic 
coding domain plus an additional 100 bp of 3’ non-coding sequence (kindly provided 
by Dr. D. Anderson, Immunex Corp.). RT-PCR of preparations from 4 RA SF 
neutrophil samples generated the expected 305 bp fragment (Figure 4.2). For control, 
p-actin was amplified, as was a positive control derived from a plasmid containing 
human IL-15Ra cDNA (Figure 4.2). RA PB neutrophils also spontaneously 
expressed IL-15Ra mRNA, consistent with a previous report that IL-15 could induce 
PB neutrophil activation (Girard, et al, 1996).
Figure 4.1 Analysis by FACS of purified neuti’ophils
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A representative analysis is shown for neutrophil which were isolated from PB and SF 
of RA patients as described in section 2.4.3.
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Figure 4.2 RT-PCR for IL-15Ra in RA synovial fluid neutrophils
IL-15Ra. 
(305bp)
P-Actin
(498bp)
Mk PI P2 P3 P4 +ve -ve
RT/PCR was perforaied to detect human IL-15Ra mRNA expression in freshly 
isolated RA SF neutrophils. Mk - 1 kb marker, P I -4 - representative RA patients, +ve 
- positive control (human IL-15Ra cDNA), -ve - negative conti’ol (dH^O & RT/PCR 
reagents), p-actin was amplified for control.
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4 .3  IL-15 induced expression of C D llb  on human neutrophils
The ability of IL-15 to modify adhesion molecule expression was of interest. In PB T 
cells, IL-15 induces uropod formation and redistiibution of cell adhesion molecules 
including ICAM-1, -2, -3, CD43 and CD44, thereby modulating the adhesive 
properties of T lymphocytes (Nieto, et al, 1996). Similar morphological changes were 
observed in IL-15 activated PB neutrophils (Girard, et al, 1996) although tlie precise 
adhesion molecules involved were not clarified. Since C D llb  and CD 11c are cmcial 
for neutrophil tr ansmigration, these markers were studied. Neutrophils were purified 
from PB and SF from 5 RA patients and expression of C D llb  and CD 11c was 
determined by FACS analysis. In paired samples, PB neutrophils from RA patients 
expressed surface levels of CD 11c that were comparable to those expressed on the 
surface of SF neutrophils. However, expression of C D llb  was signifrcantly 
increased in the SF neutrophils compared to those of PB (p<0.01, Figure 4.3), 
indicating up-regulation during recruitment to the synovial compartment. To determine 
whether factors present within SF were capable of up-regulating expression of 
C D llb , PB neutrophils isolated from above patients were incubated with 10% cell- 
free SF and expression of both C D llb  and CD 11c was measured after 3 hours 
incubation. This increase^ C D llb  cell surface expression in aU patient samples 
(p<0.01, Figure 4.3) while C D llc  expression remained unaltered. The percentage of 
CDl lb positive cells post-incubation was similar to that observed in freshly isolated 
SF neutrophils. Similar data were obtained by stimulating PB neutrophils dii'ecdy 
with recombinant IL-15. PB neutrophils cultured with 100 ng/ml of IL-15 for 4 hours 
expressed significantly higher levels of C D llb  than unstimulated cells (p<0.01, 
Figure 4.3).
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Figure 4.3 FACS analysis of RA PB neutrophils following IL-15 activation
CDllb □  C D llc
o 40
PB Neuti'ophils +IL-15 +10% SF SF Neuti'ophils
IL-15 and 10% cell-free synovial fluid upregulated expression of C D llb  on RA PB 
neutrophils. Purified RA PB neutrophils (n=5) were cultured for 3 hours in the 
presence of medium alone, IL-15 (100 ng/ml) or 10% cell-free SF. FACS analysis 
was performed at the end of the cultum period to determine the percentage of CDllb"' 
and CDllc"" cells. C D llb  expression was enhanced by addition of IL-15 or SF 
L^p<0.01, paired-T test). No significant difference in C D llc  expression was 
detected. Data are mean ± s.e.m.
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To confuTTi and extend the above findings, PB neutrophils were isolated from 12 RA 
patients and cultured either in the presence or absence of IL-15 (100 ng/ml) for 3 
hours. Figure 4.4 shows that cells cultured with IL-15 expressed significantly higher 
levels of C D llb  than unstimulated cells. By comparison, C D llc  expression were 
similar' in both conti'ol and stimulated cells. These data demonstrate that IL-15 may be 
added to the group of cytokines in SF capable of neutrophil activation which includes 
IL -la , TNF-a, GM-CSF and IL-8.
4 .4  Induction of cytokine production by IL-15 activated Neutrophils
Neutrophils, like monocytes / macrophages, have the ability to produce cytokines 
which participate in the inflammatory reaction. Activated neutrophils secrete many of 
those cytokines which are detectable within RA SF including IL-1, IL-8 and TNF-a 
(Edwards & Hallett, 1997). Although IL-15 has been shown to regulate cytokine 
production in a variety of cells including T lymphocytes, NK cells and monocytes, its 
effect on neutrophil cytokine regulation has not been described. To investigate 
whether IL-15 might induce production of pro-inflammatory cytokines, SF neutrophils 
derived from RA patients (n=10) were stimulated with increasing concentrations of IL- 
15 and the levels of IL -la , IL-8 and TNF-a in culture supernatants were determined 
by ELISA. IL-15 induced dose dependent production of IL -la , IL-8 and TN F-a in 
SF neutrophil enriched cultures (Figure 4.5). The kinetics of cytokine production 
varied: for IL -la  and TNF-a, (lie maxirual response was observed at 12 hours while 
that of IL-8, was noted at 24 hours (Figure 4.6). AH culture supernatants were 
therefore compared for peak cytokine production at 100 ng/ml IL-15 after either 12 
hours (IL -la  and TNF-a) or 24 hours (IL-8). The addition of IL-15 induced 
significant cytokine production in all 10 RA SF neutrophil cultures (Figure 4.7). In 
medium control cultures, only IL-8 synthesis was consistently detected (2552 ± 1084 
pg/ml. Table 4.1).
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Figure 4.4 IL-15 upregulated CDllb  expression on RA PB neutrophils
■  Medium 
□  IL-15
P 20
C D llb C D llc
IL-15 upregulated expression of C D llb  on PB neutrophils. C D llb  expression on 
purified RA PB neuti’ophils was enhanced by stimulation with IL-15 (100 ng/ml) for 3 
hours (11=12, *p<0.01). No significant difference in CDl Ic expression was detected. 
Data are mean ± s.e.m.
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F igu re  4.5 IL-15 induced cytokine production by synovial fluid neutrophils
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Dose response for IL-15 induced TNF-a, IL -la  and IL-8 production, by synovial 
fluid neutrophils from a RA patient (*p<0.01 compai*ed with medium alone). Data ai'e 
mean ± s.e.m., representative of 10 similar experiments.
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Figure 4.6 Production of cytokines by IL-15 activated synovial fluid neuti'ophils
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Time course of cytokine production by synovial neutrophils from a RA patient. 
Pai'allel cultures were established and haivested at the time points indicated, then 
stored at -20^C prior to ELISA. For TNF-a and IL -la , production with IL-15 was 
significantly higher than basal levels (p<0.001, Mann-Whitney) at all time point 
between 12-48 hours. For IL-8, production was significantly enhanced at aU time 
points (p<0.001) with maximal production observed at 24 hours. Data are mean ± 
s.e.m., representing 6 similar experiments.
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F igure  4,7 Cytokine production by synovial fluid neutrophils stimulated in vitro 
with IL-15
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IL -la , IL-8 and TNF-a production by SF neutrophils was significantly enhanced by 
addition of IL-15 (100 ng/ml). Supernatants from individual cultures were collected at 
the optimal time point for cytokine production and frozen until triplicate assay for 
cytokine concentration by ELISA. Data aie mean of individual patients (n=10).
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Table 4.1 IL-15 stimulated the production of cytokines by purified SF neutrophils
IL-15 (ng/ml) IL -la
Cytokine levels (pg/ml) 
(11= 10)
IL-8 TNFa
0 1.4 ± 0.6 2552.6 ± 1084.8 5.4 ± 4.5
1 2.5 ± 1.2 5717.5 + 2741.2 5.5 + 4.6
10 13.3± 3.4* 8471.5 ± 3447.1 20.3 ± 6.0*
50 36.2 ± 9,4** 12,782.5 + 4811.7** 53.2 ± 16.1*
100 53.7 ± 14.6** 17,203.1 ± 5661.8** 75.0 + 22.0*
Purified neuti'ophils were cultured in RPMI medium containing 10% FCS and 
increasing concentrations of recombinant IL-15. Cytokine levels in supernatants were 
determined by ELISA after 12hr (IL -la  and TNFa) or 24hr (IL-8), Data aie 
expressed as mean ± s.e.m. of 10 RA patients. *p<0.05, **p<0.01 as compared with 
medium control.
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4 .5  Induction of de novo protein synthesis by IL-15
It was next impoitant to determine the ability of IL-15 to induce de novo cytokine 
synthesis in neutrophils since it has been suggested that cytokine secretion in 
neutrophils requires active gene expression (Edwards & Hallett, 1997). Moreover, it 
was necessary to mle out the possibility of cytokine “leakage” as a result of apoptosis. 
Freshly isolated SF neutrophils from RA patients (n=4) were pre-treated with 
cycloheximide or actinomycin D (2 pg/ml) for 30 min before addition of an optimal 
dose of IL-15. As shown in Figure 4.8, cycloheximide significantly inhibited the 
induction of IL -la , IL-8 and TNF-a production by IL-15 (p<0.005), suggesting that 
these cytokines were newly synthesized rather than derived from pre-formed 
inti'acellular pools. Similai* results were obtained with actinomycin D, demonstrating 
that transcription of mRNA was required. Finally, basal IL-8 production was 
sensitive to botli inhibitors; neutrophils pre-treated with actinomycin D exhibited 
marked reduction of IL-8 synthesis (p<0.03) and similar inhibition was observed with 
cycloheximide (p<0.05).
Legend to figure 4.8 (next page)
Transcription and translation was required for cytokine production by IL-15 stimulated 
RA SF neutrophils. Supernatants from individual cultures (n=4) were collected at 
optimal time points and cytokine concentrations were estimated by ELISA. The 
synthesis of IL -la , TNF-a and IL-8 was increased by IL-15 (100 ng/ml, solid bai) 
and could be successfully inhibited by actinomycin D (dotted bar, p<0.005) or 
cycloheximide (hatched bar, p<0.005). Furthermore, basal IL-8 production was 
sensitive to both actinomycin D (p<0.03) and cycloheximide (p<0.05). Date are mean 
± s.e.m.
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F igu re  4.8 De novo synthesis of cytokines by neutrophils in response to IL-15
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Legend figure 4.8 previous page
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D iscu ssion
Neuti’ophils play an important role in host defence which likely extends beyond that of 
phagocytosis and release of cytotoxic compounds. In particular, they aie considered 
to be capable of synthesizing de novo proteins such as cytokines with the potential to 
function in the afferent and efferent limbs of the immune response (Lloyd & 
Oppenheim, 1992; Cassatella, 1995). It is also cleai’ the cytokines and other pro- 
inflammatory stimuli are capable of modulating a number of neutiophil responses.
IL-15 mediates its activity through a heterotiimeric receptor consisting of a unique IL- 
15Ra chain, in combination with the P and y chains of the IL-2 receptor (Tagaya, et
al, 1996b). Recently, both of these components were shown to be present on human 
neutrophils (Liu, et al, 1994; Nakarai, et al, 1994). However, the IL-2a chain is 
absent on neutrophils and seems to be non-inducible, either at the mRNA or protein 
level (Giri, et al, 1994, Djeu, et al, 1993). However, by using RT-PCR IL-15Ra 
mRNA was detected in freshly isolated RA PB and SF neutrophils. That this was 
associated with the presence of a functional receptor complex for IL-15 binding was 
suggested by the ability of IL-15 to induce adhesion molecule (CDl lb) expression and 
de novo cytokine production. Formal proof of protein expression awaits the 
availability of appropriate reagents capable of specificially binding human IL-15Ra 
chain, since it is possible that IL-15 can bind to and mediate activity through Py 
dimers. Also, the IL-15RX is described on mast cells and may so present on 
neutrophils (Tagaya, et al, 1996a).
In RA, the full spectmm of cellulai’ and humoral elements of the immune system are 
activated and likely contribute to disease pathology. RA has usually been considered a 
T-cell, monocyte / macrophage, or fibroblast driven disease (Fox, 1997; Feldmann, et 
al, 1996) despite considerable evidence for neutrophil involvement in synovial 
inflammation (Edwards & Hallett, 1997). SF from RA patients is heavily infiltrated
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with neutrophils, in addition to high concentrations of immune complexes and 
cytokines. Neutrophils isolated from the RA SF exhibit biochemical properties 
characteristic of primed and activated cells (Nurcombe, et al, 1991; Robinson, et al, 
1993a). Furthermore, many of the cytokines found within SF including IL-1, IL-8, 
TNF-a and TGF-p may be secreted by neutrophils (Beaulieu & McColl, 1994; 
Cassatella, 1995).
Data presented here suggest that once recruited into the synovium, IL-15 may 
modulate cytokine production by activated neutrophils. Dose-dependent enhancement 
of IL -la , IL-8 and TNF-a production was observed. Inhibition studies with 
actinomycin D and cycloheximide confirmed that this was not secondary to preformed 
cytokine release. However, although neutrophils have the ability to produce cytokines 
that paiticipate in the inflammatory reaction, their quantity is generally less than that 
produced by monocyte / macrophages, leading to the suggestion that the contribution 
of neutrophils to the total pool of cytokines may be limited (Lloyd & Oppenheim, 
1992). Activated neutrophils can produce lai'ge amounts of IL-8, reaching at least 
10% of that produced by mononuclear phagocytes (Bazzoni, et al, 1991), Since the 
majority of cells present in the SF aie neutrophils, it is likely that IL-8 derived from 
neutrophils represents an important intra-articular cytokine source. IL-8 in turn has 
various biologic effects on neutrophils in vitro, including induction of directional 
migration, release of storage enzymes, oxygen metabolite synthesis, expression of 
adhesion molecules, and transendothelial migration (Baggiolini, el al, 1994). 
Moreover, it is a potent T cell chemokine (Wilkinson & Newman, 1992; Al-Mughales, 
et al, 1996). In rats, subcutaneous injection of IL-8 has been shown to induce 
neutiophil accumulation in vivo (Kudo, et al, 1991). In vitro studies have 
demonstrated that IL-8 produced by cytokine-activated endothelial cells (EC) has 
chemotactic activity for neutrophils. This is associated with decreased expression of 
L-selectin and concomitant increased expression of CDl lb/CD 18, thereby 
strengthening neutrophil interactions with EC and subsequent transmigration (Huber,
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et al, 1991). IL -la  and TNF-a mediate numerous proinflammatory effects in the 
synovium (Arend & Dayer, 1995). Of particular relevance in this context may be their 
ability to increase the expression of endothelial adhesion molecules involved in }
leukocyte recaiitment, such as ICAM-1 (Mojcik & Shevach, 1997). Thus, it is cleai* 
that neuU'ophils can generate mediators capable of inducing an inflammatory response 
within the joint and that IL-15 produced within the synovium, may potentiate this 
process. It is uncertain whether IL-15 can modulate adhesion molecule and cytokine 
expression on EC. EC were recently shown to express the IL-15Ra chain and the IL- 
2/15R P and Y chains. Furthermore, IL-15 may induce rapid tyrosine phosphoiylation 
of proteins in EC and functions as a stimulator of angiogenesis in vivo (Angiolillo, et 
al, 1997). Thus, effects on both blood leukocytes and the EC path of entry may be 
hypothesised for IL-15.
Neutrophil transmigration from the circulation into synovium requires expression of 
the adhesion molecule CDllb/CD18 (Mac-1) which interacts with ICAM-1 on 
endothelial cells (Mojcik & Shevach, 1997). Consistent with previous results, SF 
neutrophils showed enhanced expression of CDl lb when compared to PB neutrophils 
(Watson, et al, 1993). A short incubation of “unprimed” PB neutrophils with cell-free 
SF or IL-15 could induce similar patterns of receptor expression. Although IL-15 has 
no direct effect on neutrophil chemotaxis (Wilkinson & Liew, 1995), the above 
observations may provide an alternative whereby it can contribute to the large influx of 
neutrophils present within SF. It is interesting that the levels of IL-15 detectable in SF 
were significantly higher than those found in paired serum samples (Figure 3.3a).
Activated neutrophils also possess a range of potent serine proteinases, hydrolases and 
matiix metalloproteinases which have direct effects on cartilage degradation (Kitsis & 
Weissmann, 1991; Edwards & Hallett, 1997). IgG aggregates in SF may activate 
neutrophils to release superoxide radicals (Robinson, et al, 1992a). Furthermore, they 
can secrete IL-1 receptor antagonist (IL-lra), which blocks IL-1 receptor function and
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can promote an anti-inflammatory response (McColl, et al, 1992; Beaulieu & McColl, 
1994). It remains to be determined whether IL-15 can also modulate these properties 
of neutrophils. Thus, these data extend the functional role of IL-15 in RA synovitis 
beyond that of T cell and macrophage activation, to include polymorphonuclear cell 
activation. They also provide further evidence for a crucial role for IL-15 during eaily 
stages of innate immune responses.
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Chapter 5
sIL -lS R a administration prevents 
murine collagen-induced arthritis
141
Introduction
The foregoing data clearly indicate a potential role for IL-15 in inflai'nmatoi'y arthritis. 
This was next investigated in vivo. Numerous experimental models which closely 
imitate human RA, have been characterized as a means to understanding disease 
pathophysiology and identifying new strategies for treatment. The two animal models 
of RA that have been studied in greatest detail are the collagen-induced arthritis (CIA) 
model in mice and adjuvant aithritis (AA) model in rats. CIA is induced by the 
intiadermal injection of native type II collagen in complete Freund’s adjuvant (CFA) 
into susceptible sti'ains of mice (Trentham, et al, 1977; Staines & Wooley, 1994). 
This elicits an inflammatory polyarthritis, characterized by hypeiplasia of the 
synovium with infiltration of polymoiphonuclear and mononuclear cells into the 
synovial tissue, which is followed by destruction of joint cartilage and osteolysis 
(Stuart, et al, 1988). The genetics of CIA have been extensively studied, with 
susceptibility linked to the haplotype (Wooley, et al, 1985). Both B and T 
lymphocytes aie required for the full development of pathology. The generation of 
antibodies to type II collagen represents one similaiity with clinical RA. The 
involvement of T cells, particularly of the CD4'*' subset, is evidenced by the protection 
obtained following T cell depletion in vivo (Osman, et al, 1993). Thus an advantage 
of CIA over AA is the presence of an autoimmune response to a major component of 
aidcular cai hlage rather than to a bacterial antigen in the former. The CIA model has 
been widely used for the evaluation of potential anti-rheumatic agents. For instance, 
CIA in DBA/1 mice can successfully be tmated with antibodies to TNF-a (reviewed 
by Feldmann, et al, 1996), IL -lo/p (Joosten, et al, 1996) and CD4 (Williams, et al,
1994) and have provided the rationale for initiating clinical trials with anti-TNF-a 
antibody therapy in RA patients (Elliot, et al, 1994; Rankin, et al, 1995; Moreland, et 
al, 1997).
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In order to investigate the role of IL-15 in the evolution of immune responses in CIA, 
a soluble fragment of the murine IL-15 receptor a  chain (sIL-15Ra) was generated. 
The sIL-15Ra offers the following advantages: (i) specificity, (no antibody to muiine 
IL-15 was available during this study), (ii) high binding affinity approximating to 
Ix10“ M‘^  (1,000-fold higher affinity than that of IL-2Ra for IL-2 (Giri, et al,
1995)), thus allowing the receptor to work at extiemely low concentration, and (iii), 
potential avoidance of neuti*alizing anti-globulin response as previously obseiwed in the 
anti-TNF-a antibody study (William, et al, 1994).
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5 .1  Bioactivity of soluble IL -15R a chain in vitro
A soluble IL-15Ra fragment was generated by Mr. Holger Ruchatz (Dept, of 
Immunology, University of Glasgow) using a sequence corresponding to the 
extracellulai* domain of muiine IL-15Ra (Figure 5.1 a & b). mRNA was prepared 
from an IFN-y activated muiine macrophage cell line (J774) by nested PCR and 
reversed transcribed to cDNA which was inserted into an expression vector and 
expressed in E. colt. The soluble protein was then exti’acted and purified to 
homogeneity as a 6x Histidine tagged fusion protein using a nickel tagged agaiose 
purification system. The purified sIL-15Ra was analysed on SDS-PAGE stained for 
total protein, or by Western blot analysis against anti-IE-15 antibody following 
binding with recombinant simian IL-15. A single band at 26 kDa moleculai* weight 
was observed in both blots (Figure 5.1 c & d).
To determine the neutralising activity of sIL-15Ra. Murine CD4^ T cell line (DIO) was 
exposed to sIL-15Ra (200 ng/ml) and increasing concentrations of recombinant IL-15 
(0.01 - 50 ng/ml). As shown in Figure 5.2, T cells proliferated vigorously to rIL-15 
in a dose-dependent manner. Addition of sIL-15Ra resulted in inhibition of 
proliferation, which was most maiked when sIL-15Ra was pre-incubated with IL-15 
prior to addition to cells. Similar results were obtained using the murine CD8"^ CTLL- 
2 T cell line. This inhibition was unlikely to be due to cytotoxicity as cell viability 
remained unaffected throughout culture as assessed by tiypan blue. Furthennore, it 
could be successfully overcome by addition of excess IL-15 (Figure 5.2). To verify 
the specificity of neutralization, another member of the short chain four a  helix bundle 
cytokine family was used, namely IL-2. In the presence of sIL-15Ra, IL-2 induced T 
cell clone proliferation remained unaffected. These data demonstrated the specificity 
and bio-activity of sIL-15Ra, and indicated that it represented an ideal reagent with 
which to explore the role of IL-15 synthesis in CIA.
F igure  5.1 Cloning and expression of sIL-15Ra
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Schematic representation of sIL-15Ra (a) and native full length of IL-15Ra (b). The 
purified sIL-15Ra was analysed on SDS-PAGE stained for total protein with 
coomassie blue (c), or by Western blot and developed with ECL (Amersham 
International, UK) (d). Western blot was probed with recombinant simian IL-15 and 
was detected with anti-IL-15 monoclonal antibody. Figures khidly provided by Mr. 
Holger Ruchatz, Dept, of Immunology, University of Glasgow.
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Figure 5.2 Neutralising activity of sIL-15Ra
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Murine €04"" Tcell line (DIO) was exposed to sIL-15Ra (200 ng/ml) and increasing 
concentrations of recombinant human IL-15 (0.01 - 50 ng/ml). rIL-15 induced T cell 
proliferation in a dose-dependent manner which could be inhibited by the addition of 
sIL-15Ra. This was most maiked when sIL-15Ra was pre-incubated with rIL-15 
prior to addition to cells. The inhibition was reversible by addition of excess iiL-15. 
Data are mean ± s.e.m. of triplicate cultures.
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5 .2  sIL -15R a administration prevents development of CIA
Susceptible DBA/1 mice injected intmdermally with type II collagen in CFA developed 
severe arthritis when challenged intraperitoneally 21 days later with collagen. Animals 
were divided randomly into those receiving daily sIL-15Ra (40 |ag/animal) beginning 
the day after collagen challenge (day 22) for a duration of 14 days or controls which 
received human serum albumin (HSA, Figure 5.3). Mice were monitored daily for 
signs of arthritis as described in section 2.7.3 and results are presented in Figure 5.4 
& 5.5.
Collagen primed mice which leceived sIL-15Ra proved less susceptible to induction 
of arthritis, since the incidence rate was significantly less than in HSA control mice 
(Figure 5.4a, p<0.005). The mean clinical score in sIL-15Ra treated mice was 
significantly reduced (p<0.001, Figure 5.4b). In addition, paw-swelling was 
markedly reduced in the sIL-15Ra tmated group relative to HSA controls (p<0.002,
Figure 5.5a). In CIA, new arthritic paw involvement is an important indicator of the 
progression of disease. In control mice tliere was a progressive increase in paw 
involvement, which reached approximately 75% by the end of the treatment period 
(d36). In contrast, less than 10% of paws were involved in mice which received daily 
sIL-15Ra (p<0.002, Figure 5.5b).
5 .3  Histological analysis of joint destruction
After establishing that sIL-15Ra was effective in inhibiting the onset of detectable 
inflammatory synovitis, histological examination was earned out to determine whether 
erosion of cai'tilage and bone was also prevented. At day 36, hind limbs from both 
groups (n=5) were evaluated and histological scores were derived (Figure 5.6).
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Figure 5.3 Induction and sIL-15Ra treatment of collagen induced arthritis in mice
Collagen in C.F. A. (i.d.)
Collagen in PBS (i.p.)
Daily injection of sIL-15Ra 
or placebo
End of treatment period
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At day 0, male DBA/1 mice (6-8 weeks old) received 200 |ig of bovine type II 
collagen in Freund’s complete adjuvant (CFA) by intradermal injection (i.d.). 
CoUagen (200 (ig in PBS) was given again on d21 by intraperitoneal (i.p.) injection. 
Daily injections of sIL-15Ra (40 pg/animal) or HSA (40 |ig/animal) were 
administered i.p. from d22 for two weeks. In order to determine the duration of 
biological effects of sIL-15Ra, animals were observed for up to 14 days post­
treatment (d50).
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F igure  5.4 Recombinant sIL- 15Ra inhibited development of CIA 
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Collagen-piimed DBA/l mice were divided into groups of 10, challenged on day 21, 
and received 14 daily Lp. injections of 40 jig of sIL-15Ra (O) or 40 jig of HSA ( • ) ,  
starting from d22. Mice were monitored daily for disease progression quantified as 
incidence rate (a) or mean clinical score (b). At the end of treatment (d36), 20% of 
mice developed mild CIA in the sIL-15Ra-treated group compared with 90% which 
developed severe CIA in the HSA control group (p<0.05, Mann-Whitney). Data aiie 
mean ± s.e.m.
149
Figure 5.5 sIL-15Ra administration prevented development of CIA
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Comparison of sIL-15Ra (40 pg/animal) vs. the same dose of iirelevant protein 
control (HSA, 40 jig/animal). Mice were tieated as in Figure 5.4. (a) Paw-swelling 
was markedly reduced in the sIL-15Ra Heated group compared to the HSA control
(p<0.002, Mann-Whitney). (b) Mean number of affected joints for each tieatment 
group; significant reduction was observed in mice which received sIL-15Ra 
(p<0.002, Mann-Whitney). There were 10 mice per group, data are mean ± s.e.m.
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F igure  5.6 Histological assessment of the effect of sIL- 15Ra on CIA
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sIL-15Ra significantly reduced histological parameters of articular inflammation and 
destruction. Immediately following 14 days of sIL-15Ra administration, hindlimbs (5 
mice / group) were removed, formalin-fixed and decalcified and H&E sections were 
prepared (d36). Histologic appearances in knee, carpus and interphalangeal joints in 
parallel sections (HSA n=17, sIL-15Ra n=13) were scored independently (0-3) by
two tieatment-blinded histologists. Extensive erosion (p<0.002), inflammatory 
infiltration (p<0.001) and synovial hyperplasia (p<0.001) were observed in HSA 
tieated animals. Data aie mean ± s.e.m., the Wilcoxon rank test was used for 
statistical comparisons.
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Representative images of the ankle joints of a sIL-15Ra treated and conti'ol mice are 
shown ill Figure 5.7. Extensive inflammatory changes were obseiwed in the joints of 
control mice, with hyperplasia of the synovial membrane, and heavy infiltration of 
mononucleai" and polymorphonuclear cells, together with the presence of pannus 
fonnation. These features were markedly reduced in the sIL- 15Ra treated mice.
5 .4  Decreased humoral response to collagen in sIL-15Ra treated mice
Murine susceptibility to CIA is associated with high anti-collagen antibody responses 
(Seki, et al, 1988). To deteraiine whether the neutralization of IL-15 could modify the 
humoral response to collagen, pooled serum samples were collected at the end of 
treatment (d36). Figure 5.8 shows the total IgG and isotype profile of anti-collagen 
Abs in the two groups of mice. Humoral responses, including total IgG, as well as 
the IgG2a and IgGl, were significantly reduced in recipients (p<0.01).
5 .5  Reduction of serum cytokine levels in sIL -15R a treated mice
Previous studies have established a role for Thl cells and several pro-inflammatory 
cytokines, including TNF-a and IL-ip (Mauri, et al, 1996; Joosten, et al, 1996) in 
CIA. To study the influence of IL-15 on cytokine modulation, serum samples were 
analyzed for the presence of IL-4, IL-5, IL-6, IE-10, TNF-a and IFN-y at day 36. 
TNF-a levels were low and comparable in each group, compatible with previous 
reports of only transient early up-regulation of serum TNF-a in CIA. In contrast, IL- 
6 was easily detected and was significantly reduced in IL-15Ra treated animals 
(267±5 vs 193+15, p<0.05). Similar significant reduction of IFN-y and IL-10 levels 
were observed in actively treated mice (Figure 5.9). No detectable of IL-4 and IL-5 
could be measured in either group of mice.
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Figure 5.7 Reduction in knee joint destinetion in sIL- 15Ra treated mice
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m m
F - fi| * ■
I # '' ' j f  I
H&E secdons of knee joints on day 36 of CIA. (a) Aithritic knee joint of a mouse 
treated with HSA control and (b) knee joint of a mouse treated with sIL-15Ra. 
Reduction of both mono- and polymoiphonuclear cells infiltration in the synovial 
membrane, together with reduction in pannus formation and joint erosion can be seen 
in the sIL-15Ra treated animal.
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Figure S.8 Attenuation of serum anti-collagen antibody response in sIL-15Ra- 
treated mice
a
h
1.4 p<0.01 sIL-15R-Ueated1.2 —
Ü 10-  
0 .8 -
'o  0.6-  H 0 .4 -
HSA Contiol
0.2 -
0.0
2 4 8 16 32 64 128 256 512 1024
0.45 p<0.01
0 .3 5 -
0.25-
0 .1 5 -
0.05
20 40 80 160 320 640 1280 2560 5120
p<0.011.6 -
1 .4 -
S  10-
.bp 0 8 -
0.6 -
0 .4 -
0 .2 —
0.0 -
2 4 8 16 32 64 128 256 512 1024
Reciprocal serum dilution
Anti-collagen antibody isotype distribution in sIL-15Ra (O) and HSA (# ) tæated 
mice. Anti-collagen antibody titres, total IgG (a), IgGl (b) and IgG2a (c), were 
measured at the end of tieatment (day 36) by ELISA, Data aie from pooled serum (5 
mice per group), expressed as mean absorbance (O.D. 630 nm) from doubling 
dilutions ± s.e.m. The Wilcoxon rank test was used for statistical comparisons.
154
Fi gure 5.9 Effect of sIL- 15Ra treatment on senam cytokine levels
HSA Contiol 
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Serum cytokine levels in sIL-15Ra and HSA treated mice immunised with collagen. 
Pooled sera (n=5) were collected at the end of treatment (d35) and serum cytokine 
concentrations were analysed by ELISA. Data aie mean ± s.e.m., *p<0.05, 
*'*'p<0.005, Mann-Whitney test.
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5 .6  In vitro immunologic consequences of in v ivo  sIL -15R a  
administration
To fuither explore the effect of sIL-15Ra on immunological responses, spleen cells 
were haiwested from mice (n=5) after two weeks of treatment with sIL-15Ra, or 
control HSA and cultured with type II collagen in vitro. Cells from aithritic mice 
which mceived control protein, proliferated vigorously in response to collagen in a 
dose-dependent manner. In contrast proliferation to collagen was significantly reduced 
in sIL-15Ra-treated mice-derived cultures (Figure 5.10a, p<0.001). The suppression 
of the immune response was not universal, as the T cell mitogen, concanavalin A (Con 
A) stimulated equally high levels of proliferation by spleen cells from both group of 
mice (Figure 5.10b). To detemaine whether the altered disease phenotype in sIL- 
15Ra treated mice in vivo was due to the modification of Thl or Th2 responses, or of 
both, pai'allel cultures were established and antigen specific cytokine production was 
measured by ELISA. Spleen cells from the slL-15Ra-treated mice produced less 
IFN-y (Figure 5.11a, p<0.05) than control mice in response to collagen, indicating 
suppression of Thl responses. Moreover, lL-4 was undetectable and IL-10 was 
found only at low levels (100-120 pg/ml) which were indistinguishable between both 
groups, suggesting that the mechanism of disease suppression by slL-15Ra was not 
preferential enhancement of Th2 cells. lL-6 production was significantly reduced in 
sIL-15Ra-treated animals (Figure 5.11b, p<0.05). TNF-a synthesis however was 
not detected, consistent with previous observations (Mauri, et al, 1996).
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F igure  5.10 Effect of sIL-15Ra treatment on antigen specific T cell proliferation
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Suppression of proliferative responses in vitro to collagen by sIL-15Ra-treated mice. 
Spleen cells (pooled from 5 mice per group) were collected from sIL-15Ra-treated or 
HSA-treated mice at the end of the two week treatment phase (d36) and (a) cultured 
with graded concentrations of collagen or (b) with Con A for 96 hours. T cell 
proliferation, determined by [^H] thymidine uptake, is expressed as mean stimulation 
index (S.I.) ± s.e.m. of triplicate cultures (medium control ranged from 3500-5000 
cpm) or for Con A, cpm ± s.e.m. *p<0.001, Mann-Whitney test.
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F igure  5.11 Effect of sIL- 15Ra tieatment on antigen specific cytokine production
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Assessment of in vitro cytokine production to collagen by spleen cells from mice 
treated with sIL--15Ra or HSA. Supernatants from parallel cultures prepared as 
desciibed in figure 5.10 were collected after 72 h and IFN-y (a) and IL-6 (b) 
concentrations determined by ELISA and expressed as mean ± s.e.m. *p<0.05, 
Mann-Whitney test.
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5 .7  Discontinuation of s IL -lS R a  administration facilitates d isease  
expression
To determine the duration of disease suppression, sIL-15Ra administration was 
withdrawn after 14 days. Onset of CIA was observed clinically 5-7 days after 
cessation of tieatment and after 10 days, 90% of previous sIL-15Ra-recipients
developed arthritis indistinguishable from the control animals. Thus, tieated mice 
developed acute CIA soon after discontinuation of sIL-15Ra which was reflected in 
immune responsiveness in vitro. Two weeks after cessation of treatment, spleen cells 
from sIL-15Ra-treated mice proliferated with the same magnitude in response to 
collagen as control spleen cells (Figure 5.12). Furthermore, higher concentrations of 
IL-6 and IFN-y were found m these cultures when compared either with parallel 
cultures from HSA controls (Figure 5.13, p<0.05), which were by then in the chronic 
phase of CIA, or with spleen cell responses obtained earlier from littemiates at the end 
of sIL-15Ra treatment. IL-4 remained undetected and levels of IL-10 were similai* in
both groups.
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F igure 5.12 Discontinuation of sIL-15Ra administration facilitated antigen specific 
T cell responses
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Loss of suppression of collagen-specific T cell responsiveness following sIL-15Ra 
withdrawal. Two weeks after cessation of treatment (d50), spleen cells (pooled from 
3 mice per group) from previously sIL-15Ra- or HSA-treated mice were cultured with 
collagen as before. T cell proliferation was measured as previously described aiid 
found to be similar in both groups. Data are expressed as mean stimulation index 
(S.I.) ± s.e.m. of triplicate cultures (medium control ranged from 3000-4500 cpm)
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F igu re  5.13 Cytokine production by spleen cells following sIL-15Ra withdrawal
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Parallel culture supernatants prepared as described previously in figure 5.12 were 
collected at 72 hours and IFN-y (a) and IL-6 (b) synthesis was determined by ELISA. 
Data are means of triplicate cultures, *p<0.05, Mann-Whitney test.
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D iscu ssio n
Interleukin-15 mediates pleiotropic effects on a variety of immune cells (Tagaya, et al, 
1996). However, unlike IL-2, with which it shares paitial functional homology, IL- 
15 may be generated not only by cells within the immune system, but also by cells 
belonging to other tissues, including kératinocytes and synoviocytes (Mohamadzadeh, 
et al, 1995; Mcinnes, et al, 1996b; Thurkow, et al, 1997). By this means, host tissues 
may contribute significantly to the regulation of protective, or autoimmune responses. 
Functional effects of IL-15 demonstrated thus fai' include activation of NK cells and 
neutrophils, and autocrine regulation of macrophages, and an important role for IL-15 
in early, innate defence has been proposed (Carson, et al, 1995; Girard, et al, 1996; 
Alieva, et al, 1997). However, IL-15 also induces activation of T cell blasts and will 
support maturation and isotype switching of B lymphocytes. Thus, a role in 
development of antigen-specific responses might be predicted, although formal 
demonstration of this in vivo has until now been lacking.
IL-15 expression has been detected in several human diseases including RA, 
pulmonary sarcoidosis, inflammatoiy bowel disease and chronic active hepatitis, 
providing circumstantial evidence for a role in chronic immunopathology (Chapter 3; 
Mcinnes, et al, 1996b; Thurkow, et al, 1997; Agostini, et al, 1996; Kirman & 
Nielsen, et al, 1996; Kakumu, et al, 1997). The mechanisms whereby it could modify 
such inflammatoiy tissue destmction have not been clearly defined. The present data 
indicate that IL-15 expression is required for the induction of erosive inflammatoiy 
arthritis following challenge of collagen-primed DBA/1 mice. Moreover, the altered 
serum immunoglobulin levels detected, and in vitro evidence for suppressed spleen 
cell proliferation and cytokine production indicate that the collagen-specific response 
has been significantly modified. Since IL-15 induces T cell chemotaxis in vivo and in 
vitro (Mcinnes, et al, 1996b; Wilkinson & Liew, 1995), and proliferation, adhesion 
molecule expression and cytokine production in vitro (Mcinnes, et al, 1997; Kanegane
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& Tosato, 1996), it is therefore possible that IL-15 mediates effects in inflammatoiy 
arthritis, at least in part, through its activities on antigen-specific T cells. Several 
recent data have provided suggestive evidence for antigen-driven T cell clonal 
expansion in patients with long-standing RA (Schmidt, et al, 1996; Scotet, et al, 
1996). Further possible explanations for these observations include alteration of 
antigen-presentation or subsequent T cell co-stimulation, since both peripheral blood- 
and skin-derived dendritic cells aie known to express IL-15 (Jonuleit, et al, 1997), or 
modification of adjuvant activity, since IL-15 up-regulation has been detected during 
mycobacterial infection (Jullien, et al, 1997).
The CIA model provides an opportunity to study the relative conüibution of immune 
pathways to the development of inflammatoiy arthritis. Several groups have shown 
that CIA can be treated effectively with anti-TNFa antibody or other TN Fa inhibitors. 
Monoclonal antibodies to TNFa ameliorated CIA when administered prior to disease 
onset (Thorbecke, et al, 1992; Piguet, et al, 1992). In addition, anti-TNFa 
monoclonal antibody treatment was used successfully after disease onset (Williams, et 
al, 1994) and analogous results have been obtained using IgG-TNF-receptor fusion 
protein as an inhibitor of TNFa activity (Wooley, et al, 1993). Subsequent clinical 
trials with neutralising antibodies against TNFa and soluble TN Fa receptors have 
demonstrated efficacy in human RA (Elliott, el al, 1994; Rankin, et al, 1995; 
Moreland, et al, 1997), vindicating the use of the CIA as a suiïogate for determining 
the role of cytokines in RA.
The evidence in the literature regarding the deleterious role of IFN-y in CIA, a Thl 
cytokine is controversial. IFN-y induced IgG2a anti-collagen antibody can elicit mild 
arthritis when passively transfeiTed to normal DBA/1 recipients (Watson, et al, 1985; 
Terato, et al, 1992) and administration of IFN-y to collagen primed mice exacerbates 
the disease (Cooper, et al, 1988). However, it has been suggested that the outcome of 
anti-IFN-y treatment depends on the time of antibody administration, with early
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tieatment at the time of immunization being associated with reduced severity of arthritis 
and late tieatment being associated with aggravation of disease (Boisser, et al, 1995; 
Williams, et al, 1993). Similar contradictory findings have been reported in AA 
(Jacob, et al, 1989; Wiesenberg, et al, 1989). Moreover, IFN-y receptor knockout 
mice developed CIA more readily than their wild-type counteipai'ts (Vermeire, et al, 
1997; Manoury-Schwartz, et al, 1997). Interestingly, IL-15 blockade also profoundly 
suppressed serum IL-10 levels. Although many properties of IL-10 aie compatible 
with anti-inUammatoiy and immunoregulatory effects, the reduction of IL-10 may be 
beneficial to the host as its B cell stimulatory effects may be important in the 
production of rheumatoid factors (Rousset, et al, 1992). Recently, enhanced IL-10 
production by IL-15 activated T cells has been reported (Korholz, et al, 1997). Thus 
the efficacy and effect of IL-15Ra in CIA aie potentially of great interest, in particular 
the appaient capacity to down-regulate Thl responses as evidenced by the reduction of 
IFN-y and IgG2a anti-collagen antibody.
Besides its postulated function in innate immunity (Carson, et al, 1995; Girard, et al, 
1996), a critical role in modulation of acquired immunity is suggested for IL-15. IL- 
15 R a  administration effectively suppressed collagen-specific responses measured in 
vivo by serum immunoglobulin, and in vitro by spleen cell responses. This was 
unexpected since the animals were IL-2 replete. IL-15 and IL-2 share occupancy of 
the IL-2/15R P chain and of the common y chain, and transduce similar JAK-l/JAK-3, 
STAT-3/STAT-5 dependent pathways thereafter (Johnston, et al, 1995b), leading to 
the suggestion that some functional redundancy might exist. However, soluble IL- 
15Ra chain exhibited no binding to IL-2 in vitro, nor did it inhibit IL-2-mediated 
murine T cell proliferation (DIO and CTLL-2), making it unlikely that cross-reactivity 
could explain these observations. Rather, it is lUcely that early IL-15 production 
during antigen-challenge is necessary for normal development of specific immune 
responses. Availability of soluble IL-15Ra will facilitate future studies to investigate 
the precise relationship and functional crossover, if any, between IL-2 and IL-15.
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Thus, soluble IL-15Ra profoundly suppressed the development of CIA and markedly 
inhibited the onset of the humoral and Thl cell-mediated anti-collagen responses. 
These results provide in vivo data to show a role for IL-15 in inflammatoiy arthiitis 
and suggest that antagonists to this cytokine could be of therapeutic benefit. Wider 
application to other chronic inflammatory conditions in which IL-15 expression has 
been localised should also be considered.
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Chapter 6 i
il
Nitric oxide and Cytokine synthesis in Asthma
166
Introduction
Nitric oxide (NO) has emerged as an important mediator in several inflammatory 
diseases (Moncada & Higgs, 1993; Nathan, 1997). NO is formed when L-aiginine is 
emzymatically converted to L-citrulline by nitric oxide synthase (NOS). Several 
isoforms of NOS have been described including endothelial NOS (eNOS) and 
neuronal NOS (nNOS), which constitutively produce small amounts of NO, and an 
inducible NOS (iNOS). The latter is upregulated in response to bacterial products, 
such as LPS and SEE, or by inflammatory cytokines, including IFN-y, TNF-a and 
IL I-p, resulting in the formation of large amounts of NO (Bredt & Synder, 1994; 
Nathan & Xie, 1994; Michel & Feron, 1997; Mcinnes & Liew, 1998).
NO is an important regulator to pulmonary physiology. Effects include modifying 
airway tone, regulating pulmonary vascular tone, stimulating mucin secretion, 
modulating mucociliary clearance through effects on ciliary beat frequency, and 
immune surveillance, including tumoricidal and bactericidal effects (Schmidt & 
Waiter, 1994). NO has also emerged as an important pathological mediator in asthma 
(Gaston, et al, 1994; Barnes & Liew, 1995). Increased exhaled NO has been 
demonstrated in asthmatic patients (Kharitonov, et al, 1994 & 1996). Expression of 
iNOS mRNA and protein can be induced in airway epithelial cells and NO is produced 
by bronchial epithelial cells in culture derived from nonnals and asthmatic patients 
(Robbins, et al, 1994; Watkins, et al, 1997). In addition to this, a role for NO as a 
regulator of inflammatory responses is suggested by studies showing that NO 
modulates cytokine synthesis in a variety of cells (Deakin, et al, 1995; Mcinnes, et al, 
1996a; Yan, et al, 1997), raising the possibility that a similar role may exist in 
pulmonaiy inflammation. Local production of cytokines such as IL-1, IL-5, IL-8 and 
TN F-a has been demonstrated in asthmatic patients (Gelder, et al, 1995) and is 
thought to contribute to pathogenesis, through promotion of chemotaxis, and through 
direct effects within the bronchial mucosa (Till, et al, 1995). Recently, expression of
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the novel macrophage-derived cytokine, IL-15, has been described in chionic 
inflammatory conditions including sarcoidosis, rheumatoid arthritis, and inflammatory 
bowel disease (Agostini, et al, 1996; Mcinnes, et al, 1996b; Kirman & Nielsen, 
1996). However, a role for IL-15 in asthma has not previously been described.
The experiments described in the present chapter set out to establish whetlier human 
respiratory cells were indeed capable of significant NO production, and if so to 
detennine the cellular location of such synthesis. Thereafter, the effect of 
corticosteroid therapy on NO and inflammatoiy cytokine expression was explored. 
Finally a potential link between NO, and cytokine synthesis, namely TNF-a and IL- 
15, was investigated.
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6 .1  Assay for nitrite in bioiogical fluids
NO production was estimated by the concenti*ation of its oxidative products nitrite and 
nitrate ions in culture supernatants and serum. Two methods were employed.
(a) The Griess reaction was peifonned to detect nitiite in either fresh, or previously 
frozen (-20“C) culture supernatants, with typical sensitivity of 2p,M (Figure 6.1a).
(b) The Griess reaction develops at acid pH raising the possibility of protein 
precipitation in test samples. Total serum nitrite levels were therefore measured by 
chemiluminescence, after reduction of nitiate to nitiite using nitiate reductase. A 
typical standard curve is shown in Figure 6.1b, demonstrating sensitivity of 2jiM.
6 .2  Nitrite / nitrate in serum from asthmatic patients
Serum samples were collected from 32 steroid-treated asthmatic patients and stored at 
-20“C prior to assay for nitrite / nitrate concentration using chemiluminescence. 
Figure 6.2 shows that the mean concentration of nitrite, representing total nitiite / 
nitiate levels after enzymatic nitrate reduction, was significantly reduced when 
compared with a similar number (n=32) of age and gender matched normal controls 
(p<0.001; Mann-Whitney). However, serum samples from non-steroid treated patient 
were not available during the present study, thus it was not possible to compare the 
effects of steroid within asthmatic patients. These data are compatible with those 
obseiwed in patients receiving either oral (Massaro, et al, 1995) or inhaled steroid 
therapy (Kharitonov, et al, 1996) in which significant reduction in exhaled NO was 
noted.
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Figure 6.1 Standard cui*ves for nitrite /nitrate estimation
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(a) Standard curve derived from triplicate sodium nitrite dilutions in Dulbecco’s MEM 
estimated by Griess reaction as described in section 2.10.1. (b) Standard curves
derived from dilutions of sodium nitiite and (O) and sodium nitrate ( • )  in Dulbecco’s 
MEM estimated by chemiluminescence as described in section 2.10.2.
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F igure  6.2 Nitiate concentration in semm obtained from asthmatic patients
IBI
p<0.001
Normal Semm Asthmatic Semm
Total nitrite / nitrate levels were assayed using chemiluminescence (section 2.10.2). 
Nitrite / nitiate levels were compaied in serum from asthmatic patients (n=32) and 
healthy nornial conti'ols (n=32). Significant reduction of total nitiite / nitiate levels 
were observed in asthmatic patients (mean ± s.e.m., 6.5±0.5 vs 29.1+3.6 jiM,
p<0 .001).
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6 .3  Expression of INOS mRNA in induced sputum samples
Inducible NOS expression in human respiratory tract samples obtained in induced 
sputum was determined first at the mRNA level. RT/PCR was performed using 
primers specific for human chondrocyte iNOS (Charles, et al, 1993). Induced sputum 
samples from 5 patients were collected and RT/PCR was performed. In 4/5 samples, 
the PCR generated the expected 500 bp product, consistent with that predicted from 
human chondrocyte iNOS (Figure 6.3). This product was sequenced by Dr. X.Q. 
Wei (Dept, of Immunology, University of Glasgow) and found to be identical to 
human iNOS (Charles, et al, 1993), thereby confirming the specificity of the reaction. 
For control, p-actin was amplified and found to be similarly expressed among all 5 
samples.
Figure 6.3 RT-PCR for iNOS in human respiratory samples
INOS
(SOObp)
P-Actin
(498bp)
Mk 1 2
RT/PCR was performed to detect human iNOS mRNA expression in freshly isolated 
sputum samples. Lane 1-5 - representative asthmatic patients, lane 6 - positive control 
(human iNOS cDNA), lane 7 - negative control (dH^ O + RT/PCR reagents). 
Subsequent sequencing confirmed that the PCR product was identical to human iNOS. 
p-actin mRNA was amplified for control.
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6 .4  Nitric oxide production in induced sputum cells
Since the principal objective of this study was to obtain direct evidence for NO 
production by human respiratory cells, primaiy heterogeneous ceU cultures were 
established from samples obtained from induced sputum. The induction of sputum 
from asthmatic patients allowed the identification of pro-inflammatoiy factors ex-vivo 
which could be readily compared with normal control subjects. Induced sputum 
samples from a total of 8 normal volunteers [all non-smokers, 6 males, 2 females, 
aged (mean±SD, range): 33.4+8.5, 23-47 year] and 17 astlimatic patients [all non- 
smokers, 13 males and 4 females, aged: 42.4113.1, 20-69 year] were included in this 
study. Asthmatics were subdivided into those taking inhaled P-2 agonist alone (non 
steroid-treated, n=8), and those on additional inhaled steroid therapy (steroid-treated, 
n=9). Corticosteroids are the most effective foim of therapy in asthma (Laitinen, et al, 
1992), They inhibit the transcription of most pro-inflammatory cytokines in asthma 
(Barnes, 1996), probably via an indirect effect on critical transcription factors, and 
may inhibit iNOS expression by inhibiting NF-kB binding (Xie, et al, 1994). While 
there aie increasing data on the influence of steroids on regulation of many genes 
relevant to asthma, there is a relative lack of clinical data to support proposed 
mechanisms of action of corticosteroids in asthmatic cells or tissues. Differential cell
i
counts for both patient treatment groups and normal conti'ols aie listed at table 6.1; no 
significant difference was observed. Spontaneous nitrite generation in vitro by 
sputum cells as determined by the Greiss reaction was measured after 48 hours (Table 
6.2) and found to be extremely low and identical in each study population. These data 
indicated that NO production was tightly regulated and indicated that iNOS expression 
might require constant stimulation.
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Table 6.1 Distiibution of cells in induced sputum samples
Study Subjects Cell type (%) mean ± S.D.
Epithelial Macrophages Polymorphs
Normal Controls 60.2 ± 9.0 27.4 ± 8.8 12.5 ± 7.8
(n = 8)
Steroid-treated 64.2 ± 19.6 25.5 ± 13.7 9.2 ± 7.2
(n = 8)
Non-steroid treated 47.8 ± 22.0 25.7 ± 14.3 24.3 ± 24.0
(n = 9)
Sputum cells were isolated as described in section 2.4.4, cytospin preparations were 
made and at least 300 cells were counted per sample. No significant differences 
between asthmatic patients and normal controls was obseiwed (Mann-Whitney test). 
Data are mean ± s.d.
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6o5 Induction of NO production in vitro in induced sputum cultures
The precise cytokine requirements for activation of iNOS in human pro-inflammatoiy 
cells remain unclear. The superantigen, staphylococcal enterotoxin B (SEE), induces 
T lymphocyte proliferation and cytokine production through interaction with tlie T cell 
receptor and can also up regulate mononuclear cell cytokine expression following 
MHC class II binding (Marrack & Kappler, 1990; Trede, et al, 1993). SEE stimulates 
NO production by murine macrophages in the presence of T lymphocytes (Isobe & 
Nakashima, 1992) as well as in human macrophages and fibroblasts (Mclniies, et al, 
1996a). SEE was therefore chosen as a stimulus for sputum cell NOS induction. 
Parallel experiments also utilised EPS, a potent iNOS upregulator in rodents (Liew & 
Cox, 1991).
Sputum cells from normal donors cultured with SEE exhibited dose- and time- 
dependent upregulation of NO production (Figure 6.4 a & b). A similar pattern was 
obseiwed in samples derived from non-steroid treated asthmatic patients. Thus, all 
cultures were compared for peak nitiite production using 1 pg/ml SEE stimulation for 
48 hours. The addition of SEE induced significant nitrite production in both non­
steroid ti'eated asthmatic patients (p<0.01, Mann-Whitney) and normal contiols 
(p<0.05, Mann-Whitney, Table 6.2). However, sputum cells derived from patients 
ti'eated with corticosteroids exhibited significantly less enhancement of NO synthesis 
to SEE in vitro compared with either normals or non-steroid treated patients (p<0.05). 
Initial experiments detei*mined that EPS alone ( 1 jig/ml) was less effective than SEE in 
inducing nitrite production. Furthermore, when the two agents were combined, 
addition of EPS reduced SEE-mediated enhancement of NO synthesis in both controls 
and non-steroid tieated patients (Table 6.2). This may reflect the local synthesis of 
anti-inriammatoi'y cytokines, such as IE-10 or TGF-p. Production of nitrite in vitro
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Figure 6.4 Production of NO by induced sputum cultures
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(a) Dose response for SEB-induced ( • )  nitiite production by heterogeneous sputum 
cells from a representative asthmatic patient. Production of nitrite was significantly 
inhibited by L-NMMA (O), p<0.01, Mann-Whitney. (b) Time course of nitrite 
production by sputum cells. Paiallel cultures were established and hai vested at the 
time points indicated, then stored prior to nitrite assay. Production with SEB was 
significantly greater than basal levels (A) (p<0.01, Mann-Whitney) at all time points 
from 24 hours. Data are mean ± s.e.m., representing 3 similar experiments.
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Table 6.2 Nitrite production by induced sputum cultures
Patients
(n)
Nitrite (pM) luean ± SEM 
SEB SEB + EPS Medium
Control 8 19.9* ±7 .6 13.9* ± 4 .8 2.6 ± 0.8
Steroid-treated 8 5.6 ± 2.8 3.3 ±0.8 2.6 ± 0.8
Non steroid 
-tieated 9 35.1** ± 14.3 16.2* ± 4 .0 2.2 ± 0 .4
Sputum cells were cultured either in medium alone or stimulated with SEB ± EPS 
(both at 1 M-g/ml). Supernatants were haiwested after 48 h and nitrite levels determined 
by the Griess reaction. Significant (*p<0.05, ’*^*p<0.01) amounts of nitrite were 
detected when compared with medium controls after culture with SEB or SEB together 
with EPS. Furthermore, sputum cells derived from non steroid-treated asthmatic 
patients produced significantly luore (p<0.05) nitrite upon stimulation with SEB ± 
EPS when compared with steroid-treated patients. Nitrite production could be 
completely inhibited by E-NMMA (5 mM).
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was completely inhibited by addition of 5 mM L-NMMA (Figure 6.4b), confiiming 
the specificity of the system. Sputum cell viability was not affected by L-NMMA 
throughout culture as assessed by trypan blue exclusion.
Together these data clearly demonsti'ated that high levels of NO synthesis by sputum 
cells was possible. Moreover, they strongly suggested that one effect of steroids may 
be to suppress the ability of lespiratoiy mucosal cells to generate NO in response to 
local stimuli. It was next of interest to determine the precise cell of origin.
6 .6  Cellular localisation of iNOS in induced sputum cells
Initial efforts to localise iNOS in human respiratory tissues employed cross-reacting 
antibodies developed against rodent iNOS, raising the possibility of target non- 
specifrcity or of cross-reactivity witli other NOS isoforms, or with P450 reductase 
enzymes (Hamid, et al, 1993). Those antibodies investigated in the present study are 
listed in table 2 .1. Several monoclonal and polyclonal anti-murine iNOS antibodies 
exhibited extensive staining which was not readily neutralized by recombinant iNOS 
protein, thus considerable doubt remained as to the specificity of these reagents.
To overcome this problem, a'rabbit antisemm raised specifically against the C-terminal 
peptide (YRASLEMSAL) of human iNOS was obtained (N053, Nicholson, et al,
1996). This sequence is not present on either eNOS or cNOS, nor on rodent iNOS 
and has been shown to specifically bind to human iNOS in tissues cryosections 
(Nicholson, et al, 1996; Mcinnes, et al, 1996a). Following stimulation of sputum 
cells with SEB for 48 hours, cytopreps were made. Staining was observed in cells 
from all non steroid-treated asthmatic patients (Figure 6.5a). In contrast, the 
frequency of staining was markedly reduced in preparations from patients tieated with 
corticosteroids (p<0.05. Table 6.3). The percentage of positive cells vaiied
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Figure 6.5 Immunohistochemical identification of iNOS in induced sputum cells
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Immunocytochemistry of iNOS in 
sputum cells from a representative 
(n=6) non steroid-treated asthmatic 
patient. Sputum  cells were 
stimulated with SEB+LPS in vitro 
for 24 h and cytospin preparations 
were stained with (a) anti-human 
iNOS antiserum (fast red), (b) anti- 
iNOS serum after pre-incubation 
with human iNOS peptide, (c) 
normal rabbit IgG. No staining was 
observed in unstimulated sputum 
cells cultured in medium alone. 
(Magnification x200)
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Figure 6.6 Co-locaüsation of non-specific esterase and iNOS in induced sputum 
cells
9
To identify iNOS expression in macrophages, (a) sputum cells were double stained 
(indicated with aiTOw) with anti-human iNOS (fast blue), then with NSE (red brown). 
No nucleai- counterstain was used, (b) Specificity of staining was demonsti'ated by 
pre-incubation with human iNOS peptide. (Magnification x400)
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Table 6.3 Immunohistochemical localisation of iNOS in sputum cells
Study Subjects
Normal controls (n=5)
Positive cells (%) mean ± s.d.
Total Macrophages Epithelial cells
10.6 + 3.1 2.9 ± 1.1 7.7 ± 2.5
Steroid-tieated (n=4) 3.7 ± 1.8* 0.6 ±  0 .6* 2.1 ± 1.3*
Non-steroid treated (n=5) 15.6 ± 7.1 6.3 ± 4.4 9.3 ± 6.8
Sputum cells from noimal controls and asthmatic patients were stimulated with 
SEB+LPS in vitro and stained with a polyclonal anti-iNOS antibody as described 
(section 2.6). iNOS expression was gieater in non-steroid tieated asthmatic patients 
when compaied with the steroid-treated group (p<0.05, Mann-Whitney). No 
difference was observed between normal controls and non-steroid tieated patients. At 
least 300 cells were counted per sample, data are mean (%) ± s.d.
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considerably between different patients, as predicted by the heterogeneity of nitrite 
production in in vitro culture. Staining levealed intracellular localisation, and was 
neutralised by pre-incubation of the anti-semm against immunising human iNOS 
peptide (N054, Figure 6.5c).
The identity of iNOS positive cells was next sought. Consistent with previously 
published data (Robbins, et al, 1994; Watkins, et al, 1997), epithelial cells, identified 
by distinctive morphology, from the non steroid-tieated patients were found to be 
iNOS positive (Figure 6.5a). By double staining with NSE and anti-iNOS antibody, 
alveolar macrophages in this cell population expressing iNOS protein were also clearly 
identified (Figure 6.6a).
6 .7  Do similar culture conditions induce human monocytes to 
produce NO?
The ability of human monocytes / macrophages to produce NO remains controversial 
(Schneemann, et al, 1993, Dugas, et al, 1995). Light microscopic data presented here 
clearly indicated that human macrophages activated in an inflammed environment aie 
capable of expressing iNOS. Similar results have been reported in monocytes / 
macrophages collected from other chronic inflammatory conditions including alcoholic 
hepatitis, endemic malaria, RA, osteoarthritis (reviewed by MacMicking, et al, 1997), 
as well as in patients with hepatitis A under treatment with IFN-a (Sharara, et al,
1997). However, when similai’ culture conditions as induced NO synthesis by 
sputum cells were applied to either purified blood monocytes or the monocytic cell 
lines THP-1 and U937, no combination of reagents or in vitro conditions was capable 
of inducing consistent NO production as measured by the Griess reaction. Murine 
macrophage, J774 cells, served as a positive control and reproducibly generated NO in 
vitro.
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6 .8  Cytokine expression in Sputum derived leukocytes
NO is a labile molecule which may perfoim important biological roles both within cells 
in which it is synthesized, as well as in interactions with nearby cells and molecules 
(Stamler, 1994). iNOS appears to play both regulatory and effector roles (Schmidt & 
Walter, 1994). However, the cytokines that regulate iNOS expression have been only 
partially characterised in asthma (Guo, et al, 1997). It was therefore decided to 
investigate cytokine synthesis in the present culture system.
(a) In vitro TNF-a synthesis
TNF-a is a pleiotropic cytokine produced mainly by activated monocytes / 
macrophages, but also by other cells including T lymphocytes and NK cells. It has a 
wide range of biological effects including induction of adhesion molecules such as E- 
selectin, intracellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule 
(VCAM-1) which promote cell migration and adhesion, and induction of inflammatory 
and tissue-damaging molecules, such as prostaglandins. Moreover, it is a recognised 
stimulator of iNOS expression (Nathan & Xie, 1994) in rodents and in human airway 
epithelial cells (Watkins, et al, 1997). Sputum cells from normal controls and steroid- 
treated patients cultured with medium alone produced low concentration of TNF-a 
whereas non-steroid treated sputum cells produced signifrcantly higher amounts of 
TNF-a spontaneously (Table 6.4, p<0.05). This synthesis was further augmented by 
the presence of SEB and EPS.
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Table 6.4 Production of TNF-a by cultured sputum cells
Patients
(n)
Normal Controls 6
Steroid-treated 7
Non steroid-treated 7
TNF-a (pg/ml) mean ± SEM
Medium
31 + 31 
148 ± 88 
650 + 308
SEB & EPS
107 + 64 
237 ± 150 
1265 + 436*
Sputum cells were cultured either alone or with SEB + EPS at 1 pg/ml for 48h. 
Supernatants were harvested and TNF-a was determined by EEISA. Non-steroid 
tieated asthmatic patients produced significantly more TNF-a either spontaneously or 
after stimulation when compared with nonnal controls (p<0.02, Mann-Whitney) or 
steroid-tieated patients (p<0.05). * Significant upregulation of TNF-a post­
stimulation when compared with baseline levels (p<0.05, paired t-test).
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(b ) C ellu lar localisation of IL-15 expression
Previous chapters described data linking TNF-a with the synthesis of IL-15. In order 
to test whether IL-15 was present in asthmatic bronchial tissues, the distribution of IL- 
15 in freshly isolated sputum cells was investigated by immunohistochemistry, using 
monoclonal anti-human IL-15 antibody (M ill ,  Immunex and MAB647, R&D 
System). IL-15 expression was detected mostly in epithelial cells, and to a lesser 
extent in NSE positive alveolar* macrophages (Figure 6.7 a&d). To confirm the 
specificity of the binding, neutralisation was caiiied out by pre-incubating the 
detecting antibody with recombinant human IL-15, which abolished the IL-15 staining 
(Figure 6.7 b). Interestingly, cells from non steroid-treated asthmatic patients showed 
strongly positive staining compared to those from steroid-tieated patients which 
showed weak and inconsistent staining (p<0.001, Figure 6.8), thus suggesting 
increased expression of IL-15 in asthmatic patients airways which can be reduced by 
the administration of steroid, Nonnal controls exhibited low and inconsistent staining, 
suggesting that IL-15 may not consitulively present at the protein level.
Legend to Figure 6.7
Immunocytochemistry for IL-15 expression in sputum cells isolated from a 
representative (of 5) non steroid-treated asthmatic patient. Freshly isolated sputum 
cells were stained with anti-human IL-15 mAh (fast red) (a). Both epithelial cells 
(large) and macrophages were positively stained. Specificity of staining was 
demonstrated by pre-incubation with rIL-15 (b), or normal muiine IgGl (c). For 
localisation of IL-15 in macrophages, sputum cells were double stained (indicated by 
arrow) with anti-human IL-15 (fast blue) and NSE (brown) (d). (Magnification x200)
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F igure 6.7 Immunohistochemical localisation of IL-15 in induced sputum cells
î
-y'
t'
%
' % .
t i r '
fel V' #
186
Figure 6.8 Percentage distribution of IL-15 expression in induced sputum cells
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Freshly isolated sputum cells were stained with anti-human IL-15 antibody and the 
positively stained cells counted by light microscopy (%). At least 300 cells were 
counted per sample. Asthmatic patients were subdivided into those who were taking 
inhaled steroid (n=5) and those who were not (n=5). Cells from normal controls 
(n=5) were also included. p<0.001, Mann-Whitney test; N.S., not significant.
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6 .9  NO and IL-15 dependent regulation of TNF-a production
NO and IL-15 can independently induce TNF-a synthesis in human inflammatory 
conditions such as rheumatoid arthritis (Mcinnes, et al, 1996a & 1997). Moreover, 
direct autocrine regulation of macrophage function by IL-15 has been reported (Alieva, 
et al, 1997). Thus the possibility that NO and IL-15 might modulate TNF-a synthesis 
by sputum cells was investigated. Initially, the human monocytic cell line TFIP-1 was 
used to established the kinetics of TNF-a synthesis. CeUs were primed with IFN-y 
(50 lU/ml) and SEB (1 pg/ml) for 16 hours, then cultured at 2 x 10  ^ / ml in the
presence of the NO donor, S-nitroso-N-acetylpenicillamine (SNAP, ImM) and IL-15 
(100 ng/ml), and the levels of TNF-a were determined by ELISA. Cells cultured with 
either IL-15 or SNAP alone produced low to inteimediate levels of TNF-a. Levels 
were maikedly enhanced by the presence of both stimuli, resulting in high levels of 
TNF-a synthesis in a time-dependent manner (Figure 6.9a). This was reproduced in
sputum cell cultures derived from normal donors, but not in those from patients treated 
with inhaled steroid (Figure 6.9 b&c). The analogue N-acetylpenicillamine (NAP) 
which does not release NO, failed to induce TNF-a synthesis. These data suggest the 
presence of complex regulatory feedback loops involving NO and cytokine synthesis 
in asthma. «
Legend to Figure 6.9
TNF-a production in response to IL-15 and SNAP by (a) pre-activated THP-1 cells 
(representative of 3 experiments), or (b) sputum cells from a representative (of 4) 
normal donor, or (c) sputum cells from a representative (of 3) steroid-treated asthmatic 
patient. Cells were cultured with IL-15 (100 ng/ml) and SNAP (1 mM) for up to 72 h 
(a), or graded concentrations of SNAP for 48 h (b, c). In all cases, the conti'ol 
compound NAP was without effect. Data aie mean ± s.d. of tiiplicate cultures, 
*p<0.05, **p<0.01.
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Figure 6.9 Induction of TNF-a synthesis by IL-15 and NO
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D iscu ssio n
The pathophysiological consequences of increased NO production in the respiratory 
tract are not yet known,iNOS activity has been delected in a vaiiety of cells including 
alveolai’ macrophages from tuberculosis patients, epithelial cells and activated 
eosinophils (Nicholson, et al, 1996; Watkins, et al, 1997; Del Pozo, et al, 1997). 
Using RT/PCR, freshly isolated sputum samples from asthmatic patients were iNOS 
positive. However, when cultured in vitro, sputum cells failed to generate NO 
spontaneously. Stimulation with SEB induced dose- and time- dependent 
upregulation of NO production. It has been suggested that normal human large­
airway epithelium is iNOS positive (Kobzik, et al, 1993, Guo, et al, 1995), probably 
as a result of constant exposure to inductive stimuli including ozone, EPS and airborne 
pathogens. Interestingly, culture of airway epithelial cells ex vivo without stimulation 
leads to loss of iNOS gene expression, thus, it is difficult to conclude whether iNOS 
expression in aiiway epithelium is “constitutive” or is continually “induced”. 
Recently, the same group suggested that a combination of IFN-y / IL-4, which is 
present in lung epithelial lining fluid, leads to maintenance of iNOS expression in 
human aiiivay epithelium through production of “soluble mediators” and stabilization 
of mRNA (Guo, et al, 1997). The present study therefore suggests that confiimed 
stimulation is a pre-requisite for iNOS expression and NO synthesis.
Immunohistochemical localisation identified iNOS expression in epithehal cells and 
macrophages from asthmatic patients as well as normal controls. The anti-iNOS 
antibody employed here also detected alveolai* macrophages expressing iNOS in 
pulmonai*y tuberculosis patients (Nicholson, et al, 1996). Neutralisation studies 
confiimed that it did not cross-react with either rodent iNOS or human eNOS. The 
iNOS staining pattern observed contrasted with tliat reported using antibody raised 
against muiine iNOS, which suggested more extensive iNOS expression (Hamid, el
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al, 1993). The latter may leflect some cross reactivity chaiacteristic of anti-rodent 
iNOS antisera.
Controversy over the issue of NO production by human macrophages has been intense 
(Denis, 1991, Dugas, et al, 1995, Schneemann, et al, 1993 & 1997). iNOS has been 
difficult to demonstrate in human macrophages derived in vitro from normal donor 
monocytes. However, when monocytes / macrophages are taken from patients with 
inflam matoiy or infectious diseases and studied either directly or following stimulation 
in vitro with cytokines, results now emerging seem consistently positive (reviewed by 
MacMicking, et al, 1997). Thus, the problems encountered in vitro aie more 
appropriately viewed as a deficiency in culture techniques and immunologic 
knowledge than as an inadequacy of the cell.
NO is likely to influence numerous immunoregulatory pathways in asthma. Aii"way 
inflammation is chai*acterized by activation of mast cells and macrophages, and 
infiltration of eosinophils. Moreover, there is clear evidence suggesting that T-helper 
(Th) cells are activated in the airway mucosa, with pæferential proliferation of Th2 
cells and expression of IL-5 mRNA (Hamid, et al, 1991). NO can down regulate the 
Thl cell response (Wei, et al, 1995; Mcinnes, et al, 1998), thus enhancing the 
differentiation of Th2 cells to produce IL-4, and IL-5 which is important for 
recnaitment of eosinophils into the airway. This process could be further augmented 
by IL-15 which can both induce lL-5 production from human Th2 cell clones (Mori, et 
al, 1996) and seiwiiig as a T cell lecruitment factor (Wilkinson & Liew, 1995). 
Recently, IL-15 has been shown to enhanced pro-inflammatory cytokine production 
including TNF-a, lL-1 and lL-6 in activated macrophages (Alieva, et al, 1997), 
suggesting an important role in monokine regulation. Moreover, a novel IL-15 
receptor has been reported on mast cells (Tagaya, et al, 1996), raising the possibility 
that IL-15 may contiibute to mast cell degranulation in asthma. Thus, the finding of
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IL-15 in the aii*way of asthmatics, and together with the presence of NO, provides an 
important new pathway through which inflammation may be perpetuated.
TNF-a has a postulated role in the pathogenesis of asthma. Cells from 
bronchoalveolai* lavage (BAL) fluid from stable atopic asthmatics express more TNF- 
a  mRNA when compared with nonnals (Ying, et al, 1991), and iTiai'ked elevation of 
TNF-a levels has been reported in BAL fluid from patients with symptomatic asthma 
(Broide, et al, 1992). Immunohistochemical techniques show a similar pattern, with 
bronchial biopsies showing an increase in TNF-a positive cells in symptomatic 
subjects compared with asymptomatic and control subjects (Ackeiman, et al, 1994). 
TNF-a has been shown to induce bronchial hyperresponsiveness in rats (Kips, et al, 
1992) and is a recognised inducer of iNOS expression in animal systems (Nathan & 
Xie, 1994; Liew, 1994). The mechanism by which NO in turn regulates TNF-a 
synthesis remains unclear. In peripheral blood raononucleai* cells, the upregulation of 
TNF-a by NO has been associated with changes in the binding activity of NF-kB, a 
transcriptional factor that increases TNF-a synthesis at the promoter level (Lander, et 
al, 1993). The present study clearly demonstrates the existence of complex feedback 
loops involving both proinflammatoiy cytokines and NO. The therapeutic potential of 
such observations remains unclear.
Corticosteroids, given either by inhalation or orally are the most effective form of 
therapy in asthma, with inhaled administration representing the mainstay of therapy. 
There is clear evidence of active inflammation in the airways of even newly diagnosed 
asthmatics (Laitinen, et al, 1993), and corticosteroids can be shown to reduce such 
inflammation (Laitinen, et al, 1992), with discontinuation of treatment often leading to 
exacerbation of disease (Haahtehla, et al, 1994). Corticosteroids inhibit the 
transcription of most inflammatoiy cytokines present in asthma, including IL -lp, IL- 
3, IL-4, lL-5, lL-6, TNF-a, GM-CSF and the chemokines lL-8, and RANTES along 
with monocyte and macrophage chemoaltractants (Barnes, 1996), probably via
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indirect effect on critical transcription factors. Furthermore, they inhibit iNOS 
expression by inhibiting NF-kB binding (Xie, et al, 1994). Although the effect of 
corticosteroids on IL-15 remains unclear, dexamethasone is known to down regulate 
peripheral blood mononuclear cell responses to IL-15 by inhibiting IL-15Ra 
expression, thus blocking the high affinity IL-15 to IL-15Ra interaction (Chae, et al, 
1996). These results also offer another mechanistic explanation for the efficacy of 
inhaled glucocorticoid tiieatment in asthma.
In conclusion, these results demonstrated the expression of significant levels of NO 
and IL-15 in the aiiways of asthmatic patients. Such expression was downregulated 
in steroid treated patients. NO and IL-15 ai'c therefore potential important targets for 
effective therapeutic approaches in asthma.
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Chapter 7
General Discussion
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7 .1  Rheumatoid arthritis
Neither the initiating events, nor the peipetuating factors in the pathogenesis of RA are 
well understood. The cellular components present within the synovium comprise T 
lymphocytes, monocyte / macrophages, mast cells, neuti'ophils, and plasma cells, 
together with an expanded population of activated synovial fibroblasts (synoviocytes). 
No consensus exists as to which is the principal regulatory cell, representing the 
optimal therapeutic tai-get, nor indeed, whether such regulatory contribution is stable 
with disease progression (Firestein & Zvaifler, 1990; Panayi, et al, 1992; Kingsley, et 
al, 1996).
Given the postulated autoimmune basis for RA, most debate surrounds the role of T 
lymphocytes in pathogenesis (reviewed by Fox, 1997). Several factors suggest a pro- 
inflammatoiy role for T cells in RA, including their critical role in animal arthritis 
models, the partial efficacy of T cell diiected therapies in clinical studies and, most 
persuasively, the disease association with specific HLA-DR alleles. However, T cell 
derived cytokines aie detected only at low levels in synovial membrane and bone / 
cai'tilage destruction does not necessarily conelate with the presence of synovial 
inflammation. The majority of synovial T cells ai*e CD45RB‘’™, RO"*", CD27~, 
representing a mature, memory T cell phenotype, and express a complex combination 
of early and late activation maikers, including multiple adhesion molecules. However, 
although extensive mceptor analyses have identified oligoclonality in tlie synovial T 
cell repertoire, as yet there aie no consistent data to indicate a single antigen-driven 
process. In contrast, widespread evidence exists of macrophage activation and of 
monokine synthesis. The identification of IL-15, a cytokine of macrophage or 
fibroblast derivation, which is capable of T cell recmitment and activation in the 
synovial membrane, therefore provides a novel pathway for T cells in contributing to 
the inflammatory process in RA.
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IL-15 exhibits a high degree of redundancy and pleiotropy contiolling a wide range of 
functions within the immune system. This redundancy is explained in part by the 
sharing of common receptor subunits if 1L-2R p and yc chains. In addition, a novel 
60-65 kDa receptor for IL-15 has been identified on mast cells, designated 1L-15RX, 
which requires neither IL-2Rp nor y chain for signalling. This receptor recinits 
distinct signalling pathways. Whereas IL-15apy complex signals through JAK 1/3 
and STAT 3/5, IL-15RX utilises JAK 2 and STAT 5. IL-15 mRNA is detected in RA 
synovial membrane and its relative expression vaiies with prior immunosuppressive 
therapy (Kotake, et al, 1997). IL-15 was detected by ELISA in 30/53 RA synovial 
fluids in the range 10-1128 pg/ml (median of positive samples 198 pg/ml). 
Interestingly, this activity correlated with SF TNF-a concentrations and remained after 
removal of rheumatoid factor, which might have interfered with earlier assay systems. 
IL-15 can also be detected immunohistochemically in the RA synovial membrane, 
using several monoclonal antibodies, where it is localised to macrophages and 
fibroblasts in the synovial lining layer and within lymphocytic aggregates (Mcinnes, et 
al, 1996b). Subsequent histologic studies have confiimed the presence of IL-15 in RA 
and also in synovial biopsies from reactive arthritis patients, in which synovial T cells 
also express IL-15 (Thurkow, et al, 1997). It remains unclear whether this represents 
membrane bound or synthesised cytokine and in situ mRNA studies aio awaited. 
Together these data clearly demonstrate that IL-15 can be expressed at the mRNA and 
protein level during synovial inflammation.
In normal circumstances, the interaction of T lymphocytes and macrophages is critical 
to generate cytokines from either cell type, which together regulate the nature and 
outcome of the immune response. Since outcome encompasses a spectrum from 
complete resolution to chronicity, this relationship is Hkely to be critical in RA. Data 
from animal arthritis models, in vitro synovial cultures and from recent clinical trials in 
RA patients indicate that TNF-a occupies a pivotal position in the regulation of 
synovial inflammation (Feldmann, et al, 1996). However, less is known about those
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factors which in turn up-regulate TNF-a synthesis, particulaiiy in the ælative absence 
of IFN-y. Although IL-15 induced TNF-a production by SF T cells in vitro, it
appeared not to have a direct effect on macrophages, which represent the predominant 
source of TNF-a in vivo. Immunohistochemical studies cleaiiy demonstrate 
juxtaposition of T cells and macrophages in RA synovial membrane, with concomitant 
reciprocal adhesion molecule expression, suggestive of regulatory ‘cross-talk’ 
(Mcinnes, et al, 1996b). Therefore, the possibility that IL-15 might induce 
macrophage activation through cognate interactions with activated T cells was 
explored. Previous studies have established that PFA-frxed T cells and T cell clones, 
stimulated with non-physiological mitogens (PHA, PMA, OKT3) induce 
proinflammatoiy cytokine and MMP production by macrophages and fibroblasts 
through cell-contact (Vey, et al, 1992; Isler, et al, 1993; Lacraz, et al, 1994). Using a 
similar assay system in the present study, freshly isolated synovial T cells induced 
TNF-a synthesis by blood- or synovial-derived macrophages ex vivo through ceU- 
membrane contact, with no requirement for secretory factors. This activity was 
maintained in vitro by addition of rIL-15 but not of rIL-2. Moreover, rIL-15 conferred 
similar properties upon CD45RO’' PB T cells, such that rIL-15-activated PB T cells 
from RA patients induced TNF-a synthesis in synovial macrophage / synoviocyte co­
cultures. Neutralisation studies implicated at least CD69, LFA-1 and ICAM-1 in this 
pathway. Furthermore, IL-15 was also produced by similarly activated macrophages 
via cell-contact.
Thus, it is attr active to hypothesise that under the continuing influence of IL-15, newly 
anived T cells within the synovial membrane can up regulate TN F-a production by 
macrophages, predominantly through cell membrane contact. This may generate a 
positive feedback loop, whereby IL-15 produced by activated macrophages maintains 
T cell-induced synthesis of TNF-a, which can further activate macrophages to 
produce IL-15 (Figure 3.13). In addition, T cells need have no absolute requirement 
for T cell cytokine production, nor for the recognition of local antigen.
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IL-15 may conüibute to RA synovitis by several means other than T cell activation and 
cell-contact. Effects of IL-15 on adhesion molecule redistribution on T cells have been 
reported (Nieto, et al, 1996). Furthermore, IL-15 is also a potent chemotactic factor 
for T lymphocytes. Evidence in vitro (Wilkinson & Liew, 1995; Al-Mughales, et al, 
1996) and in vivo in the cuitent study indicates that IL-15 can induce significant T cell 
recruitment. The combination of effects on adhesion and locomotion imply an 
important role for IL-15 in regulating T cell extravasation and simultaneous endothelial 
contact events, which mediate lymphocyte migration to the synovial compartment. 
Recently, neutrophil activation, cytoskeletal reaiTangement and protection from 
apoptosis by IL-15 has been reported (Girard, et al, 1996). The present study 
demonstrated that IL-15 may also promote neutrophil recruitment and activation 
through enhancement of adhesion molecule (CD 11b) and cytokine production. In 
addition, the ability to activate B cells and to induce isotype switching indicates a 
possible role in rheumatoid factor production in the synovial membrane. Significant 
numbers of plasma cells synthesising rheumatoid factor are present in synovial 
membrane, often surrounding T cell aggregates (Otten, et al, 1993; Brown, et al, 
1995), but their pathological role is unclear*. Immune complexes formed from local 
auto-antibody production can contribute to synovial inflammation, through 
complement fixation, up regulation of cytokine production, and neutrophil activation 
(Chantry, et al, 1989; Plater-Zyberk, et al, 1992; Robinson, et al, 1992a). Finally, IL- 
15Ra chain expression has been detected in activated macrophages (Giri, et al, 1995; 
Anderson, et al, 1995b), and it remains possible that IL-15 can exert direct effects on 
macrophages in an autocrine fashion (AUeva, et al, 1997).
The CIA model provides an opportunity to study the relative contr'ibution of immune 
pathways to the development of inflammatory arthritis. Using this approach, previous 
studies have demonstrated a role for Thl cells and several pro-inflammatory cytokines, 
including TNF-a and IL-lp (Arend & Dayer, 1995; Mauri, et al, 1996). Subsequent 
clinical trials with neutralising antibodies against TNF-a and soluble TNF-a receptors
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have demonstrated efficacy in human RA (Elliott, et al, 1994; Rankin, et al, 1995; 
Moreland, et al, 1997). The present data indicate that IL-15 expression is requked for 
the mduction of erosive inflammatoiy arthiitis following challenge of collagen primed 
DBA/1 mice as administration of sIL-15Ra profoundly suppressed the development of 
CIA in these animals. Moreover, the altered serum immunoglobulin levels detected, 
and in vitro evidence for reduced spleen cell proliferation and cytokine production 
indicate that the Thl collagen-specific response has been significantly modified. 
Taken together, these results provide in vitro and in vivo data which suggest a cmcial 
role for IL-15 in RA pathogenesis and suggest that antagonists to this cytokine could 
be of therapeutic benefit.
7 .2  Asthma
The present study represents the first demonstiation of IL-15 expression in asthma. 
IL-15 staining is increased in macrophages and aimay epithelial cells from steroid- 
naive asthmatics compared to normals. This increased expression is abolished in 
asthmatics receiving inhaled corticosteroids. IL-15 increases IL-5 production by 
human Th2 cell clones (Mori, et al, 1996), and mast cells proliferate and mature 
through IL-15 mediated binding to its own IL-15X receptor (Tagaya, et al, 1996a), 
indicating a possible role in type I bronchial hypersensitivity. In addition, IL-15 has 
been identified in alveolar macrophages from patients with pulmonaiy sarcoidosis 
(Agostini, et al, 1996). Moreover, it induces proinflammatoiy cytokine production 
including IL-1, IL-6 and TNF-a from activated macrophages (Alieva, et al, 1997). 
IL-15 production is strictly controlled (Bamford, et al, 1996b, Tagaya, et al, 1997) 
and rapid down regulation of IL-15Ra chain follows T cell activation, in comparison 
to IL-2Ra (Kumaki, et al, 1996), indicating that its functional role is short lived in the 
noimal event. It is therefore attractive to hypothesise, given the widespread 
expression of IL-15 mRNA, that failure to properly regulate IL-15 production
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following an initial immunologic challenge could lead to constitutive expression, 
thereby dismpting immune homeostasis in the bronchial lining tissues.
NO has been implicated in physiologic regulation and in inflammation in the lung 
(Barnes & Belvisi, 1993; Gaston, et al, 1994). Staining for iNOS was increased in 
cells from steroid-naive asthmatics, and inhaled steroid therapy resulted in decreased 
production of NO from stimulated cells from asthmatics. There is cleai* evidence 
suggesting that T-helper cells are activated in the airway mucosa, with proliferation of 
Th2 cells and expression of IL-5 mRNA (Hamid, et al, 1991). NO can down regulate 
the Thl cell response (Wei, et al, 1995, Mcinnes, et al, 1998), thus enhancing the 
differentiation of Th2 cells to produce IL-4, and IL-5 which aie important for 
recruiting eosinophils into the aiiivay. Furthermore, NO induces TNF-a synthesis by 
synovial tissues from RA patients, indicating that such observations likely have 
pathological relevance (Mcinnes, et al, 1996a). The observation that IL-15 and the 
NO donor SNAP together increase TNF-a production is of further interest raising the 
possibility that IL-15 and NO may together enhance Th2 responses in asthma.
NO likely has activities beyond effects on T cell differentiation. Endothelium-derived 
NO may be important in regulating aiiivay blood flow and, indirectly, plasma 
exudation. NO is the neurotransmitter of bronchodilator neiwes in human airways and 
counteracts the bronchoconstriction due to cholinergic neural mechanisms. iNOS is 
expressed in human epithelial cells in response to pro-inflammatory cytokines and 
oxidants, probably via activation of the transcription factor NF-kB. This is increased 
expression of iNOS in the aimay epithelial cells and alveolar macrophages may 
account for the increased concentration of NO in the exhaled air of patients with 
inflammatory aii*ways disease. Increased NO production in the aii’ways may result in 
hyperaemia, plasma exudation, mucus secretion and indirectly in increased 
proliferation of Th2 lymphocytes responsible for eosinophilic inflammation. 
Glucocorticoids inhibit the induction of iNOS in epithelial cells and reduce the elevated
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exhaled NO to iionnal values (Robbins, et al, 1994; Kharitonov, et al, 1996). The 
present study provides further evidence for direct effect of inhaled steroids on iNOS 
expression. Moreover, glucocorticoids inhibit the transcription of most inflammatoiy 
cytokines and chemokines in asthma. Interestingly, the increased expression of IL-15 
in asthmatic cells obseiwed in the cuirent study was abolished in patients receiving 
inhaled glucocoiticoids, and although the mechanism of this effect is not known, 
dexamethasone is known to downregulate PBMC response to IL-15 by inhibiting IL- 
15Ra expression, thereby blocking the high affinity IL-15 to IL-15Ra interaction 
(Chae, et al, 1996). This may offer another possible mechanism for the action of 
inhaled glucocorticoids ti'eatment in asthma.
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C o n clu sio n s
The present study investigated the role of IL-15 in chronic inflammatory responses. 
The principal conclusions aie as follows:
Through its effects on T lymphocytes via cell-contact with monocytes and fibroblasts, 
IL-15 upregulated TNF-a and its own production within the rheumatoid synovial 
membrane. IL-15 was also capable of upregulation of adhesion molecule expression 
and cytokine / chemokiiie production by neutrophils. Finally, IL-15 blockade was 
effective in preventing the onset of collagen-induced arthritis, in pait through 
modification of collagen specific immune responses. Together these data indicate an 
important role for IL-15 in articular inflammation.
IL-15 was expressed by epithelial and inflammatoiy cells induced from the human 
respiratory tr act of asthmatic patients. Similarly iNOS expression and NO production 
was demonstrated from the same cell population. NO and IL-15 were synergistically 
capable of inducing TNF-a production in respiratoiy cells in vitro, suggesting 
complex interactions between NO and cytokine production in human inflammatoiy 
tissues.
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Future Studies
Reference has been made in the text to further investigations at specific points of
interest. Key areas are the following:
® Regulation of IL-15 production - identification of molecules involved in T ceU / 
macrophage contact leading to IL-15 secretion.
• IL- 15Ra expression - to determine its distribution and regulation of its expression 
in chi'onic inflammatory sites.
* Cartilage degradation - to study whether IL-15 can modulate production of MMP, 
proteinases and hydrolases by activated T cells and neutrophils.
® NO in cytokine regulation - what is the role of NO in regulation of production of 
other proinflammatory cytokines in asthma and RA, including IL-15 and TNF-a?
203
References
204
Aaron, S. and V. Paetkau. (1991) Synovial cell secretion of IL-2 in vitro: a limiting 
dilution analysis. Clin. Exp. Rheumatol. 9:113-118.
Ackerman, V., M. Maiini, E. Vittori, A. Bellini, G. Vassali and S. Mattoli. (1994) 
Detection of cytokines and their cell sources in bronchial biopsy specimens 
from asthmatic patients: Relationship to atopic status, symptoms, and level of 
airway hypeiresponsiveness. Chest. 105:687-696.
Aderka, D., H. Engelman, Y. Maor, C. Brakebusch and D. Wallach. (1992) 
Stabilisation of the bioactivity of TNF by its soluble receptors. J. Exp. Med. 
175:323-329.
Afeltra, A., M. Galeazzi, G. M. Ferri, A. Amoroso, O. De Pita, F. Porzio and L. 
Bonomo. (1993) Expression of CD69 antigen on synovial fluid T cells in 
patients with rheumatoid arthritis and other chronic synovitis. Ann. Rheum. 
Dis. 52:457-460.
Agostini, C., L. Trentin, M. Facco, R. Sancetta, A. Cerutti, C. Tassinari, L. 
Cimarosto, F. Adami, A. Cipriani, R. Zambello and G. Semenzato. (1996) 
Role of IL-15, IL-2, and their receptors in the development of T cell 
alveolitis in pulmonary sarcoidosis. J. Immunol. 157:910-918.
Agostini, C., L. Trentin, R. Sancetta, M, Facco, C. Tassinari, A. Cerutti, M. Bortolin,
A. Milani, M. Siviero, R. Zambello and G. Semenzato. (1997) Interleukin-15 
triggers activation and growth of the CD8 T-cell pool in extravascular tissues 
of patients with acquired immunodeficiency syndrome. Blood. 90:1115- 
1123.
Ajjan, R. A., P. F. Watson and A. P. Weetman. (1997) Detection of IL-12, IL-13, 
and IL-15 messenger ribonucleic acid in the thyroid of patients with 
autoimmune thyroid disease. J. Clin. Endocrinol. Metabol. 82:666-669.
Akbar, A. N., N. J. Borthwick, R. G. Wickremasinghe, P. Panayiotidis, D. Pilling, 
M. Bofill, S. Krajewski, J. C. Reed and M. Salmon. (1996) Interleukin-2 
receptor common gamma-chain signaling cytokines regulate activated T cell 
apoptosis in response to growth factor withdrawal: Selective induction of 
anti-apoptotic (bcl-2, bcl-chi(L)) but not pro-apoptotic (bax, bcl-chi(s)) gene 
expression. Eur. J. Immunol. 26:294-299.
205
Al-Mughales, J., T. H. Blyth, J. A. Hunter and P. C. Wilkinson. (1996) The 
chemoattractant activity of rheumatoid synovial fluid for human lymphocytes 
is due to multiple cytokines. Clin. Exp. Immunol. 106:230-236.
Albina, J. E., S. Cui, R. B. Mateo and J. S. Reichner, J.S. (1993) Nitric oxide 
mediated apoptosis in murine peritoneal macrophages. J. Immunol. 
150:5080-5085.
Alieva, D. G., S. B. Kaser, M. A. Monroy, M.J . Fenton and D. I. Beller. (1997) IL- 
15 functions as a potent autocrine regulator of macrophage proinflammatory 
cytokine production - Evidence for differential receptor subunit utilization 
associated with stimulation or inhibition. J. Immunol. 159:2941-2951.
Anderson, D. M., L. Johnson, M. B. Glaccum, N. G. Copeland, D. J. Gilbert, N. A. 
Jenkins, V. Valentine, M. N. Kirstein, D. N. Shapiro, S. W. Morris, K. 
Grabstein and D. Cosman. (1995a) Chromosomal assignment and genomic 
structure of IL15. Genomics. 25:701-706.
Anderson, D. M., S. Kumaki, M. Ahdieh, J. Bertles, M. Tometsko, A. Loomis, J. 
Giri, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, V. Valentine, D. N. 
Shapiro, S. W. Morris, L. S. Park and D. Cosman. (1995b) Functional 
characterization of the human interleukin-15 receptor alpha chain and close 
linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270:29862-29869.
Angel del Pozo, M., P. Sanchez-Mateos and F. Sanchez-Madrid. (1996) Cellular 
polarization induced by chemokines: a mechanism for leukocyte 
recruitment? Immunol. Tod. 17:127-131.
Angiolillo, A. L., H. Kanegane, C. Sgadari, G. H. Ream an and G. Tosato. (1997) 
Interleukin-15 promotes angiogenesis in vivo. Biochem. Biophys. Res. 
Commun. 233:231-237.
Aoki, T. (1990) Continuous flow determination of nitrite with membrane separation 
/ chemiluminescence detection. Biomed. Chromatog. 4:128-130.
Arai, K., F. Lee, A. Miyajima, S. Miyatake, N. Arai and T. Yokota. (1990) 
Cytokine: coordinators of immune and inflammatory responses. Annu. Rev. 
Biochem. 59:783-836.
206
Archer, S. (1993) Measurement of nitric oxide in biological models. FASEB J. 
7:349-360.
Arend, W. P. and J. M. Dayer. (1995) Inhibition of the production and effects of 
interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. 
Arthritis Rheum. 38:151-160.
Ai’mitage, R. J., B. M. Macduff, J. Eisenman, R. Paxton and K. H. Grabstein. (1995) 
IL-15 has stimulatory activity for the induction of B cell proliferation and 
differentiation. J. Immunol 154:483-490.
Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, 
et al. (1988) The American Rheumatism Association 1987 revised criteria for 
the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324.
Athanasou, N. A. and J. Quinn. (1991) Immunocytochemical analysis of human 
synovial lining cells: phenotypic relation to other marrow derived cells. Ann. 
Rheum. Dis. 50:311-315.
Athanasou, N. A. (1995) Synovial macrophages. Ann. Rheum. Dis. 54:392-394.
Baars, P. A., M. M. Maurice, M. Rep, B. Hooibrink and R. A. W. Vanlier. (1995) 
Heterogeneity of the circulating human CD4^ T-cell population - Evidence 
that the CD4^ CD45RA CD27 T-cell subset contains specialized primed T- 
cells. J. Immunol 154:17-25.
Badolato, R., A. N. Ponzi, M. Millesimo, L. D. Notarangelo and T. Musso. (1997) 
Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 
production in human monocytes. Blood. 90:2804-2809.
Baggiolini, M., B. Dewald and B. Moser. (1994) Interleukin-8 and related 
chemotactic cytokines - CXC and CC chemokines. Adv. Immunol 55:97-179.
Bamford, R. N., A. J. Grant, J. D. Burton, C. Peters, G. Kurys, C. K. Goldman, J. 
Brennan, E. Roessler and T. A. Waldmann. (1994) The interleukin (IL) 2 
receptor beta chain is shared by IL-2 and a cytokine, provisionally designated 
IL-T, that stimulates T-cell proliferation and the induction of lymphokine- 
activated killer cells. Proc. Natl Acad. ScL USA. 91:4940-4944.
■1
207
Bamford, R. N., A. P. Battiata and T. A. Waldmann. (1996a) IL -15: The role of 
translational regulation in their expression. J. Leukocyte Biol 59:476-480.
Bamford, R. N., A. P. Battiata, J. D. Burton, H. Sharma and T. A. Waldmann. 
(1996b) Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell 
line HuT-102 is associated with a human T-cell lymphotrophic vims type IR  
region/IL-15 fusion message that lacks many upstream AUGs that normally 
attenuate IL-15 mRNA translation. Proc. Natl. Acad. Sci. USA. 93:2897- 
2902.
Bamford, R. N., Y. Tagaya and T. A. Waldmann. (1997) Interleukin 15 - What it 
does and how it is controlled. The Immunologist 5:52-56.
Barnes, P. J. and M. G. Belvisi. (1993) Nitric oxide and lung disease. Thorax. 
48:1034-1043.
Barnes, P. J. and F. Y. Liew. (1995) Nitric oxide and asthmatic inflammation. 
Immunol. Today. 16:128-130.
Barnes, P.J. (1996) Molecular mechanisms of steroid action in asthma. J. Allergy 
Clin. Immunol. 97:159-168.
Bazan, J. F. (1990) Haemopoietic receptors and helical cytokines. Immunol. Toddy 
11:350-354.
Bazzoni, F., M. A. Cassatella, F. Rossi, M. Ceska, B. Dewald and M. Baggiolini. 
(1991) Phagocytosiiig neutrophils produce and release high amounts of the 
neutrophil-activating peptide-l/Interleukin-8. J. Exp. Med. 173:771-774.
Beasley, R., W. R. Roche, J. A. Roberts and S. T. Holgate. (1989) Cellular events in 
the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. 
Dis. 139:806-817.
Beaulieu, A. D. and S. R. McColl. (1994) Differential expression of two major 
cytokines produced by neutrophils, interleukin-8 and the interleukin- 1 
receptor antagonist, in neutrophils isolated from the synovial fluid and 
peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 
37:855-859.
208
Bentley, A. M., P. Maestrelli, M. Saetta, L. M. Fabbri, D. S. Robinson, B. L. 
Bradley, P. K. Jeffery, S. R. Durham and A. B. Kay. (1992) Activated T- 
lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced 
asthma. J. Allergy Clin. Immunol. 89:821-829.
Bentley, A. M., S. R. Durham and A. B. Kay. (1994) Comparison of the 
immunopatholgoy of extrinsic, intrinsic and occupational asthma. J. Invest. 
Allergol. Clin. Immunol. 4:222-232.
Bernareggi, M., J. A. Mitchell, P. J. Barnes and M. G. Belvisi. (1997) Dual action of 
nitric oxide on airway plasma leakage. Am. J. Respir. Crit. Care Med. 
155:869-874.
Blauvelt, A., H. Asada, V. KlausKovtum, D. J. Altman, D. R. Lucey and S. I. Katz.
(1996) Interleukin-15 mRNA is expressed by human kératinocytes, 
langerhans cells, and blood-derived dendritic cells and is downregulated by 
ultraviolet B radiation. J. Invest. Dermatol. 106:1047-1052.
Bluman, E. M., K. J. Bartynski, B. R. Avalos and M. A. Caligiuri. (1996) Human 
natural killer cells produce abundant macrophage inflammatory protein- 
1 alpha in response to monocyte-derived cytokines. J. Clin. Invest. 97:2722- 
2727.
Blyth, D. I., M. S. Pedrick, T. J. Savage, E. M. Hessel and D. Fattah. (1996) Lung 
inflammation and epithelial changes in a murine model of atopic asthma. Am. 
J. Resp. Cell Mol. Biol. 14:425-438.
Bochner, B. S., B. J. Undem and L. M. Lichtenstein. (1994) Immunological aspects 
of allergic-asthma. Annu. Rev. Immunol. 12:295-335.
Boissier, M-C., G. Chiocchia, N. Bessis, J. Hajnal, G. Garotta, F. Nicoletti and C. 
Fournier. (1995) Biphasic effect of interferon-y in murine collagen-induced 
arthritis. Eur. J. Immunol. 25:1184-1190.
Bonvoisin, B., G. Cordier, J. P. Revillard, E. Lejeune and M. Bouvier. (1984) 
Increased DNA and/or RNA content of synovial fluid cells in rheumatoid 
arthritis: a flow-cytometric study. Ann. Rheum. Dis. 43:222-227.
209
Borish, L., J. J. Mascali, J. Dishuck, W. R. Beam, R. J. Martin and L. H. 
Rosenwasser. (1992) Detection of alveolar macrophage-derived XL-1(3 in 
asthma. J. Immunol. 149:3078-3082.
Bousquet, J., P. Chanez, J. Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. 
Venge, S. Ahistedt, J. Simonylafontaine, P. Godard and F. B. Michel. (1990) 
Eosinophilic inflammation in asthma. New Engl. J. Med. 323:1033-1039.
Bradding, P., I. H. Feather, P. H. Howarth, R. Mueller, J. A. Roberts, K. Britten, J. 
P. A. Bews, T. C. Hunt, Y. Okayama, C. H. Heusser, G. R. Bullock, M. K. 
Church and S. T. Holgate. (1992) Interleukin-4 is localized to and released 
by human mast-cells. J. Exp. Med. 176:1381-1386.
Bradley, B. L., M. Azzawi, M. Jacobson, B. Asssoufi, J. V. Collins, A-MA. Irani, L.
B. Schwartz, S. R. Durham, P. K. Jeffery and A. B. Kay. (1991) Eosinophils, 
T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy 
specimens from atopic subjects with asthma: Comparison with biopsy 
specimens from atopic subjects without asthma and normal control subjects 
and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 
88:661-674.
Brandes, M. E., J. B. Allemn, Y. Ogawa and S. M. Wahl. (1991) TGF(3l suppresses 
acute and chronic arthritis in experimental animals. J. Clin. Invest. 87:1108- 
1113.
Bredt, D. S. and S. H. Snyder. (1994) Nitric oxide: A physiological messenger 
molecule. Annu. Rev. Biochem. 63:175-195.
Brennan, F. M., D. Chantry, A. Jackson, R. N. Maini and M. Feldmann. (1989) 
Inhibitory effect of TN Fa antibodies on synovial cell interleukin-1 
production in rheumatoid arthritis. Lancet 2:244-247.
Brezinschek, R. I., P. E. Lip sky, P. Galea, R. Vita and N. Oppenheimer-Marks. 
(1995) Phenotypic characterisation of CD4'" T cells that exhibit a 
transendothelial migratory capacity. J. Immunol. 154:3062-3077.
Broide, D. H., M. Lotz, A. J. Cuomo, D. A Coburn, E. C. Federman and S. I. 
Wasserman. (1992a) Cytokines in the symptomatic asthma airways. J. 
Allergy Clin Immunol. 89:958-967.
210
Broide, D. H., M. M. Paine and G. S. Firestein. (1992b) Eosinophils express 
interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA 
at sites of allergie inflammation in asthmatics. J. Clin. Invest. 90:1414-1424.
Brostjan, C., J. Anrather, V. Csizmadia, G. Natarajan and H. Winkler. (1997) 
Glucocorticoids inhibit E-Selectin expression by targeting NK-kB and not 
ATF/c-Jun. J. Immunol. 158:3836-3844.
Brown, K. A., M. E. PeiTy, Y. Mustafa, S. K. Wood, M. Crawley, N. Taub and D. C. 
Dumonde. (1995) The distiibution and abnormal morphology of plasma cells 
in rheumatoid synovium. Scand. J. Immunol. 41:509-517.
Brusselle, G., J. Kips, G. Joos, H. Bluethmann and R. Pauwels. (1995) Allergen- 
induced airway inflammation and bronchial responsiveness in wild-type and 
interleukin-4-deficient mice. Am. J. Resp. Cell Mol. Biol. 12:254-259.
Buchan, G., K. Barrett, T. Fujita, T. Taniguchi, R. N. Maini and M. Feldmann.
(1988) Detection of activated T cell products in the rheumatoid joint using 
cDNA probes to interleukin-2, IL-2 receptor and interferon-y. Clin. Exp. 
Immunol. 71:295-302.
Bucht, A., P. Larsson, L. Weisbrot, C. Thorne, P. Pisa, G. Smedegard, E.C. 
Keystone and A. Gronberg. (1996) Expression of interferon-garama (IFN- 
gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) 
mRNA in synovial fluid cells from patients in the early and late phases of 
rheumatoid arthritis (RA). Clin. Exp. Immunol. 103:357-367.
Bukrinsky, M. I., H. Nottet, H. Schmidtmayerova, L. Dubrovsky, C. R. Flanagan, M. 
E. Mullins, S. A. Lip ton and H. E. Gendelman. (1995) Regulation of nitric 
oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)- 
infected monocytes: Implications for HIV-associated neurological disease. J. 
Exp. Med. 181:735-745.
Buimester, G. R., P. Locher and B. Koch. (1983) The tissue architecture of synovial 
membranes in inflammatory and non-inflammatory joint diseases. I. The 
localization of the major synovial cell populations as detected by monoclonal 
reagents directed towards la and monocyte-macrophage antigens Rheumatol. 
Internat. 3:173-181.
211
Buiinester, G., B. Jahn, P. Rohwer, J. Zacher, R. J. Winchester and J. R. Kalden.
(1987) Differential expression of la antigens by rheumatoid synovial lining 
cells. J. Clin. Invest. 80:595-604.
Burton, J. D., R. N. Bamford, C. Peters, A. J. Grant, G. Kurys, C. K. Goldman, J. 
Brennan, E. Roessler and T. A. Waldmann. (1994) A lymphokine, 
provisionally designated interleukin T and produced by a human adult T-cell 
leukemia line, stimulates T-cell proliferation and the induction of 
lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA. 91:4935-4939.
Butler, D. M., A. M. Malfait, L. J. Mason, P. J. Warden, G. Kollias, R. N. Maini, M. 
Feldmann and F. M. Brennan. (1997) DBA/1 mice expressing the human 
TNF-alp ha transgene develop a severe, erosive arthritis - Characterization of 
the cytokine cascade and cellular composition. J. Immunol. 159:2867-2876.
Campion, G. V., M. E. Lebsack, J. Lookabaugh, G. Gordon, M. Catalano and the IL- 
Ira arthritis study group. (1996) Dose-range and dose-frequency study of 
recombinant interleukin-1 receptor antagonist in patients with rheumatoid 
arthritis. Arthritis Rheum. 39:1092-1101.
Carson, D.A. (1997) Unconventional T-cell activation by IL-15 in rheumatoid 
arthritis. Nature Med. 3:148-149.
Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. 
Anderson, J. Eisenmann, K. Grabstein and M. A. Caligiuri. (1994) 
Interleukin (IL)-15 is a novel cytokine that activates human natural killer 
cells via components of the IL-2 receptor. J. Exp. Med. 180:1395-1403.
Carson, W. E., M. E. Ross, R. A. Baiocchi, M. J. Marien, N. Boiani, K. Grabstein 
and M. A. Caligiuri. (1995) Endogenous production of interleukin-15 by 
activated human monocytes is critical for optimal production of interferon- 
gamma by natural killer cells in vitro. J. Clin. Invest. 96:2578-2582.
Carson, W. E., T. A. Fehniger, S. Haidar, K. Eckhert, M. J. Lindemann, F. Lai C, C. 
M. Croce, H. Baumann and M. A. Caligiuri. (1997) A potential role for 
interleukin-15 in the regulation of human natural killer cell survival. J. Clin. 
Invest. 99:937-943.
212
Cassatella, M. A. (1995) The production of cytokines by polymorphonuclear 
neutrophils. Immunol. Today. 16:21-26.
Cavazzana-Calvo, M., S. HaceinBey, G. De Saint Basile, C. De Coene, F. Selz, F. 
Le Deist and A. Fischer. (1996) Role of interleukin-2 (IL-2), IL-7, and IL-15 
in natural killer cell differentiation from cord blood hematopoietic progenitor 
cells and from gammac transduced severe combined immunodeficiency XI 
bone marrow cells. Blood. 88:3901-3909.
Chae, D. W., Y. Nosaka, T. B. Strom and W. Maslinski. (1996) Distribution of IL- 
15 receptor alpha-chains on human peripheral-blood mononuclear-cells and 
effect of immunosuppressive drugs on receptor expression. J. Immumol. 
157:2813-2819.
Chantry, D., C. G. Winearls, R. N. Maini and M. Feldmann. (1989) Mechanism of 
immune complex mediated damage: induction of IL-1 by immune complexes 
and synergy with IFN and TNFa. Eur. J. Immunol. 19:189-192.
Charles, I. G., R. M. J. Palmer, M. S. Hickery, M. T. Bayliss, A. P. Chubb, V. S. 
Hall, D. W. Moss and S. Moncada. (1993) Cloning, characterization, and 
expression of a cDNA encoding an inducible nitric oxide synthase from the 
human chondrocyte. Proc. Nat. Acad. Sci. USA 90:11419-11423.
Chattopadhyay, C., H. Chattopadhyay, J. B. Natvig, T. E. Michaelsen and O. J. 
Mellbye. (1979). Lack of suppressor cell activity in rheumatoid synovial 
lymphocytes. Scand. J. Immunol. 10:309-316.
Chehimi, J., J. D. Marshall, O. Salvucci, I. Frank, S. Chehimi, S. Kawecki, D. 
Bachelier, S. Rifat and S. Chouaib. (1997) IL-15 enhances immune functions 
during HIV infection. J. Immunol. 158:5978-5987.
Chen, E., E. C. Keystone and E. N. Fish. (1993) Restricted cytokine expression in 
rheumatoid arthritis. Arthritis Rheum. 36:901-910.
Cho, H. J., Q. W. Xie, J. Calalcay, R. A. Mumford, T. D. Lee and C. Nathan. (1992) 
Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. 
Med. 176:599-604.
213
Chu, C. Q., M. Field, E. Abney, R. Q. H. Zheng, S. Allard, M. Feldmann, M and R. 
N. Maini. (1991a) TGF|3l in rheumatoid synovial membrane and cartilage 
pannus junction. Clin. Exp. Immunol. 86:380-386.
Chu, C. Q., M. Field, M. Feldmann and R. N. Maini. (1991b) Localisation of 
Tumour Necrosis Factor alpha in synovial tissue and at the cartilage-pannus 
junction in rheumatoid arthritis. Arthritis Rheum. 34:1125-1132.
Chu, C. Q., M. Field, S. Allard, E. Abney, M. Feldmann and R. N. Maini. (1992) 
Detection of cytokines at the cartilage pannus junction in patients with 
rheumatoid arthritis: implications for the role of cytokines in cartilage 
destruction and repair. Brit. J. Rheumatol. 31:653-661.
Cluzel, M., M. Damon, P. Chanez, J. Bousquet, A. Crastes de Paulet, F. B. Michel 
and P Godard. (1987) Enhanced alveolar cell lurainol-dependent 
chemiluminescence in asthma. J. Allergy Clin. Immunol. 80:195-201.
Cohen, S. B. A., P. D. Katsikis, C. Q. Chu, H. Thomssen, L. M. C. Webb, R. N. 
Maini, M. Londei and M. Feldmann. (1995) High level of interleukin-10 
production by the activated T cell population within the rheumatoid synovial 
membrane. Arthritis Rheum. 38:946-952.
Colville-Nash, P. R. and D. L. Scott. (1992) Angiogenesis and rheumatoid arthritis: 
pathogenic and therapeutic implications. Ann. Rheum. Dis. 51:919-925.
Cooper, C. L., C. Mueller, T-A. Sinchaisri, C. Pirmez, J. Chan, G. Kaplan, S. M. M. 
Young, 1. L. Weissman, B. R. Bloom, T. H. Rea and R. L. Modlin. (1989) 
Analysis of naturally occurring deiayed-type hypersensitivity reactions in 
leprosy by in situ hybridization. J. Exp. Med. 169:1565-1581.
Cooper, S. M., S. Sriram and G. E. Ranges. (1988) Suppression of murine collagen- 
induced arthritis with monoclonal anti-la antibodies and augmentation with 
IFN-gamma. J. Immunol. 141:1958-1962.
Cope, A., D. Aderka, M. Doherty, H. Engelman, D. Gibbons, A. C. Jones, F. M. 
Brennan, R. N. Maini, D. Wallach and M. Feldmann. (1992) Increased levels 
of soluble tumour necrosis factor receptors in the sera and synovial fluid of 
patients with rheumatic diseases. Arthritis Rheum. 35:1160-1169.
214
Corrigan, C. J., A. Hartnell and A. B. Kay. (1988) T lymphocyte activation in acute 
severe asthma. Lancet. 1:1129-32.
Corry, D. B., H. G. Folkesson, M. L. Warnock, D. J. Erie, M. A. Matthay, J. P. 
Wienerkronish and R. M. Locksley. (1996) Interleukin 4, but not interleukin 
5 or eosinophils, is required in a murine model of acute airway 
hyperreactivity. J. Exp. Med. 183:109-117.
Coyle, A. J., F. Erard, C. Bertrand, S. Walti, H. Pire her and G. Legros. (1995) Virus- 
specific CD8(4-) cells can switch to interleukin-5 production and induce 
airway eosinophilia. J. Exp. Med. 181:1229-1233.
Coyle, A.J., K. Wagner, C. Bertrand, S. Tsuyuki, J. Bews and C. Fleusser. (1996) 
Central role of immunoglobulin (Ig)-E in the induction of lung eosinophil 
infiltration and T-helper-2 cell cytokine production - Inhibition by a non- 
anaphylactogenic anti-IgE antibody. J. Exp. Med. 183:1303-1310.
Cronstein, B. N. and G. Weissman. (1993) The adhesion molecules of inflammation. 
Arthritis Rheiun. 36:147-157.
Cush, J. J. and P. E. Lipsky. (1988) Phenotypic analysis of synovial tissue and 
peripheral blood lymphocytes isolated from patients with rheumatoid 
arthritis. Arthritis Rheiun. 31:1230-1238.
Cush, J. J., P. Pietschman, N. Oppenheimer-Marks and P. E. Lipsky. (1992) The 
intrinsic migratory capacity of memory T cells contributes to their 
accumulation in rheumatoid synoviom. Arthritis Rheiun. 35:1434-1444.
Damjanovich, S., L. Bene, J. Matko, A. Alileche, C. K. Goldman, S. Sharrow and T. 
A. Waldmann. (1997) Preassembly of interleukin 2 (IL-2) receptor subunits 
on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: 
A fluorescence resonance energy transfer study. Proc. Natl. Acad. Sci. USA. 
94:13134-13139.
Daniels, S. E„ S. Bhattacharrya, A. James, N. I. Leaves, A. Y ong, M. R. Hill, J. A. 
Faux, G. F. Ryan, P. N. Lesouef, G. M. Lathrop, et al. (1996) A genome- 
wide search for quantitative .trait loci underlying asthma. Nature 383:247- 
250.
215
Dayer, J-M., B. de Rochmontieux, S. Burrus, S. Demezcuk and C. A. Dinarello. 
(1986) Human recombinant interleukin-1 stimulates collagenase and 
prostaglandin E2 production by human synovial cells. J. Clin. Invest. 77:645- 
651.
de Jong, J. L. O., N. L. Earner, M. B. Widmer, J. G. Giri and P. M. Sondel. (1996) 
Interaction of IL-15 with the shared IL-2 receptor beta and gamma(c) 
subunits: The IL-15/beta/gamma(c) receptor-ligand complex is less stable 
than the IL- 2/beta/gamma(c) receptor-ligand complex. J. Immunol. 
156:1339-1348.
Deakin, A. M., A. N. Payne, B. J. R. Whittle and S. Moncada. (1995) The 
modulation of IL-6 and TNF-alpha release by nitric oxide following 
stimulation of J774 cells with LPS and INF-gamma. Cytokine. 7:408-416.
del Pozo, V., E. D. Arruda-Chaves, B. D. Andres, B. Cardaba, A. Lopez-Farre, S. 
Gallardo, I. Cortegane, L. Vidarte, A. Jurado, J. Sastre, P. Palomino and C. 
Lahoz. (1997) Eosinophils transcribe and translate messager mRNA for 
inducible nitric oxide synthase. J. Immunol. 158-859-864.
Deleuran B. W., C. Q. Chu, M. Field, F. M. Brennan, P. Katsikis, M. Feldman and 
R. N. Maini. (1992) Localization of interleukin-la, Type 1 interleukin-1 
receptor and interleukin-1 receptor antagonist in the synovial membrane and 
cartilage-pannus junction in rheumatoid arthritis. Brit.J. Rheum. 31:801- 
809.
Deleuran, B. W., P. Lemche, M. Kristensen, C. Q. Chu, M. Field, J. Jensen and K. 
Stengaard-Pederson. (1994) Localisation of IL-8 in the synovial membrane, 
cartilage-pannus junction and chondrocyte in rheumatoid arthritis. Scand. J. 
Rheumatol. 23:2-7.
Denis, M. (1991) Tumour necrosis factor and granulocyte colony stimulating factor 
stimulate human macrophages to restrict growth of virulent Mycobacterium  
avium and to kill avirulent M. avium: killing effector mechanism depends on 
generation of reactive nitrogen inteimediates. J. Leuk. Biol. 49:380-387.
Djeu, J. Y, J. L. Liu, S. Wei, H. Rui, C. A. Pearson, W. J. Leonard and D. K. 
Blanchard. (1993) Function associated with IL-2R-(3 on human neutrophils:
216
Mechanism of activation of antifimgal activity against Candida albicans by 
IL-2. J. Immunol. 150:960-970.
Dobrina, A., R. Menegazzi, T. M. Carlos, E. Nardon, R. Cramer, T. Zacchi, J. M. 
Harlan and P. Patriarca. (1991) Mechanisms of eosinophil adherence to 
cultured vascular endothelial cells: eosinophils bind to the cytokine-induced 
endothelial ligand vascular cell adhesion molecule-I vai the very late 
activation antigen-4 integrin receptor. J. Clin. Invest. 88:20-26.
Doherty, T. M., R. A. Seder and A. Sher. (1996) Induction and regulation of IL-15 
expression in murine macrophages. J. Immunol. 156:735-741.
Dolhain, R., N. T. Ter Haar, S. Hoefakker, P. P. Tak, M. De Ley, E. Claassen, P. C. 
Breed veld and A. M. M. Miltenburg. (1996) Increased expression of 
interferon (IFN)-gamma together with IFN-gamma receptor in the 
rheumatoid synovial membrane compared with synovium of patients with 
osteoarthritis. Brit. J. Rheumatol. 35:24-32.
Dreher, R. (1982) The origin of type A synoviocytes in inflammation; an 
experimental approach. Immunobiology 161:232-245.
Duff, G.W. (1993) Cytokines and Anti-cytokines. Brit. J. Rheum 32, (Suppl 1) 15- 
20.
Dugas, B., M. D. Mossalayi, C. Damais and J. P. Kolb. (1995) Nitric oxide 
production by human monocytes: Evidence for a role of CD23. Immunol. 
Today. 16:574-580.
Duke, O., G. S. Panayi, G. Janossy and L. Poulter. (1982) An immunohistochemical 
analysis of lymphocyte subpopulations and their microenvironment in the 
synovial membrane of patients with rheumatoid arthritis using monoclonal 
antibodies. Clin. Exp. Immunol. 49:22-30.
Ebina, M., T. Takahashi, T. Chiba and M. Motomiya. (1993) Cellular hypertrophy 
and hyperplasic of airway smooth muscle underlying bronchial asthma. Am. 
Rev. Respir. Dis. 148:720.
Edwards, J. C. W. (1995) Fibroblastic synovial lining cells (Synoviocytes) in 
‘Mechanisms and Models of Rheumatoid Arthritis’, pp 153-161 Eds:
217
Henderson, B., J. C. W. Edwards and E. R. Pettipher. London, UK, 
Academic Press.
Edwards, J. C. W. and D. A. Willoughby. (1982) Demonstration of bone marrow 
derived cells in synovial lining by means of giant intracellular granules as 
genetic markers. Ami. Rheum. Dis. 41:177-182.
Edwards, S. W. and M. B. Hallett. (1997) Seeing the wood for the trees: the 
forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 18:320- 
324.
Eigler, A., B. Sinha and S. Entires. (1993) Nitric oxide-releasing agents enhance 
cytokine-induced tumor necrosis factor synthesis in human mononuclear 
cells. Biochem. Biophys. Res. Common. 196:494-501.
Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. 
Leeb, F. C. Breed veld, J. D. Macfarlane, H. Bijl and J.N. Woody. (1994) 
Randomised double-blind comparison of chimeric monoclonal antibody to 
tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. 
Lancet. 344:1105-1110.
Empey, D. W., L. A. Lai linen, L. Jacobs, W. M. Gold and J. A. Nadei. (1976) 
Mechanims of bronchial hyperreactivity in normal subjects after uppe'r 
respiratory tract infection. Am. Rev. Resp. Dis. 113:131-139.
Evans, D.M. and S. H. Ralston. (1996) Nitric oxide and bone. J. Bone Min. Res. 
11:300-305.
Fahy, J. V., J. Liu, H. Wong and H. A. Boushey. (1993) Cellular and biochemical 
analysis of induced sputum from asthmatic and from healthy subjects. Am. 
Rev. Respir. Dis. 147:1126-1131.
Fang, F.C. (1997) Mechanisms of nitric oxide-related antimicrobial activity. J. Clin.- 
Invest. 99:2818-2825.
Fava, R. A., N. Olsen, J. Keki-Oja, H. Moses and T. Pincus. (1989) Active and latent 
forms of TGF(3 activity in synovial effusions J. Exp. Med. 169:291-296.
218
Fava, R. A., N. J. Olsen, A. E. Postlethwaite, K, N. Broadley, C. Lucas and A. S. 
Townes. (1991) TG ppi induced neutrophil recruitment to synovial tissues: 
implications for TGFp driven synovial inflammation and hyperplasia. /. Exp. 
Med. 173:1121-1129.
Feldmann, M., F.M. Brennan and R.N. Maini. (1996) Role of cytokines in 
rheumatoid arthritis. Annu. Rev. Imniimol. 397-440.
Fernandez-Gutierrez, B., C. Hernandez-Garcia, A. A. Banares and J. A. Jover.
(1995) Characterisation and regulation of CD69 expression on rheumatoid 
arthritis synovial fluid T cells. J. Rheumatol. 22:413-420.
Firestein, G. S. and N. J. Zvaifler. (1987) Peripheral blood and synovial fluid 
monocyte activation in inflammatory synovitis II. Low levels of synovial 
fluid and synovial tissue interferon suggest that y-interferon is not the 
primaiy macrophage activating factor. Arthritis Rheum. 30:864-871.
Firestein, G. S., W. D. Xu, K. Townsend, D. Broide, J. M. Alvaro-Gracia, A. 
Glasebrook and N. J. Zvaifler. (1988) Cytokines in chronic inflammatory 
arthritis. Failure to detect T cell lymphokines (IL-2 and IL-3) and presence 
of macrophage colony stimulating factor (CSF-1) and a novel mast cell 
growth factor in rheumatoid synovitis. J. Exp. Med. 168:1573-1586.
Firestein, G.S. and N. J. Zwaifler. (1990) How important are T cells in chronic 
rheumatoid synovitis? Arthritis Rheum. 33:768-773.
Firestein, G. S., M. M. Payne and B. H. Littman. (1991) Gene expression 
(collagenase, tissue inhibitor of MMP, complement and HLA-DR) in 
rheumatoid arthritis and osteoarthritis synovium. Arthritis Rheum. 34:1094- 
1101.
Firestein, G. S., D. L. Boyle, C. Yu, M. M. Paine, T. D. Whisenand, N. J. Zvaifler 
and W. P. Arend. (1994) Synovial interleukin- 1 receptor antagonist and 
interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37:644-652.
Firestein, G. S., M. Yeo and N. J. Zvaifler. (1995) Apoptosis in rheumatoid arthritis 
synovium. J. Clin. Invest. 96:1631-1638.
219
Firestein, G.S., F. Echeverri, M. Yeo, N J. Zvaifler and D.R. Green. (1997) Somatic 
mutations in the p53 tumor suppressor gene in rheumatoid arthritis 
synovium. Proc. Natl. Acad. Sci. USA. 94:10895-10900.
Flamand, L., I. Stefanescu and J. Menezes. (1996) Human herpesvirus-6 enhances 
natural killer eell cytotoxicity via IL- 15. J. Clin. Invest. 97:1373-1381.
Foster, P. S., S. P. Hogan, A. J. Ramsay, K. I. Matthaei and I. G. Young. (1996) 
Interelukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and 
lung damage in a mouse asthma model. J. Exp. Med. 183:195-201.
Fox, D. A. (1997) The role of T cells in the immunopathogenesis of rheumatoid 
arthritis. Arthritis Rheum. 40:598-609.
Freemont, A.J. (1987) Molecules controlling lymphocyte-endothelial interactions in 
lymph nodes are produced in vessels of inflammed synovium. Ann. Rheum. 
Dis. 46:924-928.
Garcia-Monzon, C., R. Moreno-Otero and J. M. Pajares. (1990) Expression of a 
novel activation antigen on intrahepatic CDS"' lymphocytes in viral chronic 
active hepatitis. Gastroenterology 98:1029-1035.
Gaston, B., J. M. Drazen, J. Loscalzo and J. S. Stamler. (1994) The biology of 
nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 149:538-551.
Gavett, S. H., X. Chen, F. Finkelman and M. Wills-Karp. (1994) Depletion of 
murine CD4"  ^ T lymphocytes prevents antigen-induced airway hyper­
reactivity and pulmonary eosinophilia. Am. J. Resp. Cell Mol. Biol. 10:587- 
593.
Gearing, A. J. H. and W. Newman. (1993) Circulating adhesion molecules in 
disease. Immunol. Today 14:506-512.
Geha, R. S. (1992) Regulation of IgE synthesis in humans. J. Allergy Clin. Immunol. 
90:143-150.
Gelder, C. M., P. S. Thomas, D. H. Yates, I. M. Adcock, J. F. J. Morrison and P. J. 
Barnes. (1995) Cytokine expression in normal, atopic, and asthmatic subjects
220
using the combination of sputum induction and the polymerase chain 
reaction. Thorax. 50:1033-1037.
Geller, D. A., A. K. Nussler, M. Di Silvio, C. J. Lowenstein, R. A. Shapiro, S. C. 
Wang, R. I. Simmons and T. R. Billiar. (1993) Cytokines, endotoxin, and 
glucocorticoids regulate the expression of inducible nitric oxide synthase in 
hepatocytes. Proc. Nat. Acad. Sci. USA 90:522-526.
Gilat, D., L. Cahalon, R. Hershkoviz and O. Lider. (1996) Interplay of T-cells and 
cytokines in the context of enzymatically modified extracellular-matrix. 
Immunol. Today. 17:16-20.
Gilbert, R. S. and H. R. Herschman. (1993) TGF beta differentially modulates the 
iNOS gene in distinct cell types. Biochem. Biophys. Res. Commun. 195:380- 
384.
Girard, D., M. E. Paquet, R. Paquin and A. D. Beaulieu. (1996) Differential effects 
of interleukin-15 (IL-15) and IL-2 on human neutrophils: Modulation of 
phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by 
Ih-lS. Blood. 88:3176-3184.
Girard, J-P. and T. A. Springer. (1995) High endothelial venules: specialized 
endothelium for lymphocyte migration. Immunol. Tod. 16:449-457.
Giri, J. G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. 
Namen, L. S. Park, D. Cosman and D. Anderson. (1994) Utilization of the 
beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. 
EMBOJ. 13:2822-2830.
Giri, J. G., S. Kumaki, M. Ahdieh, D. J. Friend, A. Loomis, K. Shanebeck, R. 
DuBose, D. Cosman, L. S. Park and D. M. Anderson. (1995) Identification 
and cloning of a novel IL-15 binding protein that is structurally related to the 
alpha chain of the IL-2 receptor. EMBO J. 14:3654-3663.
Giuliani, C., M. Saji, G. Napolitano, L. A. Palmer, S. I. Taniguchi, M. Shong, D. S. 
Singer and L. D. Kohn. (1995) Hormonal modulation of MHC class I gene 
expression involves an enhancer A-binding complex consisting of Fra-2 and 
the p50 subunit of NK-kB. J. Biol. Chem. 270:11453-11462.
221
Gleich, G. J. (1990) The eosinophil and bronchial asthma: current understanding. J. 
Allergy Clin. Immunol. 85:422-436.
Goldenberg, D. L. and A. S. Cohen. (1976) Acute infectious arthritis. A review of 
patients with nongonococcal joint infections. Am. J. Med. 60:369.
Gosset, P., A. Tsicopoulos, B. Wailaert, C. Vannimenus, M. Joseph, A. B. Tonnel 
and A. Capron. (1991) Increased secretion of tumor-necrosis-factor-alpha 
and interleukin-6 by alveolar macrophages consecutive to the development of 
the late asthmatic reaction. J. Allergy Clin. Immunol. 88:561-571.
Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. 
Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, L. Johnson, M. R. 
Alderson, J. D. Watson, D. M. Anderson and J. G. Giri. (1994) Cloning of a 
T cell growth factor that interacts with the beta chain of the interleukin-2 
receptor. Science. 264:965-968.
Gravellese, E. M., J. M. Darling, A. L. Ladd, J. N. Katz and L. FI. Glimcher. (1991) 
In situ hybridisation studies of stromelysin and collagenase mRNA 
expression in rheumatoid synovium. Arthritis Rheum. 34:1076-1085.
Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok and S. R. 
Tannenbaum. (1982) Analysis of nitrate, nitrite and (^^N) nitrate in biological 
fluids. Anal. Biochem. 126:131-140.
Guo, F. H., H. R. Deraeve, T. W. Rice, D. J. Stuehr, F. Thunnissen and S. C. 
Erzurum. (1995) Continuous nitric-oxide synthesis by inducible nitric-oxide 
synthase in normal human airway epithelium in-vivo. Proc. Natl. Acad. Sci.
92:7809-7813.
Guo, F. H., K. Uetani, S. J. Haque, B. R. G. Williams, R. A. Dweik, F. Thunnissen, 
W. Calhoun and S. C. Erzurum. (1997) Interferon gamma and interleukin 4 
stimulate prolonged expression of inducible nitric oxide synthase in human 
airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 
100:829-838.
Haahtehla, T., M. Jarvinen, T. Kava, K. Kiviranta, S. Koshinen, K. Lehtonen, K, 
Nikander, T. Persson, O. Selroos, A. Sovijarvi, B. Stenius-Aarniala, T. 
Svahn, R. Tammivaara and L. A. Laitinen. (1994) Effects of reducing or
222
discontinuing inhaled budesonide in patients with mild asthma. New Engl. J. 
Med. 331:700-705.
Hale, L. P., M. E. Martin, D. E. McCollum, J. A. Nunley, T. A. Springer, L. H. 
Singer and B. P. Haynes. (1989) Immunohistologic analysis of the 
distribution of cell adhesion molecules within the inflammatory synovial 
environment. Arthritis Rheum. 32:22-30.
Hamid, Q., D. R. Springall, V. RiverosMoreno, P. Chanez, P. Howarth, A. 
Redington, J. Bousquet, P. Godard, S. Holgate and J. M. Polak. (1993) 
Induction of nitric oxide synthase in asthma. Lancet. 342:1510-1513.
Hamid, Q., M. Azzawi, S. Ying, R. Moqbel, A. J. Wardlaw, C. J. Corrigan, B. 
Bradley, S. R. Durham, J. V. Collins, P. K, Jeffery, D. J. Quint and A. B. 
Kay. (1991) Expression of mRNA for interleukin-5 in mucosal bronchial 
biopsies from asthma. J. Clin. Invest. 87:1541-1546.
Hansel. T. T, and C. Walker. (1992) The migration of eosinophils into the sputum of 
asthmatics: the role of adhesion molecules. Clin. Exp. Allergy. 22:345-356.
Heiss, L. N., J. R. Lancaster, J. A. Corbett and W. E. Goldman. (1994) Epithelial 
autotoxicity of nitric-oxide - role in the respiratory cytopathology of 
pertussis. Proc. Natl. Acad. Sci. USA. 91:267-270.
Henderson, W. Jr. (1994) Role of leukotrienes in asthma. Ann. Allergy 72:272-278.
Hirst, S. J. (1996) Airway smooth muscle cell culture: application to studies of 
airway wall remodelling and phenotype plasticity in asthma. Eur. Respir. J. 
9:808-820.
Hogman, M., C. G. Frostell, H. Hedenstrom and G. Hedenstierna. (1993) Inhalation 
of nitric oxide modulates adult human bronchial tone. Am. Rev. Respir. Dis. 
148:1474-1478.
Horgan, K. J., Y. Tanaka, G. E. Ginther Luce, G. A. van Seventer, T. B. Nutman and 
S. Shaw. (1994) CD45RB expression defines two interconvertible subsets of 
human CD4"" T cells with memory function. Eur. J. Immunol. 24:1240-1243.
223
Hosaka, S., T. Akshoshi, C. Wada and H. Kondo. (1994) Expression of the 
chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol. 97:451- 
457.
Howat, D. W., L. E. Glynn, L. Bitensky and J. Chayen. (1987) The origin of the 
apparent synovial lining hyperplasia in rheumatoid arthritis: evidence for a 
deep stem cell Brit. J. Exp. Pathol. 68:259-266.
Howell, M. D., J. P. Diveley, K. A. Lundeen, A. Esty, S. T. Winters, D. J. Carlo and 
S. W. Brostoff. (1991) Limited T cell receptor p-chain heterogeneity among 
IL-2 receptor positive synovial T cells suggests a role for superantigen in 
rheumatoid arthritis. Proc. Nat. Acad. Set. USA 88:10921-10925.
Huang, P. L., Z. Huang, H. Mashimo, K. D. Bloch, M. A. Moskowitz, J. A. Bevan 
and M. C. Fishman, (1995) Hypertension in mice lacking the gene for 
endothelial nitric oxide synthase. Nature 377:239-242.
Huber, A. R., S. L. Kunkel, R. P. Todd and S. J. Weiss. (1991) Regulation of 
transendothelial neutrophil migration by endogenous interleukin-8. Science. 
254:99-102.
lannone, P., V. M. Corrigall, G. H. Kingsley and G. S. Panayi. (1994) Evidence for 
continuous recruitment and activation of T cells into the joints of patients 
with rheumatoid arthritis. Eur. J. Immunol. 24:2706-2713.
Isler, P., E. Vey, Z-H. Zhang and J-M. Dayer. (1993) Cell surface glycoproteins 
expressed on activated human T cells induce production of interleukin-1 beta 
by monocytic cells: a possible role of CD69. Eur. Cytok. Net. 4:15-23.
Isobe, K. and J. Nakashima. (1992) Feedback suppression of staphylococcal 
enterotoxin-stimulated T-lymphocyte proliferation by macrophages through 
inductive nitric oxide synthesis. Infect. Immun. 60:4832-4837.
Isomaki, P., R. Luukkainen, P. Toivanen and J. Punnonen. (1996) The presence of 
interleukin-13 in rheumatoid synovium and its antiinflammatory effects on 
synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis 
Rheum. 39:1693-1702.
224
Jacob, C. O., J. Holoshitz, P. Vaiidermeide, S. Strober and H. O. McDevitt. (1989) 
Heterogeneous effects of IFN-gamma in adjuvant arthritis. J. Immunol. 
142:1500-1505.
John, M., S. J. Hirst, P. J. Jose, A. Robichaud, N. Berkraan, C. Witt, C. H. C. Twort, 
P. J. Barnes and K. F. Chung. (1997) Human airway smooth muscle cells 
express and release RANTES in response to T helper 1 cytokines - 
Regulation by T helper 2 cytokines and corticosteroids. J. Immunol. 
158:1841-1847.
Johnson, B. A., G. K. Haines, L. A. Harlow and A. E. Koch. (1993) Adhesion 
molecule expression in human synovial tissue. Arthritis Rheum. 36:137-146.
Johnston, J. A., L. M. Wang, E. P. Hanson, X. J. Sun, M. F. White, S. A. Oakes, J. 
H. Pierce and J. J. O'Shea. (1995a) Interleukins 2, 4, 7, and 15 stimulate 
tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. 
Potential role of JAK kinases. J. Biol. Chem. 270:28527-28530.
Johnston, J. A., C. M. Bacon, D. S. Finbloom, R. C. Rees, D. Kaplan, K. Shibuya, J. 
R. Ortaldo, S. Gupta, C. Yi Qing, J. D. Giri and J. J. O'Shea. (1995b) 
Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus 
kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. USA. 92:8705-8709.
Jonuleit, H., K. Wiedemann, G. Muller, J. Degwert, U. Hoppe, J. Knop and A. H. 
Enk. (1997) Induction of IE-15 messenger RNA and protein in human blood- 
derived dendritic cells - A role for IE-15 in attraction of T cells. J. Immunol. 
158:2610-2615.
Joosten, E. A. B., M. M. A. Helsen, F. A.J . Van de Eoo and W. B. Van den Berg.
(1996) Anticytokine treatment of established type II collagen-induced 
arthritis in DBA/1 mice: A comparative study using anti-TNFalpha, anti-IE- 
1 alpha/beta, and IE- IRa. Arthritis Rheum. 39:797-809.
Joosten, E. A. B., E. Eubberts, P. Durez, M. M. A. Helsen, M. J. M. Jacobs, M. 
Goldman and W. B. Van Den Berg. (1997) Role of interleukin-4 and 
interleukin-10 in murine collagen-induced arthritis: Protective effect of 
interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis 
Rheum. 40:249-260.
225
Jullien, D., P. A. Sieling, K. Uyeraura, N. D. Mar, T. H. Rea and R. L. Modlin.
(1997) IL-15, an immunomodulator of T cell responses in intracellular 
infection. /. Immunol. 158:800-806.
Kacani, L., H. Stoiber and M. P. Dierich. (1997) Role of IL-15 in HIV-1-associated 
hypergammaglobulinaemia. Clin. Exp. Immunol. 108:14-18.
Kacmarek, R. M., R. Ripple, B. A. Cockrill, K. J, Bloch, W. M. Zapol and D. C. 
Johnson. (1996) Inhaled nitric oxide: A bronchodilator in mild asthmatics 
with methacholine-induced bronchospasm. Am. J. Respir. Crit. Care Med. 
153:128-135.
Kakumu, S., A. Okumura, T, Ishikawa, M. Yano, A. Enomoto, H. Nishimura, K. 
Yoshioka and Y. Yoshikai. (1997) Serum levels of IE-10, IE-15 and soluble 
tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver 
disease. Clin. Exp. Immunol. 109:458-463.
Kanegane, H. and G. Tosato. (1996) Activation of naive and memory T cells by 
interleukin-15. Blood. 88:230-235.
Kaplan, D. (1996) Autocrine secretion and the physiological concentration of 
cytokines./mmw«o/. Tod. 17:303-306.
Kapsenberg, M. E., E. A. Wierenga, J. D. Bos and E. M. Jansen. (1991) Functional 
subsets of allergen-reactive human CD4+ T cells. Immunol. Today. 12:392- 
395.
Katsikis, P., C. Q. Chu, F. M. Brennan, R. N. Maini and M. Feldmann. (1993) 
Immunoregulatory role of interleukin-10 in rheumatoid arthritis. J. Exp. Med. 
179:1517-1526.
Kawasaki, E. S. (1990) Amplification of RNA. in ‘PCR Protocols’ Eds: Innis, M.A., 
Gelfand, D.H., Sninsky, J.J. & White, T.J. London, Academic Press, Inc.
Keffer, J., E. Probert, H. Cazlaris, S. Georgopolous, E. Kaslaris, D. Kioussis and G. 
Kollias. (1991) Transgenic mice expressing human tumour necrosis factor; a 
predictive genetic model of arthritis. EMBO J. 10:4025-4029.
226
Kelly, C. A., S. C. S teuton, C. Ward, G. Bird, D, J, Hendrick and E. H. Walters.
(1989) Lymphocyte subsets in bronchoalveolar lavage fluid obtained from 
stable asthmatics, and their correlations with bronchial responsiveness. Clin. 
Exp, Allergy. 19:169-175.
Kennedy, M. K. and L. S. Park. (1996) Characterization of interleukin-15 (IL-15) 
and the IL-15 receptor complex. J. Clin. Immunol. 16:134-143.
Kennedy, T. D., C. Plater-Zyberg, T. A. Partridge, D. F. Woodrow and R. N. Maini.
(1988) Morphometric comparison of synovium from patients with 
osteoarthritis and rheumatoid arthritis. Clin. Pathol. 41:847-852.
Kharitonov, S. A., D. Yates, R. A. Robbins, R. LoganSinclair, E. A. Shinebourne 
and P. J. Barnes. (1994) Increased nitric oxide in exhaled air of asthmatic 
patients. Lancet. 343:133-135.
Kharitonov, S. A., D. H. Yates, K. F. Chung and P. J. Barnes. (1996) Changes in the 
dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic 
patients. Eur. Resp. J. 9:196-201.
Kimura, I., Y. Tanizaki, K. Saito, K. Takahashi, N. Ueda and S. Sato. (1975) 
Appearance of basophils in sputum of patients with bronchial asthma. Clin. 
Allergy 5:95-98.
Kingsley, G., J. Lanchbury and G. S. Panayi. (1996) Immunotherapy - an idea whose 
time has come - or gone? Immunol. Tod. 17:9-12.
Kips, J. C., J. H. Tavernier, G. F. Joos, R. A. Peleman and R. A. Pauwels. (1993) 
The potential role of tumour necrosis factor a  in asthma. Clin. Exp. Allergy 
23:247.
Kips, J. C., J. Tavernier and R. A, Pauwels. (1992) Tumor necrosis factor causes 
bronchial hyperresponsiveness in rats. Am. Rev. Respir. Dis. 145:332-336.
Kirby, J. G., F. E. Hargreave, G. J, Gleich and P. M. O’Byrne. (1987) 
Bronchoalveolar cell profiles of asthmatic and non-asthmatic subjects. Am. 
Rev. Respir. Dis. 136:379-383.
227
Kirman, I. and O.H. Nielsen. (1996) Increased numbers of interleukin-15-expressing 
cells in active ulcerative colitis. Am. J. Castro. 91:1789-1794.
Kishimoto, T., T. Taga and S. Akira. (1994) Cytokine signal transduction. Cell 
76:253-262.
Kitis, E. and G. Weissmami. (1991) The role of neutrophil in rheumatoid arthritis. 
Clin. Orthopaed. ReL Res. 265:63-72.
Klareskog, L., U. Forsum, U. Malmas-Tjeiiurd, D. Kabelitz and A. Wigren. (1981) 
Appearances of anti-HLA-DR reactive cells in normal and rheumatoid 
synovial membrane. Scand. J. Immunol. 14:183-189.
Kleinert, H., C. Euchenhofer, I. Ihrigbiedert and U. Fors term ann. (1996) 
Glucocorticoids inhibit the induction of iNOS by downregulating cytokine 
induced activity of transcription factor nuclear factor-xB. Mol. Pharmacol. 
49:15-21.
Klimiuk, P. A., J. J. Goronzy, J. Bjornsson, R. D. Beckenbaugh and C. M. Weyand,
(1997) Tissue cytokine patterns distinguish variants of rheumatoid synovitis. 
Am. J. Pathol. 151:1311-1319.
Kobayashi, T., S. Hashimoto, K. Imai, E. Amemiya, M. Yamaguchi, A. Yachi and' 
T. Ho lie. (1994) Elevation of serum soluble intercellular adhesion molecule- 
1 (sICAM- 1) and sE-selectin levels in bronchial asthma. Clin. Exp. 
Immunol. 96:110-115.
Kobzik, L., D. S. Bredt, C. J. Lowenstein, J. Drazen, B. Gaston, D. Sugarbacker and 
J. S. Stamler. (1993) Nitric oxide synthase in human and rat lung: 
immunocytochemical and histochemical localization. Am. J. Respir. Cell 
Mol. Biol. 9:371-377.
Koch, A.E., S. L. Kunkel, J. C. B u i t o w s , H. L. Evan off, G. K. Haines, R. M. Pope 
and R. M. Stricter. (1991) Synovial tissue macrophages as a source of the 
chemotactic cytokine IL-8. J. Immunol. 147:2187-2195.
Koch, A.E., S. L. Kunkel, L. A. Harlow, B. Johnson, H. L. Evanoff, G. K. Haines, 
M. D. Burdick, R. M. Pope and R. M. Stricter. (1992) Enhanced production
228
of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 
90:772-779.
Koch, A.E., S. L. Kunkel, L. A. Harlow, D. D. Mazarakis, G. K. Haines, M. D. 
Burdick, R. M. Pope and R. M. Stricter. (1994a) Macrophage inflammatory 
protein-1 alpha. A novel chemotactic cytokine for macrophages in 
rheumatoid arthritis. J. Clin. Invest. 93:921-928.
Koch, A.E., S. L. Kunkel, L. A. Harlow, D. D. Mazarakis, G. K. Haines, M. D. 
Burdick, R. M. Pope, A. Walz and R. M. Stricter. (1994b) Epithelial 
neutrophil activating peptide-78; a novel chemotactic cytokine for 
neutrophils in arthritis. J. Clin. Invest. 94:1012-1018.
Kohem, C. L., R. I. Brezinschek, H. Wisbey, C. Tortorella, P. E. Lipsky and N. 
Oppenheimer-Marks. (1996) Enrichment of differentiated CD45RBdim, 
CD27" memory T cells in peripheral blood, synovial fluid and synovial tissue 
of patients with rheumatoid arthritis. Arthritis Rheum. 39:844-854.
Korholz, D., U. Banning, H. Bonig, M. Grewe, M. Schneider, C. MauzKorholz, A. 
KleinVehne, J. Krutmann and S. Burdach. (1997) The role of interleukin-10 
(IE-10) in IL-15-mediated T-cell responses. Blood. 90:4513-4521.
Kotake, S., Schumacher Hr, Jr., C.H. Yarboro, T. K. Arayssi, J. A. Pando, K. S. 
Kanik, M. F. Gourley, J. H. Klippel and R. L. Wilder. (1997) In vivo gene 
expression of type 1 and type 2 cytokines in synovial tissues from patients in 
early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc. 
Assoc. Am. Physicians. 109:286-302.
Kozak, M. (1987) An analysis of 5'-noncoding sequences from 699 vertebrate 
messenger- RNAs. Nucl. Acids Res. 15:8125-8148.
Kozak, M. (1991) An analysis of vertebrate messenger-rna sequences - intimations 
of translational control. J. Cell Biol. 115:887-903.
Krug, N., J. Madden, A. E. Redington, P. Lackie, R. Djukanovic, U. Schauer, S. T. 
Holgate, A. J. Frew and P. H. Howarth. (1996) T-cell cytokine profile 
evaluated at the single cell level in BAL and blood in allergic asthma. Am. J. 
Resp. Cell Mol. Biol. 14:319-326.
229
Kudo, C., A. Araki, K. Matsushima and F. Sen do. (1991) Inhibition Of IL-8-induced 
W3/25'' (CD4'') lyraphocyte-T recruitment into subcutaneous tissues of rats 
by selective depletion of in vivo neutrophils with a monoclonal-antibody. J. 
Immumol 147:2196-2201.
Kumaki, S., R. Armitage, M. Ahdieh, L. Park and D. Cosman. (1996) Interleukin-15 
upregulates interleukin-2 receptor a  chain, but downregulates its own high 
affinity binding sites on human T and B cells. Eur. J. Immunol. 26:1235- 
1239.
Kunz, D., G. Walker, W. Eberhardt and J. Pfeilschifter. (1996) Molecular 
mechanisms of dexamethasone inhibition of nitric oxide synthase expression 
in IL-1 stimulated mesangial cells: evidence for the involvement of 
transcriptional and posttranscriptional regulation. Proc. Nat. Acad. Sci. USA 
93:255-259.
Kuo, H. P., S. Liu and P. J. Barnes. (1992) The effect of endogenous nitric oxide on 
neurogenic plasma exudation in guinea pig airways. Eur. J. Pharmacol. 
211:385-388.
Kuruvilla, A. P., R. Shah, G. M. Hochwald, H. D. Liggit, M. A. Palladino and G. J. 
Thorebeck. (1991) Protective effect of TFGp in experimental autoimmune 
diseases in mice. Proc. Nat. Acad. Sci. USA 88:2918-2925.
Lacraz, S., P. Isler, E. Vey, H. G. Welgus and J-M Dayer. (1994) Direct contact 
between T lymphocytes and monocytes is a major pathway for induction of 
metalloproteinase expression. J. Biol. Chem. 269:22027-22033.
Laffon, A., R. GarciaVicuna, A. Humbria, A. A. Postigo, A. L. Corbi, M. O. De 
Landazuri and F. SanchezMadrid. (1991) Upregulated expression and 
function of VLA-4 fibronectin receptors on human activated T cells in 
rheumatoid arthritis. J. Clin. Invest. 88:546-552.
Laitinen, L. A., A. Laitinen and T. Haahtehla. (1992) A comparaive study of the 
effects of an inhaled corticosteroids, budesonide, and a beta-2 agonist, 
terbutaline, on airway inflammation in newly diagnosed asthma: a 
randomised, double-blind parallel group controlled trial. J. Allergy Clin. 
Immunol. 90:32-42.
230
Laitinen, L. A., A. Laitinen and T. Haahtehla. (1993) Airway mucosal inflammation 
even in patients with newly diagnosed asthma. Am Rev, Respir. Dis. 147:697- 
704.
Lander, H, M., P. Sehajpal, D. M. Levine and Novogrodsky (1993) Activation of 
human peripheral blood cells by nitric oxide generating compounds. J. 
Immunol. 150:1509-1516.
Leclercq, G., V. Debacker, M. De Smedt and J. Plum. (1996) Differential effects of 
interleukin-15 and interleukin-2 on differentiation of bipotential T/Natural 
killer progenitor cells. J. Exp. Med. 184:325-336.
Lee, J. L., M, P. McGarry, S. C. Farmer, K. L, Denzler, K. A. Larson, P. E. 
Carrigan, I. E. Brenneise, M. A. Horton, A. Haczku, E. W. Gelfand, G. D. 
Leikauf and N. A. Lee. (1997) Interleukin-5 expression in the lung 
epithelium of transgenic mice leads to pulmonary changes pathognomonic of 
asthma. J. Exp. Med. 185:2143-2156.
Lefer, D. J., R. Scalia, B. Vcampbell, T. Nossuli, R. Hayward, M. Salmon, J. 
Grayson and A. M. Lefer. (1997) Peroxynitrite inhibits leukocyte endothelial 
cell interactions and protects against ischaemia perfusion injury in rats. J. 
Clin. Invest. 99:684-691.
Lemanske, R. F., E. C. Dick, C. A. Swenson, R. F. Vrtis and W. W. Busse (1989) 
Rhinovirus upper respiratory infection increases airway hyperactivity and 
late asthmatic reactions. J. Clin. Invest. 83:1-10.
Leonard, W. J. (1996) The molecular basis of X-linked severe combined 
immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 
47:229-239.
Liew, F. Y. and F. E. G. Cox. (1991) Non specific defence mechanism: the role of 
nitric oxide./mmnno/. Tod. 12:A17-A2L
Liew, F. Y. (1994) Regulation of nitric oxide synthesis in infectious and 
autoimmune diseases. Immunol. Letts. 43:95-98.
Lin, J. X., T. S. Migone, M. Tsang, M. Friedmann, J. A. Weatherbee, L. Zhou, A. 
Yamauchi, E. T. Bloom, J. Mietz, S. John and W. J. Leonard. (1995) The
231
role of shared receptor motifs and common stat proteins in the generation of 
cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. 
Immunity. 2:331-339.
Liu, J. H., S. Wei, D. Ussery, P. K. Epling-Burnette, W. J. Leonard and J. Y. Djeu. 
(1994) Expression of interleukin-2 receptor y chain on human neutrophils. 
Blood. 84:3870-3875.
Lloyd, A. R. and J. J. Oppenheim. (1992) Polys Lament - the neglected role of the 
polymorphonuclear neutrophil in the afferent limb of the immune response. 
Immunol. Today. 13:169-172.
Lyons, C. R. (1995) The role of nitric oxide in inflammation. Ariv. Immunol. 60:323- 
360
MacMicking, J., Q. W. Xie and C. Nathan. (1997) Nitric oxide and macrophage 
function. A/mj/. Rev. Immunol. 15:323-350.
Maini, R. N., C. A. Chu and M. Feldmann. (1995a) Aetiopathogenesis of rheumatoid 
arthritis in ‘Mechanisms and Models of Rheumatoid Arthritis’, pp 25-47 Eds: 
Henderson, B., J. C. W. Edwards and E. R. Pettipher. London, UK, 
Academic Press.
Manie, S., J. Kubar, M. Limouse, B. Ferma, M. Ticchinoi, J. P. Breittmayer, J. F. 
Peyron, L. Schaffar and B. Rossi. (1993) Anti-CD3 stimulated Jurkat T cells 
mediate IL -ip  production in monocytic THP-1 cells: a role of LFA-1 
molecule and participation of CD69. Eur. Cytoine Netw. 4:7-13.
Manoury-Schwartz, B., G. Chiocchia, N. Bessis, O. Abehsira-Amar, F. Batteux, S. 
Muller, S. Huang, M. C. Boissier and C. Fournier. (1997) High susceptibility 
to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. 
Immunol. 158:5501-5506.
Marrack, P. and J. Kappler. (1990) The staphylococcal enterotoxins and their 
relatives. Science 248:705-711.
M atthews, N., P. Emery, D. Pilling, A. Akbar and M. Salmon. (1993) 
Subpopulations of primed T helper cells in rheumatoid arthritis Arthritis 
Rheum. 36:603-607.
232
Mauri, C., R. O. Williams, M. Walmsley and M. Feldmann. (1996) Relationship 
between Thl/Th2 cytokine patterns and the arthrite genic response in 
collagen-induced arthritis. Eur. J. Immunol. 26:1511-1518.
McBride, D. E., J. Q. Koenig, D. L. Luchtel, P. V. Willaims and W. Henderson, Jr. 
(1994) Inflammatory effects of ozone in the upper airways of subjects with 
asthma. A/n. J. Resp. Crit. Care Med. 149:1192-1197.
McCachren, S. S. (1991) Expression of metalloproteinases and metalloproteinase 
inhibitors in human arthritic synovium. Arthritis Rheum. 34:1085-1092.
McCain, G. A. (1985) Helper T cell function of rheumatoid synovial tissue 
lymphocytes. J. Rheumatol. 11:438-447.
Mclnnes, I. B., B. P. Leung, M. Field, X. Q. Wei, F. P. Hueng, R. D. Sturrock, A. 
Kinninmonth, J. Weidner, R. Mumford and F. Y. Liew. (1996a) Production 
of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis 
patients. J. Exp. Med. 184:1519-1524.
Mclnnes, I. B., J. AlMughales, M. Field, B. P. Leung, F. P. Huang, R. Dixon, R. D. 
StuiTOck, P. C. Wilkinson and F. Y. Liew. (1996b) The role of interleukin-15 
in T-cell migration and activation in rheumatoid arthritis. Nature Med. 2:175- 
182.
Mclnnes, I. B., B. P. Leung, R. D. Sturrock, M. Field and F. Y. Liew. (1997) 
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor- 
alpha production in rheumatoid arthritis. Nature Med. 3:189-195.
Mclnnes, I. B., B. P. Leung, X-Q, Wei, C. G. Gemmell and F. Y. Liew. (1998) 
Septic arthritis following Staphylococcus aureus infection in mice lacking 
inducible nitric oxide synthase. J. Immunol. 160:308-315.
Mclnnes, I. B. and F. Y. Liew. (1998) Nitric oxide in bone and joint disease. Eds: 
Hukkanen, M. V. J., J. Polak and G. Plughes. Cambridge University Press, 
(in press)
McMoll, S. R., R. Paquin, C. Menard and A. D. Beaulieu. (1992) Human neutrophils 
produce high levels of the interleukin 1 receptor antagonist in response to
233
granulocyte/macrophage colony-stimulating factor and tumor necrosis factor
a . J. Exp. Med. 176:593-598.
Meazza, R., A. Gaggero, F. Neglia, S. Basso, S. Sforzini, R. Pereno, B. Azzarone 
and S. Ferrini. (1997) Expression of two interleukin-15 mRNA isoforms in 
human tumors does not correlate with secretion: Role of different signal 
peptides. Eur. J. Immunol. 27:1049-1054.
Meazza, R., S. Verdiani, R. Biassoni, M. Coppolecchia, A. Gaggero, A. M. Orengo, 
M. P. Colombo, B. Azzarone and S. Ferrini. (1996) Identification of a novel 
interleukin-15 (IL-15) transcript isoform generated by alternative splicing in 
human small cell lung cancer cell lines. Oncogene. 12:2187-2192.
MeiTyman, P. F., R. M. Clancy, X. Y. He and S. B. Abramson. (1993) Modulation of 
human T cell responses by nitric oxide and its derivative S- 
nitrosoglutathione. Arthritis Rheum. 36:1414-1422.
Michel, T. and O. Feron. (1997) Nitric oxide synthases: Which, Where, How, and 
Why? J. Clin. Invest. 100:2146-2152.
Miltenburg, A. M. M., J. M. Van Laar, R. de. Kuiper, M. R. Daha and F. C. 
Breedveld. (1992) T cells cloned from human rheumatoid synovial 
membrane functionally represent the Thl subset. Scand. J. Immunol. 35:603- 
610.
Minami, Y., T. Kono, T. Miyazaki and T. Taniguchi. (1993) The IL-2 receptor 
complex: Its structure, function and target genes. Ann. Rev. Immunol. 11:245- 
267.
Miossec, P., M. Elhamiani, B. Chichehian, A. D. D’Angeae, J. Sany and M. Him.
(1990) Interleukin-2 inhibitor in rheumatoid synovium: correlation with 
prognosis and soluble IL-2 receptor levels. J. Clin. Immunol. 10:115-120.
Miyazaki, T., Z. J. Liu, A. Kawahara, Y. Minami, K. Yamada, Y. Tsujimoto, E. L. 
Barsoumian, R. M. Perlmutter and T. Taniguchi. (1995) Three distinct IL-2 
signaling pathways mediated by bcl-2, c-myc, and Ick cooperate in 
hematopoietic cell proliferation. Cell 81:223-231.
234
Modlin, R. L., J. Melancon-Kaplan, S. M. M. Young, C. Pirmez, H. King, J. Convit, 
T. H. Rea and B. R. Bloom. (1988) Learning from lesions: patterns of tissue 
inflammation in leprosy. Proc. Nat. Acad. Sci. USA 85:1213-1217.
Mohamadzadeh, M., A. Takashima, I. Dougherty, J. Knop, P. R. Bergstresser and 
Cruz Pd, Jr. (1995) Ultraviolet B radiation up-regulates the expression of IL- 
15 in human skin. J. Immunol. 155:4492-4496.
Mojcik, C. F. and E. M. Shevach. (1997) Adhesion molecule: A rheumatologic 
perspective. Arthritis Rheum. 40:991-1004.
Moncada, S. and A. Higgs. (1993) The L-arginine-nitric oxide pathway. N ew  
England J. o f Medicine. 329:2002-2012.
Moreland, L. W., S. W. Baumgartner, M. H. Schiff, E. A. Tindall, R. M. 
Fleischmann, A. L. Weaver, R. E. Ettlinger, S. Cohen, W. J. Koopman, K. 
Mohler, M. B. Widmer and C. M. Blosch. (1997) Treatment of rheumatoid 
arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc 
fusion protein. New Engl. J. Med. 337:141-147.
Mori, A., M. Suko, O. Kaminuma, S. Inoue, T. Ohmura, Y. Nishizaki, T. Nagahori, 
Y. Asakura, A. Hoshino, Y. Okumura, G. Sato, K. Ito and H. Okudaira.
(1996) IL-15 promotes cytokine production of human T helper cells. J. 
Immunol. 156:2400-2405.
Mosmann, T. R., H. Cherwinshi, M. W. Bond, M. A. Giedlin and R. L. Coffman. 
(1986) Two types of murine helper T cell clone. 1. Definition according to 
profiles of lymphokine activities and secreted proteins. J. Immunol. 
136:2348-2357.
Mosmann, T. R. and R. L. Coffman. (1989) Thl and Th2 cells: different patterns of 
lymphokine secretion lead to different functional properties. Annu. Rev. 
Immunol. 1:145-173.
Mrozek, E., P. Anderson and M. A. Caligiuri. (1996) Role of interleukin-15 in the 
development of human CD56^ natural killer cells from CD34-I- hematopoietic 
progenitor cells. Blood. 87:2632-2640.
235
Mueller, J., G. Brundelre, H. Buerke, H, V. Keller, M. W. Hess and H. Cottier. 
(1975) Nonspecific acid esterase activity: a criterion for differentiation of T 
and B lymphocytes in mouse lymph nodes. Eur. J. Immunol. 5:270-274.
Nakajima, H., I. Iwamoto and S. Yoshida. (1993) Aerosolized recombinant 
interferon-gamma prevents antigen-induced eosinophil recruitment in mouse 
trachea. Am. Rev. Resp. Dis. 148:1102-1104.
Nakajima, T., H. Aono, T. Hasunuma, K. Yamamoto, T. Shirai, K. Hirohata and K. 
Nishioka. (1995) Apoptosis and functional Fas antigen in rheumatoid 
arthritis synoviocyte,s. Arthritis Rheum. 38:485-491.
Nakarai, T., M. J. Robertson, M. Streuli, Z. N. Wu, T. L. Ciardelli, K. A. Smith and 
J. Ritz. (1994) Interleukin-2 Receptor-Gamma Chain Expression On Resting 
and Activated Lymphoid-Cells. J. Exp. Med. 180:241-251.
Nathan, C. and Q. W. Xie. (1994) Nitric oxide synthases: Roles, tolls, and controls. 
Cell. 78:915-918.
Nathan, C. (1997) Inducible nitric oxide synthase: What difference does it make? J. 
Clin. Invest. 100:2417-2423,
Nicholson, S., M. D. G. Bonecini-Almeida, J. R. L. Lapa, C. Nathan, Q. W. Xie, R. 
Mumford, J. R. Weidner, J. Calaycay, J. Geng, N. Boechat, C. Linhares, W. 
Rom and J. L. Ho. (1996) Inducible nitric oxide synthase in pulmonary 
alveolar macrophages from patients with tuberculosis. J. Exp. Med. 
183:2293-2302.
Nieto, M., M. A. Del Pozo and F. SanchezMadrid. (1996) Interleukin-15 induces 
adhesion receptor redistribution in T lymphocytes. Eur. J. Immunol. 26:1302- 
1307.
Nishimura, H., K. Hiromatsu, N. Kobayashi, K. H. Grabstein, R. Paxton, K. 
Sugamura, J. A. Bluestone and Y. Yoshikai. (1996) IL-15 is a novel growth 
factor for murine gammadelta T cells induced by Salmonella infection. J. 
Immunol. 156:663-669.
236
Nurcombe, H. L., R. C. Bucknall and S. W. Edwards. (1991) Neutrophils isolated 
from the synovial-fluid of patients with rheumatoid-arthritis - priming and 
activation in vivo. Ann. Rheum. Dis. 50:147-153.
O'Byrne, P. M. (1988) Allergen-induced airway hyperresponsiveness. J. Allergy 
Clin. Immunol. 81:119-127.
Ohashi, Y., S. M otojima, T. Fukuda and S. Makino. (1992) Airway 
hyperresponsiveness, increased intracellular spaces of bronchial epithelium, 
and increased infiltration of eosinophils and lymphocytes in bronchial 
mucosa in asthma. Am. Rev. Respir. Dis. 145:1469-1476.
Ollerenshaw, S. L. and A. J. Woolcock. (1992) Characteristics of the inflammation 
in biopsies from large airways of subjects with asthma and subjects with 
chronic airflow limitation. Am. Rev. Respir. Dis. 145:922-927.
Onu, A., T. Pohl, H. Krause and S. BulfonePaus. (1997) Regulation of IL-15 
secretion via the leader peptide of two IL-15 isoforms. J. Immunol. 158:255- 
262.
Osman, G.E., M. Toda, O. Kanagawa and L.E. Hood. (1993) Characterization of the 
T-cell receptor repertoire causing collagen arthritis in mice. J. Exp. Med. 
177:387-395.
Otten, H. G., R. J. Dolhain, H. H. Rooji and F. Breedveld. (1993) Rheumatoid factor 
production by mononuclear cells derived from different sites of patients with 
rheumatoid arthritis. Clin. Exp. Immunol. 94:236-240.
Palmer, R. M. J., A. G. Ferrige and S. Moncada. (1987) Nitric oxide release accounts 
for the biologic activity of endothelium derived relaxing factor. Nature  
327:524-526.
Panayi, G. S., J. S. Lanchbury and G. H. Kingsley. (1992) The importance of the T 
cell in initiating and maintaining the chronic synovitis of rheumatoid 
arthritis. Arthritis Rheum. 35:729-735.
Panayi, G. S. (1993) The immunopathogenesis of rheumatoid arthritis. Brit. J. 
Rheum. 32 (suppl. 1), 4-14.
237
Park, K, G. M., P. D. Hayes, P. J. Garlick, H. Sewell and O. Eremin. (1991) 
Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 
337:645-646.
Paul, W. E. and R. A. Seder. (1994) Lymphocyte responses and cytokines. Cell 76: 
241-251.
Perrella, O., P. B. Carried, R. De Mercato and C. A. Buscaino. (1993) Markers of 
activated T lymphocytes and T cell receptor gamma/delta^ in patients with 
multiple sclerosis. Ear. Neurol. 33:152-155.
Piguet, P. P., G. E. Grau, C. Vesin, H. Loetscher, R. Gentz and W. Lesslauer. (1992) 
Evolution of collagen arthritis in mice is arrested by treatment with anti­
tumour necrosis factor (TNF) antibody or a recombinant soluble TNF 
receptor. Immunology. 77:510-514.
Pillinger, M. FI. and S. B. Abramson. (1995) The neutrophil in rheumatoid arthritis. 
Rheum. Dis. Clin. North Am. 21:691-714.
Pin, L, P. G. Gibson, R. Kolendowicz, A. Girgis-Gabardo, J. A. Denburg, F. E. 
Hargreave and J. Dolovich. (1992) Use of induced sputum cell counts to 
investigate airway inflammation in asthma. Thorax. 47:25-29.
Pitzalis, C., G. H. Kingsley, J. S. S. Lanchbury, J. Murphy and G. S. Panayi. (1987a) 
Expression of HLA-DR, DQ, and DP antigens and interleukin 2 receptor on 
synovial fluid T lymphocytes subsets in rheumatoid arthritis: evidence of 
frustrated activation. J. Rheumatol. 14:662-666.
Pitzalis, C., G. H. Kingsley, J. Murphy and G. S. Panayi. (1987b) Abnormal 
distribution of helper-inducer and suppressor-inducer T lymphocyte subsets 
in the rheumatoid joint. Clin. Immunol. Immunopathol. 45:252-258.
Pitzalis, C., G. H. Kingsley, D. O. Haskard and G. S. Panayi. (1988) The preferential 
accumulation of helper-inducer T lymphocytes in inflammatory lesions: 
evidence for regulation by selective endothelial and homotypic adhesion. 
Eur. J. Immunol. 18:1397-1404.
Pitzalis, C., G. H. Kingsley, M. Covelli, R. Meliconi, A. Markey and G. S. Panayi.
(1991) Selective migration of the human helper-inducer memory T cell
238
subset: confirmation by in vivo cellular kinetic studies. Eur. J. Immunol. 
21:369-376.
Pitzalis, C., G. H. Kingsley and G. S. Panayi. (1994) Adhesion molecules in 
rheumatoid arthritis: role in the pathogenesis and prospects for therapy. Ann. 
Rheum. Dis. 53:287-288.
Plater-Zyberk, C., C. M. S. Brown, E. M. Andrew and R. N. Maini. (1992) CD5"‘ B 
cells in rheumatoid arthiitis. Ann. NY. Acad. Sci. 651:540-550.
Poston, R., P. Chanez, J. Y. Lacoste, P. Litchfield, T. H. Lee and J. Bousquet.
(1992). Immuiiohistochemical characterization of the cellular infiltration of 
asthmatic bronchi. Am. Rev. Respir. Dis. 145:918-921.
Potocnik, A.J., R. Kinne, H. Menninger, J. Zacher, F. Emmiich and R. A. Ki'oczek. 
(1990) Expression of activation antigens on T cells in rheumatoid arthritis 
patients. Scand. J. Immunol. 31:213-224.
Qu, Z., C. H. Garcia, L. M. O’Rourke, S. R. Planck, M. Kohli and J. T. Rosenbaum. 
(1994) Local proliferation of fibroblast-like synoviocytes contributes to 
synovial hypeiplasia: Results of proliferating cell nuclear antigen/cyclin, c- 
myc, and nucleolar organizer region staining. Arthritis Rheum. 37:212-219.
Quayle, A. J., P. Chomarat, T. R. Miossec, O. Forre and J, B. Natvig. (1993) 
Rheumatoid inflammatory T cell clones express mostly T hl, but also Tli2 
and mixed (ThO-like) cytokine patterns. Scand. J. Immunol. 38:75-82.
Quayle, J. A., S. Adams, R. C. Bucknall and S. W. Edwards. (1995) Interleukin-1 
expression by neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. 54:930- 
933.
Quinn, L. S., K. L. Haugk and K. H. Grabstein. (1995) Interleukin-15: A novel 
anabolic cytokine for skeletal muscle. Endocrinology. 136:3669-3672.
Rankin, E. C. C., E. H. S. Choy, D. Kassimos, G. H. Kingsley, A. M. Sopwith, D. A. 
Isenberg and G. S. Panayi. (1995) The therapeutic effects of an engineered 
human antitumor necrosis factor-alpha antibody (CDP571) in rheumatoid- 
arthritis. Br. J. Rheumatol. 34:334-342.
239
Rathanaswami, P., M. Hachicha, M. Sadick, T. J. Schall and S. R. McColl. (1993) 
Expression of the cytokine RANTES in human rheumatoid synovial 
fibroblasts. Differential regulation of RANTES and IL -8 genes by 
inflammatory cytokines. J. Biol. Chem. 268:5834-5839.
Reme, T., A. Travaglio, E. Gueydon, L. Adla, C. Jorgensen and J. Sany. (1998) 
Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial 
tissue. Clin. Exp. Immunol. 111:353-358.
Remmers, E. P., H. Sano and R. L. Wilder. (1991) Platelet derived growth factors 
and heparin-binding (fibroblast) growth factors in the synovial pathology of 
rheumatoid arthritis. Semin. Arthritis Rheum. 21:191-199.
Revell, P. A., P. I. Mapp, P. A. Lalor and P. A. Hall. (1987) Proliferative capacity of 
cells in synovium as demonstrated by a monoclonal antibody Ki67. 
Rheumatol. Int. 7:183-186.
Rincon, M., M. Cebrian, F. Sanchez-Madrid and M. Lopez-Botet. (1989) Induction 
of T cell function via the gp33/27 activation inducer molecule (AIM) 
requires co-expression of the CD3/TcR complex. Eur. J. Immunol. 19-959- 
962.
Robbins, R. A., D. R. Springall, J. B. Warren, O. J. Kwon, L. D. K. Buttery, A. J. 
Wilson, I. M. Adcock, V. RiverosMoreno, S. Moncada, J. Polak and P. J. 
Barnes. (1994) Inducible nitric oxide synthase is increased in murine lung 
epithelial cells by cytokine stimulation. Biochem. Biophys. Res. Commun. 
198:835-843.
Robinson, D. S., A. M. Bentley, A. Hartnell, A. B. Kay and S. R. Durham. (1993b) 
Activation memory-T helper cells in bronchoalveolar lavage fluid from 
patients with atopic asthma - relation to asthma symptoms, lung function, and 
bronchial responsiveness. Thorax. 48:26-32.
Robinson, D. S., Q. Hamid, S. Ying, A. Tsicopoulos, J. Barkans, A. M. Bentley, C. 
Corrigan, S. R. Durham and A. B. Kay. (1992b) Predominant Th-2-like 
bronchoalveolar T-lymphocyte population in atopic asthma. New Engl. J.
326:298-304.
240
Robinson, J. J,, F. Watson, M. Phelan, R. C. Bucknall and S. W. Edwards. (1993a) 
Activation of neturophils by soluble and insoluble immunoglobulin 
aggregates from synovial fluid of patients with rheumatoid arthritis. Ann. 
Rheum. Dis. 52:347-353.
Robinson, J. J. , F. Watson, R. C. Bucknall and S. W. Edwards. (1992a) Activation 
of neutrophil reactive-oxidant production by synovial- fluid from patients 
with inflammatory joint disease - soluble and insoluble immunoglobulin 
aggregates activate different pathways in primed and unprimed cells. 
Biochem. J. 286:345-351.
Rodriguez, R. M., C. Pitzalis, G. H. Kingsley, E. M. Henderson, M. J. Humphries 
and G. S. Panayi. (1992) T-lymphocyte adhesion to fibronectin; a possible 
mechanism for T cell accumulation in the rheumatoid joint. Clin. Exp. 
Immunol. 89:439-445.
Ross, M. E. and M. A. Caligiuri. (1997) Cytokine-induced apoptosis of human 
natural killer cells identifies a novel mechanism to regulate the innate 
immune response. Blood. 89:910-918.
Rousset, F., E. Garcia, T. Deference, C. Peronne, N. Vezzio, D. H. Hsu, R. 
Kastelein, K. W. Moore and J. Banchereau. (1992) IL-10 is a potent growth 
and differentiation factor for activated human B lymphocytes. Proc. Natl. 
Acad. Sci. USA. 89:1890-1893.
Salmon, M., G. D. Kitas and P. Emery. (1989) Another inteipretation of the role of T 
helper cells in the rheumatoid synovium. Arthritis Rheum. 32:795-796.
Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. 
Hyde, A. D. D'Angeac, P. A. Bacon, P. Emery and A. N. Akbar. (1997) 
Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 
99:439-446.
Santos, L. L. and P. G. Tipping. (1994) Attenuation of adjuvant arthritis in rats by 
treatment with oxygen radical scavengers. Immunol. Cell Biol. 72:406-414.
Santos, L. L., E. F. Morand, P. Hutchinson, N. W. Boyce and S. R. Holdsworth. 
(1997) Anti-neutrophil monoclonal antibody therapy inhibits the 
development of adjuvant arthritis. Clin. Exp. Immunol. 107:248-253.
241
Schlaak, J., E. Hermann, M. Ringhoffer, P. Probst, H. Gallati, K-H. Buschenfelde 
and B. Fleischer. (1992) Predominance of Thl type T cells in synovial fluid 
of patients with Yersinia induced reactive arthritis. Eur. J. Immunol 
22:2771-2776.
Schmidt, D., J. J. Goronzy and C. M. Weyand. (1996) CD4+CD7-CD28- T cells are 
expanded in rheumatoid arthritis and are characterized by autoreactivity. J. 
Clin. Invest. 97:2027-2037.
Schmidt, H. H. H. and U. Walter. (1994) NO at work. Cell 78:919-925.
Schneemann, M., G. Schoedon, S. Hoefer, N. Blau, L. Guerrero and A. Schaffner.
(1993) Nitric oxide synthase is not a constituent of the antimicrobial 
armature of human mononuclear phagocytes J. Infect. Dis. 167:1358-1363.
Schneemann, M., G. Schoedon, P. Linscheid, R. Walter, N. Blau and A. Schaffner. 
(1997) Nitrite generation in interleukin-4-treated human macrophage cultures 
does not involve the nitric oxide synthase pathway. J. Infect. Dis. 175:130- 
135.
Schwarz, R. H. (1990) A cell culture model for T lymphocyte clonal anergy. Science 
248:1349-1356.
Scotet, E„ J. David-Ameline, M. A. Peyrat, A. Moreau-Aubry, D. Pinczon, A. Lim, 
J. Even, G. Semana, J. M. Berthelot, R. Breathnach, M. Bonneville and E. 
Houssaint. (1996) T cell response to epstein-barr virus transactivators in 
chronic rheumatoid arthritis. J. Exp. Med. 184:1791-1800.
Sebbag, M., S. L. Parry, F. M. Brennan and M. Feldmann. (1997) Cytokine 
stimulation of T lymphocytes regulates their capacity to induce monocyte 
production of tumor necrosis factor-alpha, but not interleukin-10: Possible 
relevance to pathophysiology of rheumatoid arthritis. Eur. J. Immunol. 
27:624-632.
Seder, R. A. (1996) High-dose IL-2 and IL-15 enhance the in vitro priming of naive 
CD4^ T cells for IFN-gamma but have differential effects on priming for IL-
4. J. Immunol 156:2413-2422.
242
Seder, R. A., K. H. Grabstein, J. A. Berzofsky and J. F. McDyer. (1995) Cytokine 
interactions in human immunodeficiency virus-infected individuals: Roles of 
interleukin (IL)-2, IL-12, and IL-15. J. Exp. Med. 182:1067-1078.
Seitz, M., B. Dewald, N. Gerber and M. Baggiolini. (1991) Enhanced production of 
neutrophil activating peptide-1 / interleukin-8 in rheumatoid arthritis J. Clin. 
Invest. 87:463-469.
Seki, N., Y. Sudo, T. Yoshioka, S. Sugihara, T. Fujitsu, S. Sakuma, T. Ogawa, T. 
Hamaoka, H. Senoh and H. Fujiwara. (1988) Type-II collagen-induced 
murine arthritis .1. Induction and perpetuation of arthritis require synergy 
between humoral and ceil-mediated-immunity. J. Immunol. 140:1477-1484.
Sharara, A. I., D. J. Perkins, M. A. Misukonis, S. U. Chan, J. A. Dominitz and J. B. 
Weinberg. (1997) Interferon (IFN)-alpha activation of human blood 
mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 
mRNA and protein expression: Possible relationship of induced N0S2 to the 
anti-hepatitis C effects of IFN-alpha in vivo. J. Exp. Med. 186:1495-1502.
Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzioi, J. Hakimi, M. Gately 
and G. Delespesse. (1995) Activated T cells induce interleukin-12 production 
by monocytes via CD40-CD40 ligand interaction. Ear. J. Immunol. 25:1125- 
1128.
Sieper, J. and G. Kingsley. (1996) Recent advances in the pathogenesis of reactive 
arthritis. Immunol. Tod. 17:160-163.
Sieper, J., G. FI. Kingsley, A. Palacios-Boix, C. Pitzalis, J. Treharne, R. Hughes, A. 
Keat and G. S. Panayi. (1991) Synovial T lymphocyte-specific immune 
response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum. 
34:588-598.
Simon, A. K., E. Seipelt and J. Sieper. (1994) Divergent T-cell cytokine patterns in 
inflammatory arthritis. Proc. Natl. Acad. Sci. USA. 91:8562-8566.
Sorel, M., M. Cherel, B. Dreno, I. Bouyge, J. Guilbert, S. Dubois, B. Lebeau, S. 
Raher, S. Minvielle and Y. Jacques. (1996) Production of interleukin-15 by 
human kératinocytes. Eur. J. Dermatol. 6:209-212.
243
St. Louis, J. D., J. A. Lederer and A. H. Lichtman. (1993) Costimulation deficient 
antigen presentation by an endothelial cell line induces a nonproliferative T 
cell activation response without anergy. J. Exp. Med. 178:1597-1605.
Staines, N. and P. H. Wooley. (1994) Collagen arthritis - What can it teach us? Brit. 
J. Rheum. 33:798-807.
Stamler, J. S. (1994) Redox signaling: Nitrosyiation and related target interactions of 
nitric oxide. Cell. 78:931-936.
Stefanovic-Racic, M., J. Stadler and C. H. Evans. (1993) Nitric oxide and arthritis 
Arthritis Rheum. 36:1036-1044,
Stefanovic-Racic, M., K. Meyers, C. Meschter, J. W. Coffey, R. A. Hoffman and C.
H. Evans. (1994) N-Monomethyl arginine, an inhibitor of nitric oxide 
synthase, suppresses the development of adjuvant arthritis in rats. Arthritis 
Rheum. 37:1062-1069.
Stellato, C., L. A. Beck, G. A. Gorgone, D. Proud, T. J. Schall, S. J. Ono, L. M. 
Lichtenstein and R. P. Schleimer. (1995) Expression of the chemokine 
RANTES by a human bronchial epithelial cell line: Modulation by cytokines 
and glucocorticoids. J. Immunol. 155:410-418.
Stout, R. D. and J. Suttles. (1996) The many-roles of CD40 in cell-mediated 
inflammatory responses. Immunol. Today. 17:487-492.
Strehlau, J., M. Pavlakis, M. Lipman, M. Shapiro, L. Vasconcellos, W. Harmon and 
T. B. Strom. (1997) Quantitative detection of immune activation transcripts 
as a diagnostic tool in kidney transplantation. Proc. Natl. Acad. Sci. USA. 
94:695-700.
Stuart, J. M., W. C. Watson and A. H. Kang. (1988) Collagen autoimmunity and 
arthritis. FASEB J. 2:2950-2956.
Sunyer, T., L. Rothe, X. Jiang, P. Osdoby and P. Collin-Osdoby. (1996) 
Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide 
synthase expression and nitric oxide production in avian osteoclast like cells. 
J. Cell. Biochem. 60:469-483.
244
Suzuki, H., T. M. Kundig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. 
Schmitts, J- J. Simard, P. S. Ohashi and H. Griesser. (1995) Deregulated T 
cell activation and autoimmunity in mice lacking interleukin-2 receptor p. 
Science. 268:1472-1476.
Suzuki, H., G. S. Duncan, H. Takimoto and T. W. Mak. (1997) Abnormal 
development of intestinal intraepithélial lymphocytes and peripheral natural 
killer cells in mice lacking the IL-2 receptor beta chain. J. Exp. Med. 
185:499-505.
Symons, J., J. A. Eastgate and G. W. Duff, G. (1991) Purification and 
characterisation of a novel soluble receptor for interleukin-1. J. Exp. Med. 
174:1251-1254.
Taga, T. and T. Kishimoto. (1995) Signaling mechainisms through cytokine 
receptors that share signal transducing receptor components. Curr. Opin. 
Immunol. 7:17-23.
Tagaya, Y., J. D. Burton, Y. Miyamoto and T. A. Waldmann. (1996a) Identification 
of a novel receptor/signal transduction pathway for IL-15/T in mast cells. 
EMBO 7. 15:4928-4939.
Tagaya, Y., R. N. Bamford, A. P. DeFilippis and T. A. Waldmann. (1996b) IL-15: A 
pleiotropic cytokine with diverse receptor/signaling pathways whose 
expression is controlled at multiple levels. Immunity. 4:329-336.
Tagaya, Y., G. Kurys, T. A. Thies, J. M. Losi, N. Azimi, J. A. Hanover, R. N. 
Bamford and T. A. Waldmann. (1997) Generation of secretable and 
nonsecretable interleukin 15 isoforms through alternate usage of signal 
peptides. Proc. Natl. Acad. Sci. USA. 94:14444-14449.
Tao, X. and R. Stout. (1993) T cell mediated cognate signalling of nitric oxide 
production by macrophages, requirements for macrophage activation by 
plasma membranes isolated from T cells. Eur. J. Immunol. 23:2916-2921.
Taylor-Robinson, A. W., F. Y. Liew, A. Severn, D. Xu, S. McSorley, P. Garside, J. 
Padron and R. S. Phillips. (1994) Regulation of the immune response by 
nitric oxide differentially produced by T helper type 1 and T helper type 2 
cells. Eur. J. Immunol. 24:980-984.
245
Terato, K., K. A. Hasty, R. A, Reife, M. A. Cremer, A. H. Kang and J. M. Stuart.
(1992) Induction of arthritis with monoclonal-antibodies to collagen. 7. 
Immunol. 148:2103-2108.
Testi, R., D. D’Ambrsoio, R. De Maria and A. Santoni. (1994) The CD69 receptor: a 
multipurpose cell-surface trigger for haematopoietic cells. Immunol. Tod. 
15:479-483.
Theofilopoulus, A. N., D. A. Carson and M. Tavassoli. (1980) Evidence for the 
presence of receptors for C3 and IgG Fc on human synovial cells. Arthritis 
Rheum. 23:1-9.
Thomas, R., M. Mcllraith, L. S. Davis and P. E. Lipsky. (1992) Rheumatoid 
synovium is enriched in CD45RBdim mature memory T cells that are potent 
helpers for B cell differentiation. Arthritis Rheum. 35:1455-1465.
Thomas, R., L. Davis and P. E. Lipsky. (1994) Rheumatoid synovium is enriched in 
mature antigen-presenting dendritic cells. 7. Immunol. 152:2613-2623.
Thorbecke, G. L, R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison and M. A. 
Palladino. (1992) Involvement of endogenous tumour necrosis factor a  and 
transforming growth factor p during induction of collagen type II arthritis in 
mice. Proc. Nat. Acad. Sci. USA. 89:7375-7379.
Thurkow, E. W., I. M. Van Der Heijden, F. C. Breedveld, T. J. M. Smeets, M. R. 
Daha, P. M. Kluin, A. E. Meinders and P. P. Tak. (1997) Increased 
expression of IL-15 in the synovium of patients with rheumatoid arthritis 
compared with patients with Yersinia-induced arthritis and osteoarthritis. 7. 
Pathol. 181:444-450.
Till, S., B. Li, S. Durham, M. Humbert, B. Assoufi, D, Huston, R. Dickason, P. 
Jeannin, A. B. Kay and C. Corrigan. (1995) Secretion of the eosinophil- 
active cytokines interleukin-5, granulocyte/macrophage colony-stimulating 
factor and interleukin-3 by bronchoalveolar lavage CD4^ and CD8  ^ T cell 
lines in atopies asthmatics, and atopic and non-atopic controls. Eur. 7. 
Immunol. 25:2727-2731.
246
Tomioka, M., S. Ida, Y. Shindoh, T, Ishihara and T. Takashima. (1984). Mast cells 
in bronchoalveolar lumen of patients with bronchial asthma. Am. Rev. Respir. 
Dis. 129:1000-1005.
Trede, N., R. S. Geha and T. Chatila. (1991) Transcriptional activation of monokine 
genes by MHC class II ligands. J.Immimol. 146:2310-2315.
Treiber-Held, S., D. M. Stewart, C. C. Kurman and D. L. Nelson. (1996) IL-15 
induces the release of soluble IL-2Ralpha from human peripheral blood 
mononuclear cells. Clin. Immunol. Immunopathol. 79:71-78.
Trentham, D. E., A. S. Townes and A. H. Kang. (1977) Autoimmunity to type II 
collagen: an experimental model of arthrits. J. Exp. Med. 146:857-868.
Trentin, L., A. Cerutti, R. Zambello, R. Sancetta, C. Tassinari, M. Facco, F. Adami, 
F. Rodeghiero, C. Agostini and G. Semenzato. (1996) Interleukin-15 
promotes the growth of leukemic cells of patients with B- cell chronic 
lymphoproliferative disorders. Blood. 87:3327-3335.
Ulfgren, A. K., S. Lindblad, L. Klareskog, J. Andersson and U. Andersson. (1995) 
Detection of cytokine producing cells in the synovial membrane from 
patients with rheumatoid arthritis. Ann. Rheum. Dis. 54:654-661.
Van de Stolpe, A., E. Caldenhoven, J. A. Raaijmakers, P. T. van der Saag and L. 
Koenderman. (1993) Glucocorticoid-mediated repression of ICAM-1 
expression in human monocytic and bronchial epithelial cell lines. Am. J. 
Respir. Cell Mol. Biol. 8:340-347.
Van den Berg, W. B., L. A. B. Joosten, M. Helsen and F. A. J. Van de Loo. (1994) 
Amelioration of established murine collagen-induced arthritis with anti- IL-1 
treatment. Clin. Exp. Immunol. 95:237-243.
Vermeire, K., H. Heremans, M. Vandeputte, S. Huang and P. Matthys. (1997) 
Accelerated collagen-induced arthritis in IFN-gamma receptor- deficient 
mice. J. Immunol. 158:5507-5513.
Verwilghen, J., S. Vertessen, E. A. M. Stevens, J. Dequeker and J. L. Ceuppens. 
(1990) Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. 
J. Clin. Immunol. 10:90-98.
247
Vey, E., J-H. Zhang and J-M Dayer. (1992) IFN-yand l,25(OH)2D3 induce on THP-
I cells distinct patterns of cell surface antigen expression, cytokine 
production and responsiveness to contact with activated T cells. J. Immunol. 
149:2040-2046.
Wagner Dh, Jr., R. D. Stout and J. Suttles. (1994) Role of the CD40-CD40 ligand 
interaction in CD4^ T cell contact- dependent activation of monocyte 
interleukin-1 synthesis. Eur. J. Immunol. 24:3148-3154.
Walker, C., M. K. Kaegi, P. Braun and K. Blaser. (1991) Activated T cells and 
eosinophilia in bronchoalveolar lavages from subjects with asthma correlated 
with disease severity. J. Allergy Clin. Immunol. 88:935-942.
Walsh, G. M., J. Mermod, A. Hartnell, A. B. Kay and A. J. Wardlaw. (1991) Human 
eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical 
vascular endothelial cells is a 4^1 (VLA-4) dependent. J. Immunol. 
146:3419-3423.
Wang, S. B., L. Yan, R. A. Wesley and R. L. Danner. (1997) Nitric oxide increases 
tumor necrosis factor production in differentiated U937 cells by decreasing 
cyclic AMP. J. Biol. Chem. 272:5959-5965.
Warren, H.S., B.F. Kinnear, R.L. Kastelein and L.L. Lanier. (1996) Analysis of the 
costimulatory role of IL-2 and IL-15 in initiating proliferation of resting 
(CD56(dim)) human NK cells. J. Immunol. 156:3254-3259.
Watkins, D. N., D. J. Peroni, K. A. Basel ai n, M. J. Garlepp and P. J. Thompson. 
(1997) Expression and activity of nitric oxide synthases in human airway 
epithelium. Am. J. Resp. Cell Mol. Biol. 16:629-639.
Watson, F., J. J. Robinson, M. Phelan, R. C. Bucknall and S. W. Edwards. (1993) 
Receptor expression in synovial fluid neutrophils from patients with 
rheumatoid arthritis. Ann. Rheum. Dis. 52:354-359.
Watson, W. C. and A. S. Townes. (1985) Genetic susceptibility to murine collagen-
II autoimmune arthritis - proposed relationship to the IgG2 autoantibody 
subclass response, complement C5, major histocompatibility complex 
(MHC) and non-MHC loci. J. Exp. Med. 162:1878-1891.
248
Wei, X. Q., I, G. Charles, A. Smith, J. Ure, G. J, Feng, F. P. Huang, D. Xu, W. 
Muller, S. Moncada and F. Y. Liew. (1995) Altered immune responses in 
mice lacking inducible nitric oxide synthase. Nature. 375:408-411.
Wiesenberg, I., P. H. Vandermeide, H. Schellekens and S.S. Aik an. (1989) 
Suppression and augmentation of rat adjuvant arthritis with monoclonal anti- 
interferon-gamma antibody. Clin. Exp. Immunol. 78:245-249.
Wilkinson, L. S., A. A. Pitsillides, J. G. Worrall and J. C. W. Edwards. (1992) Light 
microscopic characterisation of the fibroblastic synovial lining cell. Arthritis 
Rheum. 35:1179-1184.
Wilkinson, P. C. and I. Newman. (1992) Identification of interleukin-8 as a 
locomotor attractant for activated human lymphocytes in mononuclear cell 
cultures with anti-CD3 or purified protein derivative of M ycobacterium  
tuberculosis. J. Immunol. 149:2689-2694.
Wilkinson, P.C. and F.Y. Liew. (1995) Chemoattraction of human blood T 
lymphocytes by interleukin-15. J. Exp. Med. 181:1255-1259.
Willerford, D.M., J. Chen, J. A. Ferry, L. Davidson, A. Ma and F. W. Alt. (1995) 
Interleukin-2 receptor-a chain regulates the size and content of the peripheral 
lymphoid compartment. Immunity 3:521-530.
Williams, R. O., M. Feldmann and R. N. Maini. (1992) Anti-tumour necrosis factor 
ameliorates joint disease in murine collagen induced arthritis. Proc. Nat. 
Acad. Sci. USA. 89:9784-9788.
Williams, R. O., D. G. Williams, M. Feldmann and R. N. Maini. (1993) Increased 
limb involvement in murine collagen-induced arthritis following treatment 
with anti-interferon-gamma. Clin. Exp. Immunol. 92:323-327.
Williams, R. O., L. J. Mason, M. Feldmann and R. N. Maini. (1994) Synergy 
between anti-CD4 and anti-tumor necrosis factor in the amelioration of 
established collagen-induced arthritis. Proc. Nat. Acad. Sci. USA. 91:2762- 
2766.
249
Wilson, J. W., R. Djukanovic, P. H. Howarth and S. T. Holgate. (1992) Lymphocyte 
activation in bronchoalveolar lavage and peripheral blood in atopic asthma. 
Am. Rev. Respir. Dis. 145:958-960.
Wooley, P. H., H. S. Luthra, M. M. Griffiths, J. M. Stuart, A. Huse and C. S. David. 
(1985) Type-II collagen-induced arthritis in mice .4. Variations in 
immunogenetic regulation provide evidence for multiple arthritogenic 
epitopes on the collagen molecule. J. Immunol 135:2443-2451.
Wooley, P. H., J. D. Whalen, D. L. Chapman, A. E. Berger, K. A. Richard, D. G. 
Aspar and N. D. Staite. (1993a) The effect of an interleukin-1 receptor 
antagonist protein on type II collagen-induced arthritis and antigen-induced 
arthritis in mice. Arthritis Rheum. 36:1305-1314.
Wooley, P. H., J. Dutcher, M. B. Widmer and S. Gillis. (1993b) Influence of a 
recombinant human soluble tumor necrosis factor receptor Fc fusion protein 
on type II collagen-induced arthritis in mice. J. Immunol 151:6602-6607.
Xie, Q.W., Y. Kashiwabara and C. Nathan. (1994) Role of transcription factor NF- 
kappaB/Rel in induction of nitric oxide synthase. J. Biol Chem. 269:4705- 
4708.
Yan, L., S. Wang, S. P. Rafferty, R. A. Wesley and R. L. Danner. (1997) 
Endogenously produced nitric oxide increases tumour necrosis factor-a 
production in tiansfected human U937 cells. Blood. 90:1160-1167.
Yanni, G., A. Whelan, C. Feighery, O. Fitzgerald and B, Bresnihan. (1993) 
Morphometric analysis of synovial membrane blood vessels in rheumatoid 
arthritis: associations with the immunohistologic features, synovial fluid 
cytokine levels and the clinical course. J. Rheumatol 20:634-638.
Ying, S., D. S. Robinson, V. Varney, Q. Meng, A. Tsicopoiilos, R. Moqbel, S. R. 
Durham, A. B. Kay and Q. Hamid. (1991) TNFa mRNA expression in 
allergic inflammation. Clin. Exp. Allergy. 21:745-750.
Zembala, M,, M. Siedlar, J. Marclnkiewicz and J. Pryjma. (1994) Human monocytes 
are stimulated for nitric oxide release in vitro by some tumor cells but not by 
cytokines and lipopolysaccharide. Eur. J. Immunol 24:435-439.
250
Zvaifler, N. J. and G. S. Firestein. (1994) Pannus and pannocytes: Alternative 
models of joint destruction in rheumatoid arthritis. Arthritis Rheum. 37:783- 
789.
251
Appendix I 
Buffers
1. PBS 1x10 stockl
80g NaCl 
11.6g NaH^PO^
2g KCl
2g KH2PO4
2. PBS / Tween (0.05%)
0.5 ml Tween 20 
1000 ml PBS (xl)
3. Coating buffer lELISAl
O.lMNaHCOg, pH 8.2
4. Vector Kit buffer
O.lMTris-HCl, pH 8.2
5. TBS (ICC Wash buffer!
900 mi 0.9% NaCl 
100 ml 50mM Tris-HCl, pH 3.6 
50 mM Tris-HCl
- Add cone HCl to 25 ml 0.2M tris-HCl to pH 7.36 
Make up to 100 ml with dH^O
6. Paraform aldehyde
Ig PEA 
100 ml PBS 
50 pi IM NaOH
Heat to 60°C then gently mix until solution clears.
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7. Fast red solution
A 100 mg naphthol-AS-MX phosphate
5 ml N.N.-dimethyIformamide 
100 ml TBS, pH8.2
B 0. IM levamisole in dHzO
8. NSE stain phosphate buffers
A 9.08 g/1 KH2PO4 (0.067M)
B 11.9 g/1 Na^HPO^ 2H ,0  (0.067M)
Add 98.5 ml of A to 1.5 ml of B.
9. Griess Reaction
A 0.1% a-naphthyl-amine in dH^O
B 1% sulfanilamide in 5% phosphoric acid
Mix equal volumes for Griess reagent 
Store away from light
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